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ABSTRACT 
 
      Reduction of N-heteroaromatic compounds is a challenging and 
important reaction. Transfer hydrogenation using organic molecules as 
hydrogen donors is a safe and operationally simple alternative to 
hydrogenation with H2. However, it has been underutilised and less 
developed. In this thesis, our contribution to the transfer hydrogenation of 
N-heteroaromatic compounds is described. 
      Following a brief introduction of transfer hydrogenation of N-
heteroaromatic compounds in Chapter 1, Chapter 2 presents a novel 
method for the mild reduction of quinolines, isoquinolines and 
quinoxalines to corresponding tetrahydro products. The most significant 
discovery is the remarkable accelerating effect of the simple iodide ion, 
which acts presumably by altering the reaction mechanism.  
      Chapter 3 extends the above-mentioned system to the reduction of 
more challenging pyridines to afford not only piperidines but also the 3,4-
unsaturated variants with high chemoselectivities.  
      Chapter 4 describes a simple, complementary system, discovered 
during searching for new transfer hydrogenation catalysts, which allows 
for the hydrogenation of N-heteroaromatics with H2 using a 
cyclometalated iridium complex under exceptionally mild conditions 
(ambient temperature, 1 atm H2) in the absence of any additives.  
vi 
 
      Chapter 5 demonstrates a new reaction for the rapid and direct 
preparation of various chiral piperidines from pyridines with high yields 
and exceptional diastereo- and enantioselectivities. Key to the success is 
the introduction of a chiral amine which is incorporated into the pyridine 
ring by transamination during the transfer hydrogenation process, 
presumably via forming previously unobtainable chiral 
tetrahydropyridinium intermediate in situ. 
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CHAPTER 1 INTRODUCTION - TRANSFER 
HYDROGENATION OF N-HETEROAROMATIC 
COMPOUNDS 
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1.1 Introduction 
      Catalytic hydrogenations are amongst the largest-scale industrial 
processes in the world. From the hydrocracking of heavy oil in petroleum 
refining to pharmaceutical manufacturing with asymmetric hydrogenation 
processes, hydrogenation processes have fundamentally affected the daily 
life of human beings. Over one hundred million tonnes of ammonia are 
produced annually by the catalytic hydrogenation of N2 primarily for 
worldwide fertilising agricultural crops. In comparison to these artificial 
catalytic processes, nature has developed its own catalytic system to 
achieve the hydrogen transfer for complex chemical transformations by 
oxidoreductases. The advantages of enzymatic catalysts in combination 
with organic molecules as hydrogen donor have been highlighted by 
many efficient reductions in both chemoselective and enantioselective 
manner.
1
 For instance, in the presence of horse liver alcohol 
dehydrogenase, various carbonyl compounds could be enantioselectively 
reduced to chiral, non-racemic alcohols using NADH or NADPH as 
cofactors.
2 
Inspired by nature, transfer hydrogenation (TH) in the 
presence of catalysts, using organic molecules as hydrogen donor to 
achieve hydrogen transfer to hydrogen acceptors (Eq. 1), has attracted 
much attention in the past several decades.
3
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      In comparison to the well-known hydrogenation with H2, TH by 
using other hydrogen donors has been relatively underutilised, although it 
offers real and potentially benign advantages, particularly for modern 
synthetic chemistry. Hydrogen gas with small molecular weight, poses 
big challenges to safety, particularly when in its liquid form, due to its 
ease of diffusion and leaking, low ignition energy and extreme reactivity 
with oxidants. In contrast, the use of organic molecule-based hydrogen 
donors obviates these potential hazards and does not require the use of 
specialised equipment, affording a feasible alternative particularly for 
laboratory-scale experiments. Apart from the safer use and operational 
simplicity, TH is often found to enhance chemoselectivity and tolerate 
other reducible functionalities.
3
 Thus, TH has been extensively 
investigated and many efficient catalysts have found their applications in 
organic synthesis, with the substrate scope covering almost all the 
reducible functionalities including alkenes, carbonyls, imines, alkynes, 
azo, nitro and cyano groups.
3
  
      Direct reduction of N-heteroaromatics by TH, however, has been 
much less developed, although the corresponding reduced heterocyclic 
compounds are widely found in natural products, synthetic medicines and 
functional materials.
4
 For instance, coniine, a piperidine derivative, found 
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in hemlock and responsible for the death of ancient Greek philosopher 
Socrates, was synthesised about one hundred years ago as the first 
example of alkaloid synthesis.
5a
  L-Proline, existing in human bodies, 
was utilised as a privileged catalyst in asymmetric catalysis in organic 
synthesis.
5b
 Galipinine
5c
 and salsolidine,
5d
 as naturally occurring 
alkaloids,
 
were found to exhibit diverse bioactivities and potential 
medicinal applications. Furthermore, synthetic drugs containing N-cyclic 
amine motifs such as Abilify
5e
 and Concerta
5f
 have been prescribed as the 
most popular pharmaceuticals for the treatment of certain diseases 
(Figure 1).  
 
Figure 1: Representative examples of bioactive N-heterocyclic 
compounds 
 
Due to the broad utilities of saturated N-heterocyclic compounds, the 
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reduction of various N-heteroaromatics has been attempted through a 
number of catalytic hydrogenation and TH systems, as outlined in Figure 
2.  
 
Figure 2: Catalytic hydrogenation and TH of N-heteroaromatics 
 
      Since Adam, Adkins and Freifelder’s pioneering work,6 transition 
metal catalysed heterogeneous hydrogenation of N-heterocycles using 
hydrogen gas has been extensively investigated and found tremendous 
application in industry. Building on Wilkinson’s seminal work of 
homogeneous hydrogenation in the 1960’s,7 Knowles, Noyori and others 
have developed asymmetric hydrogenation (AH)
8
 to reduce diverse 
prochiral functionalities in enzyme-comparable enantioselectivities, 
which has a far-reaching influence in the chemistry community and has 
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been widely adopted for the preparation of chiral compounds. In the past 
decade, AH of N-heteroaromatics to directly obtain optically active 
saturated cyclic amines has attracted much attention and a number of 
efficient hydrogenation systems have been developed.
9
 However, the use 
of hydrogen donors rather than hydrogen gas, for example, alcohols, 
amines, hydrocarbons or formic acid and its derivatives, has been much 
less explored particularly for N-heterocycle reduction. In this Chapter, 
transfer hydrogenation (TH) with these hydrogen donors for the reduction 
of N-heterocycles by homogeneous and heterogeneous catalysis will be 
discussed. 
1.2 TH of N-heteroaromatics 
      Since the 1980’s, a variety of N-heteroaromatics, such as 
quinolines, isoquinolines, quinoxalines, indoles, pyridines and others, 
have been successfully reduced by TH reactions. These reactions will be 
briefly overviewed according to the structural differentiation. 
1.2.1 TH of quinolines  
      Transition metal catalysts and metal-free organocatalysts are 
generally employed in TH in the presence of commonly used hydrogen 
donors such as isopropanol (IPA), formic acid and its derivatives, and 
Hantzsch esters.
3
 As many TH systems have been successfully used for 
the reduction of quinolines, the introduction for the TH of such 
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compounds will be divided on whether the metal catalyst is used.  
1.2.1.1 TH of quinolines by transition-metal catalysts 
      In 1984, Watanabe and co-workers reported that nitroarenes could 
be reduced in excellent conversions with HCOOH catalysed by 
RuCl2(PPh3)3,
10
 as can be seen in Scheme 1. They also demonstrated for 
the first time that N-heterocycles such as quinolines could be reduced to 
1,2,3,4-tetrahydroquinolines by TH, although isoquinolines, pyridines 
and other aromatic compounds were inactive. Other commonly used 
homo- or heterogeneous Ru complexes proved of low efficiency for the 
reduction of quinolines. This system is presumably difficult to tolerate 
other functionalities, judging from the harsh conditions used (180 °C). 
 
 
 
Scheme 1: Ru-catalysed TH of quinolines with formic acid 
 
      In the 1980’s, the combination of ammonium formate and 
palladium on carbon was successfully applied to the reduction of 
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carbonyls to methylene derivatives, and nitroketals to aminoketals,
11 
although no reduction of N-heterocycles by this method was reported 
until Joule and co-workers introduced it during a synthesis study in 1990. 
They found that in refluxing methanol, HCOONH4-Pd/C could be 
employed for the reduction of quinolines under mild conditions (Scheme 
2).
12
 For instance, acridine could be hydrogenated to the 9,10-dihydro 
product in moderate yield at room temperature.    
 
 
 
Scheme 2: Pd-catalysed TH of quinolines with formic acid 
 
      In 2001, Borane-amine complexes were introduced as reducing 
agents by Couturier and co-workers to reduce a variety of functional 
groups catalysed by palladium in methanol.
13
 Non-substituted quinoline 
was tested as a representative example of N-heteroaromatics and a good 
yield was obtained (Scheme 3). In comparison to the commonly 
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employed reduction of quinoline using pyridine-borane, this method 
shows more selective character and can be carried out under milder 
conditions.  
 
 
Scheme 3: Pd-catalysed TH of quinolines with borane-amine 
 
     A breakthrough for TH of N-heteroaromatics using homogeneous 
catalysts was achieved in 2004 by Fujita and co-workers during the 
investigation of Cp*-Ir complexes.
14
 By using IPA as hydrogen donor and 
[Cp*IrCl2]2 as catalyst, a series of quinolines bearing substituents in 
various positions were hydrogenated to 1,2,3,4-tetrahydro products in 
moderate to good yields (Scheme 4). Halides, NO2 and COOH were 
found to be well tolerated and common byproducts such as 
5,6,7,8-tetrahydro- and decahydroquinolines found in heterogeneous 
hydrogenation were not detected in this system. The presence of Brønsted 
acid considerably enhanced the reduction, presumably through the 
protonation of neutral quinoline to form quinolinium, which is easier to 
reduce by the Ir-H. The formation of N-isopropyl byproduct, probably 
                                                   Chapter 1 
 
 
 
10 
 
from the reductive amination of 1,2,3,4-tehydroquinolines and in situ 
formed acetone was suppressed by the addition of H2O. Isoquinolines and 
pyridines were found to be inactive in this system. A plausible 
mechanism is proposed by the authors, as outlined in Figure 3.  
 
 
Scheme 4: Ir-catalysed TH of quinolines with IPA 
 
      The formation of iridium isopropoxide complex A from the 
reaction of the catalyst precursor [Cp*IrCl2]2 and IPA is supposed to 
initiate this reduction. Then β-elimination would occur by releasing 
acetone to form the iridium hydride B, followed by the 1,2-addition of  
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Figure 3: Proposed mechanism for TH of quinolines with IPA 
 
such hydride complex to the protonated quinoline, which was generated 
in situ in the presence of the acidic additives. The resulting cationic 
iridium-1,2-hydroquinoline intermediate would decompose to 
1,2-dihyroquinoline and regenerate the iridium isopropoxide A and 
consequently Ir-H. The resulting hydride and then insert into the C=C 
bond in the 1,2-dihyroquinoline to form the 
iridium-1,2,3,4-tetrahydroquinoline intermediate followed by 
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protonolysis with IPA to afford the desired 1,2,3,4-tetrahydroquinoline 
product. This proposed mechanism finds support from the reduction of a 
possible intermediate. Under the similar reaction conditions and without 
using the acids, 1,2-dihydroquinoline was hydrogenated to 
1,2,3,4-tetrahydroquinoline in high yield.   
      In 2006, Frediani and co-workers reported a versatile 
Rh-bipyridine catalyst which could hydrogenate an array of reducible 
functionalities, including alkenes, carbonyls and imines by using IPA as 
hydrogen source.
15
 As can be seen in Scheme 5, this catalyst could also 
be applied to the reduction of N-heterocylces, quinoline, for example, in 
reasonable conversion and good selectivity.    
 
 
Scheme 5: Rh-catalysed TH of quinolines with IPA 
      In 2010, a Pd/C/Zn combination was disclosed by Sasson and 
co-workers to generate hydrogen in water and was consequently applied 
to the reduction of carbonyl and nitro groups. Recently, this method was 
explored by Abarca and Ballesteros for the TH of quinolines
16
 and 
moderate to good yields were obtained for the 
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1,2,3,4-tetrahydroquinolines (Scheme 6). However, the harsh conditions, 
incompatibility of functionalities and the use of stoichiometric zinc 
restrict the potential application in synthetic chemistry.    
 
 
 
Scheme 6: Pd-catalysed TH of quinolines with IPA 
 
      In 2008, Crabtree and co-workers developed two mild systems for 
catalytic hydrosilylation and transfer hydrogenation of quinolines,
17
 as 
shown in Scheme 7. 1,2,3,4-Tetrahydroquinolines were obtained in 
moderate yields by using [Ir(COD)(NHC)PPh3]BF4 1 as catalyst, with 
either isopropanol or formic acid as hydrogen source. It is noteworthy 
that the hydrosilylation of quinolines catalysed by [Rh(NBD)(PPh3)2]PF6 
in the presence of PhSiH3 could afford 1,2-dihydroquinolines after a rapid 
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hydrolysis with base, which are not obtainable by direct hydrogenation.  
 
 
Scheme 7: Rh- and Ir-catalysed hydrosilylation and TH of quinolines  
 
      Since 2003, when the first example of highly enantioselective 
hydrogenation of quinolines was reported by Zhou and co-workers,
18
 
numerous catalytic systems with transition metals, such as Ir and Ru, and 
diverse ligands using H2 as hydrogen source have been developed,
19
 
allowing rapid and efficient preparation of a range of optically active 
tetrahydroquinolines. However, there are no examples of transition-metal 
catalysed ATH of quinolines. In 2009, Xiao and co-workers reported the 
first example of ATH of quinolines in water which afforded a series of 
1,2,3,4-tetrahydroquinolines in excellent enantioselectivities and yields 
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with a Rh-TsDPEN catalyst 2, by using formate as the hydrogen source.
20
 
(Scheme 8). Quinolines bearing 2-alkyl or 2-aryl substituents could be 
hydrogenated in good yields and excellent ee values. It is worth to note 
that the pH of the aqueous medium plays a crucial role for the high 
activity, while showing little influence on enantioselectivity.  
 
 
 
Scheme 8: Rh-catalysed ATH of quinolines in water 
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      As shown in Figure 4, the authors assumed that the mechanism 
begins with a hydride transfer to the pronated quinolines D, as the acidic 
medium is essential for the high reactivity. For the following hydride 
addition, there might be two options, a 1,2-, or 1,4-addition pathway.  
Based on the results obtained from computational calculation for the 
energy and distribution of LUMO orbital of 2-methylquinoline C and 
other possible intermediates, the initial 1,4-hydride addition was thought 
to be favored. The resulting enamine E was then isomerised to the 
iminium intermidate F followed by the reduction by metal hydride, 
generating 1,2,3,4-tetrahydroquinoline G as the desired product.  
 
 
Figure 4. Proposed pathway for Rh-catalysed quinoline reduction in water 
 
      In 2010, Wills and co-workers applied their tethered ruthenium 
and rhodium catalysts 3 and 4, which were excellent catalysts for ATH of 
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ketones, to the ATH of quinolines using formic acid as hydrogen source.
21
 
The reduction was found to be generally slow and satisfactory 
conversions were only obtained in up to 168 hours. The rhodium complex 
4 displayed higher enantioselectivity than the ruthenium catalyst 3, but 
significantly lower activity even with higher catalyst loading (Scheme 9).  
 
Scheme 9: Ru- and Rh-catalysed ATH of quinolines with formic acid 
 
      Inspired by Reuping’s work on organocatalytic reduction of 
quinolines
22
 (vide infra), Zhou and co-workers in 2007 introduced 
Hantzsch esters to replace H2 as hydrogen source, realising ATH of 
quinolines under mild conditions.
23
 By comparison to the results obtained 
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with hydrogen gas, compromised enantioselectivities were obtained in 
this case for 2-alkyl quinolones and this system proved less effective for 
2-aryl substrates (Scheme 10). 
 
Scheme 10: Ir-catalysed ATH of quinolines with Hanzsch ester 
      In 2010, the same group described the first AH example using 
water/silane as hydrogen source and this method has been successfully 
applied to the ATH of quinolines to tetrahydroquinolines in good yield 
and enantioselectivity (Scheme 11).
24
 The deuteration experiments 
implied that two hydrides in the hydrogenation of quinolines come from 
silane and another two are contributed by water.    
 
 
Scheme 11: Ir-catalysed ATH of quinolines with water/silane 
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      In 2012, Gong and co-workers reported an extremely active 
system for the ATH of 2-arylquinolines using an in situ formed gold 
phosphate complex from sterically demanding phosphate 5.
25
 With a 
Hanzsch ester as hydrogen donor, only 0.01 mol % of such catalyst is 
sufficient to reduce 2-arylquinolines in excellent yields and 
enantioselectivities (Scheme 12). The 10000 TON represents the best 
catalytic efficiency in ATH of quinolines, resulting from the tuning of the 
achiral ligand. However, decreased conversion and poor 
enantioselectivity was observed for 2-alkyl quinolines.  
 
Scheme 12: Au-catalysed ATH of quinolines with Hantzsch ester 
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1.2.1.2 TH of quinolines by organocatalysts 
      In the past decade, biomimetic, metal-free transformations using 
Brønsted acids as organocatalysts have attracted much attention in the 
synthetic community,
26
 as a result of arising environmental concerns and 
sustainability issues. In 2006, Reuping and co-workers extended their 
Brønsted acid catalysed TH of imines to N-heterocycles employing 
Hantzsch esters as hydrogen source.
27
 After screening various Brønsted 
acids, diphenyl phosphate (DPP) was found to be the most efficient 
organocatalyst to reduce a set of quinolines to tetrahydro products. As can 
be seen in Scheme 13, 1 mol % of DPP is sufficient to smoothly catalyse 
the reduction of quinolines possessing a range of functionalities. Better 
activities were observed when the reduction was carried out in non-polar 
solvents, such as benzene, toluene, dichloromethane and chloroform, 
which were also essential for higher asymmetric induction (vide infra).    
 
                                                   Chapter 1 
 
 
 
21 
 
 
Scheme 13: Organocatalysed TH of quinolines 
 
After successfully demonstrating the ATH of imines catalysed by chiral 
Brønsted acids and the observation of high activity with quinolines, it 
became a natural extension for Reuping and co-workers to apply the 
same asymmetric system to enantioselective hydrogenation of quinolines, 
which would represent the first example of organocatalysed reduction of 
heteroaromatic compounds.
22
 It would also allow the prompt preparation 
of optically pure 1,2,3,4-tetrahydroquinolines under metal-free conditions. 
Based on their previous work of ATH of imines, optimised conditions for 
ATH of quinolines were quickly identified after systematic examination 
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of the reaction parameters. As can be seen in Scheme 14, the chiral 
sterically congested phosphoric acid 6 based on the BINOL backbone 
emerged as the best catalysts for hydride transfer with the Hanzsch esters, 
affording excellent enantioselective induction, which was in agreement 
with the ATH of imines. Good yields and excellent ee values were 
obtained for the reduction of 2-arylquinolines using 1-5 mol % catalyst, 
while slightly diminished enantioseletivities were observed for the 
reduction of 2-alkyl substrates.  
 
                                                   Chapter 1 
 
 
 
23 
 
 
Scheme 14: Organocatalysed ATH of quinolines 
 
     As shown in Figure 5, the key feature of the proposed mechanism 
starts with the formation of a tight ion pair, the iminium ion H, between 
the chiral Brønsted acid and quinoline, followed by the hydride transfer 
from the dihydropyrine to the pronated quinoline to give the pyridium 
salt and enamine I. Reacting with the Brønsted acid, such enamine 
undergoes isomerisation in the second cycle to produce iminium J. This 
iminium was then reduced by the hydride from the Hantzsch ester to 
generate chiral 1,2,3,4-tetrahydro product K. In both cycles, final proton 
transfer regenerates the chiral Brønsted acid by releasing Hantzsch 
pyridine as byproduct. 
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Figure 5: Proposed mechanism for organocatalysed ATH of quinolines 
 
      Du and co-workers next examined the same reaction by using 
elegantly defined chiral phosphoric acid 7 derived from bis-BINOL 
unit.
28
 Comparable enantioselectivities and better yields were obtained 
                                                   Chapter 1 
 
 
 
25 
 
for the ATH of 2-substituted quinolines with considerably lower catalyst 
loading (0.2 mol %). It is worth mentioning that 2,3-disubstituted 
quinolines were also hydrogenated in good to excellent 
diastereoselectivities and enantioselectivities (Scheme 15).  
 
 
 
Scheme 15: Organocatalysed ATH of 2- and 2,3-substituted quinolines 
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      In comparison with 2-substituted quinolines, 3-substituted 
quinolines are problematic substrates for asymmetric hydrogenation and 
successful examples are rare. In 2008, Reuping and co-workers reported 
that 3-arylquinolines could be enantioselectively hydrogenated for the 
first time using a H8-BINOL derived phosphate 8 bearing a triphenylsilyl 
substituent as catalyst in high yields and ee values (Scheme 16).
29
 In 
sharp contrast to the ATH of 2- or 4-substituted quinolines, in which 
chiral Brønsted acid catalyses an enantioselective hydride addition to the 
iminium intermediates, the Brønsted acid in this case plays a key role in 
catalysing an enantioseletive protonation process via a 
hydride-proton-hydride transfer cascade in the ATH of 3-substituted 
quinolines (Scheme 16).    
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Scheme 16: Organocatalysed ATH of 3-substituted quinolines 
      Inspired by biological reactions, the same group later realised the 
first example of Brønsted acid catalysed asymmetric reduction using 
water as sole reaction medium, employing the principle of hydrophobic 
hydration.
30
 Under careful scrutiny, both sterically demanding phosphoric 
acid and Hantzsch ester were found to be essential for the best 
enantioselctivity. Sodium chloride was found to slightly enhance the 
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enantioselectivities. Compared to their early work using benzene as 
solvent, the use of aqueous medium in this process exhibits an ideal and 
ecologically sound system while maintaining the activity and 
enantioselctivity obtained in their previous work (Scheme 17).    
     
 
Scheme 17: Organocatalysed ATH of quinolines in water 
 
      In 2011, the same group expanded their ATH of N-heterocycles 
catalysed by chiral phosphoric acid to more challenging and/or 
so-far-ignored 4-substituted quinolines.
31
 Before this work, there 
appeared no direct asymmetric reduction routes available to prepare 
chiral 4-substituted-1,2,3,4-tetrahydroquinolines. A diverse collection of 
4-alkyl and 4-arylsubstituted quinolines were transfer-hydrogenated by 
using the phosphoric acid 8 and Hanzsch ester reduction system, leading 
to the corresponding optically active 4-substituted tetrahydro analogues 
in good yields and high enantioselectivities (Scheme 18). 
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Chloro-containing quinolines were found to be more efficient substrates 
with higher yields and ee values obtained, presumably for the reason that 
the presence of chloro atom enhances the electrophilicity of the substrates 
allowing easier hydride attack.    
 
Scheme 18: Organocatalysed ATH of 4-substituted quinolines 
 
1.2.2 TH of isoquinolines  
      In comparison with TH of quinolines, other N-heterocycles 
including isoquinolines, quinoxalines, pyridines, indoles, etc, have been 
much less investigated. One of the reasons is that these compounds have 
stronger aromaticity than quinolines, and therefore require increased 
activation either of catalysts or substrates. In 1990, Joule reported the 
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first TH of N-heterocycles by employing ammonium formate as hydrogen 
source and Pd/C as catalyst.
12
 Moderate yields could be obtained for 
quinolines; however, it is less efficient for isoquinolines, as can be seen in 
Scheme 19. 
 
 
Scheme 19: Pd-catalysed TH of isoquinolines with HCOONH4 
 
      Crabtree and co-workers have reported a rhodium-catalysed mild 
hydrosilylation of isoquinoline using silane as hydrogen source and by 
subsequent basic work-up, obtained tetrahydroisoquinoline as the major 
product (Scheme 20).
17
 Key to this mild reduction was ascribed to the 
presence of highly active SiH4 which was generated from initial in situ 
disproportionation of PhSiH3 to Ph2SiH2 and SiH4 catalysed by the same 
catalyst. 
 
Scheme 20: Rh-catalysed hydrosilylation of isoquinolines 
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      In 2006, Deng described [Cp*RhCl2]2 catalysed TH of quaternary 
isoquinoline salts, an activated form of isoquinolines, using formic acid 
as hydrogen source under mild conditions. A range of 
N-alkyl-1,2,3,4-tetrahydroisoquinolines including naturally occurring 
products were obtained in good to excellent yields (Scheme 21).
32
 Like 
the Pd-catalysed TH, debromination was also observed in this system; but 
nitro groups were tolerated.  
 
Scheme 21: Rh-catalysed TH of isoquinolinium salts 
1.2.3 TH of quinoxalines  
As shown in Scheme 1, the HCOOH-RuCl2(PPh3)3 system developed by 
Watanabe and co-workers in 1984, could be used to transfer-hydrogenate 
quinolines in good yields.
10
 Such system also finds utility in TH of more 
challenging quinoxalines in good yield and high selectivity (Scheme 22). 
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However, just one example was reported.  
 
Scheme 22: Ru-catalysed TH of quinoxalines with HCOOH 
 
      In 2010, Wills and co-workers revealed that the tethered 
Ru-diamine complex 3 is an efficient catalyst for the TH of quinolines 
using HCOOH-Et3N as hydrogen source,
21
 as shown in Scheme 9. When 
a quinoxaline was subjected to the TH system, however, poor conversion 
was obtained (Scheme 23).  
 
Scheme 23 Ru-catalysed TH of quinoxalines with HCOOH-NEt3 
      During the ATH of quinolines using water/silane as hydrogen 
donor,
24
 Zhou and co-workers also applied the conditions to 2-substituted 
quinoxalines, which were reduced to tetrahydroquinoxalines in good 
yields and moderate enantioselectivities (Scheme 24). 
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Scheme 24: Ir-catalysed TH of quinoxalines with water/silane 
 
      Inspired by the effect of solution pH on the TH of quinolines in 
water, Xu and co-workers found that a simple Ir-TsEN (TsEN = tosylated 
ethylene diamine) system is highly efficient for the TH of quinoxalines 
using aqueous formate as reducing agent.
33
 A number of quinoxalines 
were reduced to the corresponding tetrahydro products in good to 
excellent yields (Scheme 25). Functional groups such as halides, nitro 
and conjugated alkene were observed to be well tolerated in this TH 
system. The HOAc/NaOAc buffer solution was found essential for good 
conversions by suppressing the pH fluctuation to maintain optimal pH 
during the entire reduction process. The ATH of quinoxalines was 
attempted by replacing TsEN with chiral TsDPEN which was successfully 
used in ATH of quinolines, only 3% ee value was obtained for the 
reduction of 2-methylquinoxaline, although the TH was still fast with full 
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conversion obtained in 2 h.  
 
Scheme 25: Ir-catalysed TH of quinoxalines with formate in water 
 
      In 2010, Reuping and co-workers extended their organocatalytic 
TH of N-heterocycles to the prepration of chiral tetrahydroquinoxalines.
34
 
Employing a chiral BINOL phosphate as catalyst and Hantzsch esters as 
reducing agent, various 2-arylquinoxalines were reduced in good to 
excellent yield and enantioselectivity, which reprents the first example of 
highly enantioselective TH of quinoxalines (Scheme 26). Compared to 
the organocatalysed ATH of quinolines, the reduction of quinoxalines 
requires higher catalyst loading (10 mol %), and electron deficient 
substituents were found to enhance the enantioselectivities. 
                                                   Chapter 1 
 
 
 
35 
 
 
 
Scheme 26: Organocatalysed ATH of quinoxalines with Hantzsch esters 
1.2.4 TH of pyridines  
      In comparison with benzo-fused N-heterocycles such as 
quinolines, isoquinolines and quinoxalines, monocyclic pyridines have 
much stronger aromatic stability and successful reduction often requires 
harsh conditions or pre-activated pyridines as substrates in order to 
overcome their inactive nature. As a result, there are only two examples 
reported for the TH of pyridines. One example was described by Frediani 
and co-workers in 2006 with a Rh-bipyridine catalyst and using IPA as 
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hydrogen donor.
15
 Only two substrates were examined, which showed 
poor to moderate conversions (Scheme 27). 
 
 
Scheme 27: Rh-catalysed TH of pyridines with IPA 
 
      In 2007, Reuping and co-workers disclosed the first example of 
ATH of pyridine derivatives adopting catalytic amount of a chiral 
phosphate and using Hantzsch esters as hydrogen source.
35
 Several 
pyridines were partially reduced to the tetrahydropyridine products in 
moderate to high yields and moderate to good enantioselectivities 
(Scheme 28). The presence of EWG in the pyridine ring is crucial for the 
activity, enabling an easier 1,4-hydride addition.  
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Scheme 28: Organocatalysed ATH of pyridines with Hantzsch esters 
 
1.2.5 TH of indoles 
      In the 1970’s, the use of formic acid as reducing agent attracted 
significant attention due to its use in deprotection reactions in the 
presence of palladium black in peptide synthesis. In 1982, Kikugawa and 
co-workers found that the tryptophanyl unit was reduced to its 
2,3-dihydro analogue in 7% yield by using HCOOH-Pd system during 
the study of deprotection of the tryptophan-containing peptide. By 
increasing the temperature, a variety of indolines and their formylation 
products were obtained from TH of the corresponding indoles in 
reasonable to high yield,
36
 as can be seen in Scheme 29. Formic acid 
served as hydrogen donor as well as activator by protonating the indole to 
form an iminium salt intermediate before reduction. The formylation was 
found to be enhanced when ammonium formate was introduced as 
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co-reductant. Given the inert nature of unprotected indoles, and the 
convenience of hydrolysis of formyl group, this method could be used as 
a practicable alternative for the preparation of indolines.  
 
Scheme 29: Pd-catalysed TH of indoles with HCOOH 
      Two years later, the homogeneous catalyst RuCl2(PPh3)3 was used 
to reduce indoles by Watanabe and co-workers during their extensive 
investigations on the TH of nitroarenes and N-heteroaromatic 
compounds.
10
 Moderate conversions were obtained for two examples of 
indoles (Scheme 30).  
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Scheme 30: Ru-catalysed TH of indoles with HCOOH 
 
      In 2008, Crabtree and co-workers observed that 
rhodium-catalysed hydrosilylation of indoles followed by simple 
hydrolysis could afford indolines in high yield (Scheme 31).
17  
 
 
Scheme 31: Rh-catalysed hydrosilylation of indoles 
 
1.2.6 TH of other N-heteroaromatics  
      In 2008, Crabtree and co-workers realised the first example of TH 
of pyrazine using [Ir(COD)(NHC)(PPh3)]BF4 as catalyst and IPA as 
hydrogen donor (Scheme 32).
17 
Although only one example was 
demonstrated, the full reduction observed for the inert pyrazine was still 
very encouraging. 
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Scheme 32: Ir-catalysed TH of pyrazine with IPA 
 
      In 2008, Metallinos and co-workers reported the Brønsted 
acid-catalysed ATH of 1,10-phenanthrolines using HEH as hydrogen 
source.
37
 2-Substituted and 2,9-disubstituted 1,10-phenanthrolines were 
successfully reduced although undesired partially reduced products were 
observed in a significant degree. While the reduction of 2-substituted 
variants occurred with poor yields but good enantioselectivity, excellent 
ee values were obtained for 2,9-dialkylsubstituted 1,10-phenanthrolines, 
albeit with poor diasteroselectivities (Scheme 33). 
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Scheme 33: Organocatalysed TH of phenanthrolines 
 
1.3 Conclusion and aims of the thesis 
      In the past several decades, the use of organic molecules, rather 
than H2, as hydrogen donors in TH, has offered viable benefits for 
modern organic synthesis particularly in small or medium-scale processes. 
Appling hydrogen transfer strategy to the reduction of N-heteroaromatic 
compounds leads to the development of a number of efficient TH and 
ATH systems as a powerful complement to the well-established 
hydrogenation and emerging AH. Various N-heteroaromatics, such as 
quinolines, isoquinolines, quinoxalines, indoles and pyridines, could be 
transfer-hydrogenated to the corresponding saturated N-heterocycles with 
the help of many well-defined catalysts. As can be seen in Section 1.2, 
there are several systems currently available for the efficient TH of 
N-heteroaromatics affording multiple choices to rapidly access saturated 
N-heterocycles, particularly in their optically pure forms, which was 
almost impossible to imagine just ten years ago. By comparison with 
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hydrogenation with H2, however, catalyst loadings for both 
heterogeneous and homogeneous TH are still relatively high (>1%), 
although gold catalysed ATH afforded comparable efficiency for some 
types of quinolines at 0.01% loading. Furthermore, the current ATH 
systems are restricted mainly to quinolines and quinoxalines, while the 
progress in more challenging substrates, such as isoquinolines, indoles 
and pyridines, has been sluggish. In addition, Hantzsch esters, which are 
expensive hydrogen donors (£43/gram for Et-HEH, £65/gram for 
t
Bu-HEH, £1840/gram for Me-HEH) and of low hydrogen content 
(<0.8%), were predominantly used in highly enantioseletive hydrogen 
transfer systems, whilst much cheaper hydrogen sources, such as formic 
acid and IPA with much higher hydrogen content (>3.2%), have been less 
explored. Moreover, organocatalysed ATH commonly favors the 
aryl-substituted N-heteroaromatics while transition-metal catalysed ATH 
prefers the alkyl-substituted substrates. Therefore, general, efficient and 
economical TH and ATH methods for the reduction of N-heteroaromatics 
are still desirable.   
      The main aim of this thesis is to develop more efficient TH and 
ATH systems for N-heteroaromatics reduction. Chapter 2 reports a new 
protocol for the mild reduction of quinolines, isoquinolines and 
quinoxalines to corresponding tetrahydro products. The most important 
                                                   Chapter 1 
 
 
 
43 
 
discovery is the remarkable accelerating effect of the simple iodide ion, 
presumably by altering the reaction mechanism. Chapter 3 extends the 
above-mentioned system to the reduction of more challenging pyridines 
to afford not only piperidines but also the 3,4-unsaturated variants with 
high chemoselectivities. Chapter 4 presents a simple, complementary 
system, discovered during attempts to search for new TH catalysts, to 
hydrogenate N-heteroaromatics with H2  using a cyclometalated iridium 
complex under mild conditions (ambient temperature, 1 atm H2) without 
using any additives. Chapter 5 demonstrates a new reaction for the rapid 
preparation of various chiral piperidines from pyridines with high yields 
and exceptional diastereo- and enantioselectivities. Key to the reaction is 
the addition of a chiral amine which is incorporated into the pyridine ring 
by transamination during the TH process, presumably forming previously 
unobtainable chiral tetrahydropyridinium intermediate in situ.  
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2.1 Introduction 
 
      Among a variety of heteroaromatics, 1,2,3,4-tetrahydro- quinolines, 
isoquinolines and quinoxalines are three important sub-motifs in 
numerous natural products, pharmaceuticals, agrochemicals, dyes and 
fragrances.
1
 Examples are found in the naturally occurring alkaloids 
galipinine,
2
 augustureine
2b, 3
 and salsolidine,
4
 the anthelmintic drug 
oxamniquine,
5
 antiprotozoal and vomit-inducer emetine,
6
 and a 
cholesterylester transfer protein (CETP) inhibitor (Figure 6). 
7
 
 
Figure 6: Examples of tetrahydro quinolines, isoquinolines and quinoxalines 
 
      A great deal of attention has been paid to the synthesis of these 
compounds in both industry and academia. Considering the fact that 
many quinolines, isoquinolines and quinoxalines are commercially 
available, and there are many synthetic methods reported, their reduction 
would provide a general and direct method for the preparation of the 
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corresponding tetrahydro heterocycles. Traditionally, stoichiometric 
metal hydrides such as NaBH4 or NaBH3CN are used as reducing 
reagents in the presence of Lewis or Brønsted acids (Eqs. 2 and 3). 
Reactive metal reagents such as Na, Ni-Al alloy (Eqs. 4 and 5) and 
indium have also been used for this purpose.
8
 Apart from producing 
copious waste and using often hazardous reagents, these methods suffer 
from limited substrate scope, incompatibility with functionality and poor 
chemoselectivity.  
 
      A more attractive method is to use catalytic hydrogenation. Over the 
past several decades, numerous homogeneous and heterogeneous 
catalysts mainly based on Pt, Pd, Rh, Ru, Ir, Mo and Fe have been 
applied to the hydrogenation of heteroaromatics, including the 
asymmetric versions (Scheme 34).
9-13
 The need for high catalyst loading 
and harsh conditions such as high H2 pressure or high reaction 
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temperature, which limits the potential from industrial application, is 
often found for metal-catalysed hydrogenation.  
 
Scheme 34: Hydrogenation of quinolines with H2 
      Obviating the need for hydrogen gas, which usually requires the use 
of specialised equipment, transfer hydrogenation (TH) offers an 
alternative by using isopropanol (IPA) or formate compounds.  However, 
only a very few catalysts have been reported so far that allow for the TH 
of heteroaromatics, and in all cases the catalyst loading is relatively high 
(≥0.5 %).14 Furthermore, in either hydrogenation or TH, there appears to 
be no single catalyst capable of reducing all three classes of 
heteroaromatics: quinolines, isoquinolines and quinoxalines. This is not 
surprising, as all these compounds bear a stable aromatic system which 
appears difficult for general TH systems to reduce. Thus, a general, 
efficient and mild method for TH of these heteroaromatics is highly 
desirable. 
     Our group recently reported the first example of asymmetric transfer 
hydrogenation (ATH) of quinolines in water with formate as the 
hydrogen source.
14f 
Excellent enantioselectivities and yields for a variety 
of quinolines including some problematic substrates were obtained with a 
Rh-TsDPEN catalyst 2, [Cp*RhCl(TsDPEN)]
15
 (TsDPEN = N-(p-
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toluenesulfonyl)-1,2-diphenylethylenediamine)
16
 under buffered aqueous 
conditions (Scheme 35). Further N-alkylating the products can afford 
chiral N-alkyl tetrahydroquinolines which structurally exist in many 
natural alkaloids (see Figure 1). The N-alkylation step is generally 
achieved by substitution with alkyl halides or reductive amination with 
aldehydes, which would afford a range of potentially bioactive analogues 
of the above-mentioned naturally occurring alkaloids.
2, 3 
However, it 
would be interesting if it were possible to carry out ATH of quaternary 
quinoline salts so that chiral N-alkylated tetrahydroquinolines could be 
obtained directly. 
 
Scheme 35: ATH of quinolines in water 
       
2.2 Results and Discussion 
2.2.1 Discovery and further optimisation of reaction conditions  
      Like other common quaternary amines, N-alkylated quinolinium salts 
can be quantitatively formed by alkylation of neutral quinolines with 
alkyl halides. We chose the N-methyl-2-methylquinoline iodide salt 14a 
as a benchmark substrate which can be readily prepared by alkylation of 
quinaldine with iodomethane. The model quaternary quinoline salt along 
with other substrates was purified simply by filtration and washing with 
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acetone. The Rh-TsDPEN which was successful for ATH of neutral 
quinolines was used as the catalyst (1 mol %). However, there was little 
reduction using sodium formate as the reductant in water at 40 °C in 24 h, 
under which condition quinolines were readily reduced.
14f 
This was really 
a surprise as we believe that the quaternary form of quinoline, which is an 
activated form of quinoline, should be much easier to reduce. Bearing in 
mind the fact that the catalyst was dissolved in the top oily quinoline 
phase of an aqueous-organo biphasic system, we thought that the lack of 
reactivity for the aqueous-soluble quinoline iodide salt might be the result 
of insolubility of the catalyst in that system. This assumption was later 
proved correct. As can be seen in Scheme 36, by introducing THF as co-
solvent, 14a was successfully reduced to the corresponding N-methyl 
tetrahydro quinoline with a 69% yield. However, the product was almost 
racemic. We then wondered if the existence of stoichimetric iodide ion 
was adverse to the enantioselectivity. It was surprising to find that the ee 
value could be significantly improved to 73% by using N-methyl-2-
methylquinoline SbF6
-
 salt 14b as substrate. The isolated yield also 
increased to 84%. The SbF6 salt can be readily prepared by abstraction of 
iodide ion from the iodide substrate with AgSbF6 driven by the 
precipitation of AgI. Other weakly coordinating anions BF4
-
, PF6
-
, 
SO3CF3
-
 based salts were found to be efficient substrates as well, 
affording 53-76% ee values while maintaining the good yield. However, 
the cost of using stoichimetric silver salt as halide scavenger limits the 
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potential application of this method. Therefore, we did not continue the 
effort for further optimisation of the system. 
 
Scheme 36: ATH of quaternary quinoline salts 
 
      Changing the aqueous formate to the azeotropic HCO2H/NEt3 (ratio 
2.5:1.0) mixture led to an excellent isolated yield of 95% but a very low 
ee value of 5% for the tetrahydro product. Somewhat surprisingly, by 
using the SbF6
-
 salt as substrate, the reduction was totally inhibited under 
azeotropic HCO2H/NEt3 conditions (Scheme 36), which demonstrated the 
necessity of iodide ions for the reduction under such conditions. 
Noteworthy is that similar conversion was also observed under identical 
conditions with [(Cp*RhCl2)2] as catalyst, without adding the TsDPEN 
ligand (Scheme 37).  
 
Scheme 37: TH of quaternary quinoline salts 
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       Considering the significant impact on enantioselectivity when using 
weakly coordinating anion salts as substrates, we realised that the low ee 
value might result from the diamine ligand in Rh-TsDPEN being replaced 
by the iodide anion in the salt during the reaction. It would not be a 
surprise for the iodide replacement to happen as the concentration of 
iodide ion was 100 times greater than that of the Rh-TsDPEN catalyst 2.  
      Bearing in mind the unusual effects of iodide documented in 
catalysis
17
 and the scarcity of effective catalysts for TH of 
heteroaromatics,
14
 we thought it would be interesting to explore whether 
[(Cp*RhCl2)2] in combination with the iodide ion would lead to a simple 
but highly active catalytic system. With this hypothesis in mind, we 
chose 2-methylquinoline 12a (pKa 5.4) as a benchmark substrate, which 
is expected to be protonated when using formic acid (pKa 3.6) as the 
reductant. The TH was first carried out with 0.05 mol% [(Cp*RhCl2)2] in 
the azeotropic HCO2H/NEt3 at 40 °C. The reduction was insignificant, 
with only 6% yield of 2-methyl tetrahydroquinoline 13a obtained in 12 h 
(Table 1, entry 2), indicating that iodide might indeed be necessary for 
high conversion. To our delight, in the presence of 1 or even 0.1 
equivalent of an iodide salt, tetrabutylammonium iodide (TBAI), 12a was 
fully converted to 13a (Scheme 38 and Table 1, entries 3 and 4).  
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Scheme 38: Iodide-promoted TH of quinolines 
 
      In contrast, the analogous bromide salt TBAB is much less effective 
(Table 1, entry 5) and the chloride TBAC is ineffective for the 
acceleration of the reduction (Table 1, entry 6). The much cheaper 
potassium iodide KI, which is the most commercially available iodide 
source, was found equally effective for the TH, showing that it is the 
iodide anion, not the cation that promotes the catalysis (Table 1, entry 7). 
Remarkably, in the presence of KI, the metal loading could be further 
decreased to 0.01 mol % without affecting the conversion (Table 1, entry 
8). Such low metal loading is rare in TH of heteroaromatics. At an even 
lower loading of 0.001 mol % of rhodium with 0.5 equivalent of KI 
added, a moderate conversion of 71% was still obtained which shows the 
robust nature of this catalysis, albeit in a longer reaction time (Table 1, 
entry 9). It yields a turnover number close to 7.1× 10
4
 (Table 1, entry 10), 
which is, to the best of our knowledge, the highest TON value ever 
reported in catalytic reduction of heteroaromatics. It means that 10 moles 
of the Rh catalyst in the presence of KI can convert about 1 million moles  
Table 1. Effect of iodide on the TH of 12a.
[a] 
 
 
Entry 
Metal,
  
mol %
[b]
 
Time 
[h] 
Additive, 
equiv 
Conv. [%]
[c]
 
1 None 12 None NR 
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2 Rh, 0.1 12 None 6 
3 Rh, 0.1 12 TBAI, 1.0 100 
4 Rh, 0.1 15 TBAI, 0.1  100 
5 Rh, 0.1 15 TBAB, 0.1 42 
6 Rh, 0.1 15 TBAC, 0.1 8 
7 Rh, 0.1 15 KI, 0.1  100 
8 Rh, 0.01 12 KI, 0.2  100 
9 Rh, 0.001 48 KI, 0.5  71 
10 Ir, 0.01 12 KI, 0.2  <1 
11 Ru, 0.01 12 KI, 0.2  <1 
  12 RhCl3, 0.01 12 KI, 0.2 NR 
[a] Reaction conditions: 12a (0.5 mmol), HCO2H-NEt3 azeotrope (3 mL), 40 °C. 
[b] Rh = [Cp*RhCl2]2, Ir = [Cp*IrCl2]2 and Ru = [RuCl2(p-cymene)]2. [c] 
Conversion determined by 
1
H NMR of the crude reaction mixture and 
normalising the sum of the product and starting material integrals to 100%. NR 
= no reaction. 
 
of quinolines to their tetrahydro products. However, under similar 
conditions, other widely used metal catalysts, [Cp*IrCl2]2, [RuCl2(p-
cymene)]2 and RhCl3 for example, failed to catalyse the TH (Table 1, 
entries 10-12). 
 
2.2.2 Substrate scope  
      Having identified the optimized conditions, we subjected a variety of 
quinoline derivatives to the TH. As can be seen from Table 2, the 
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reduction affords good to excellent yields at 40 °C with 0.01-0.1 mol % 
catalyst. Notably, apart from the mild condition, the reaction can be 
carried out in air; degassing with N2 did not show any detectable 
difference in yield. The reaction is not sensitive to moisture as well.  
Quinolines bearing various alkyl substituents at the 2-position (12a-f), no 
matter of the length of the chain, proceeded successfully to give the 
corresponding hydrogenated products in excellent yields (Table 2, entries 
1-6). Delightedly, good to excellent yields were obtained for quinolines 
with bulky substituents at the 2-position (12g-k) (Table 2, entries 7-11), 
and in particular, 1,2,3,4-tetrahydro-2-tert-butylquinoline (13i) was 
obtained in 99% yield. In homogeneous hydrogenation, the best result 
previously reported for this substrate was 43% conversion after 48 hours, 
employing 2 mol % of a rhodium catalyst.
14g
 2,3-Disubstituted and 3-
substituted quinolines (12s, 12t and 12z) (Table 2, entries 19, 20 and 26) 
and acridine 12u can be smoothly reduced to 9,10-dihydroacridine 12u 
(Table 2, entry 21). It is noteworthy that the isolated C=C bond in 12v, 
which is often reduced in heterogeneous hydrogenation with molecular 
hydrogen, was well tolerated (Table 2, entry 22). A problem was 
encountered with the less basic 2-arylquinolines (12w-y) however, where 
good yields were only obtained with a higher metal and iodide loading as 
well as a longer reaction time (Table 2, entries 23-25). 4-Substituted 
quinolines proved problematic, affording very low conversion even with 
much higher catalyst loading (Table 2, entry 27). This appears to be in 
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agreement with the proposed mechanism starting the reduction from 1,4-
hydride addition (vide infra). 
 
Table 2. TH of quinolines with [Cp*RhCl2]2-KI in the HCO2H-NEt3 
azeotrope.
[a] 
 
Entry   Product    S/C
[b]
 
Time 
[h] 
 
 
 
Yield 
[%]
[c]
 
 
1 
 
    
  10000 
 
12  91 
 
2 
 
10000 15  93 
 
3 
 
10000 12  93 
  
4 
 
10000 15  96 
  
5 
 
10000 15  84 
  
                                                                                                                             Chapter 2 
 
60 
 
6 
 
10000 10  72 
  
7 
 
 
10000 15  91 
  
8 
 
10000 12  93 
  
9 
 
10000 15  99 
  
10 
 
10000 15  85 
  
11 
 
10000 11  96 
  
12 
 
10000 12  76 
  
13 
 
10000 12  74 
  
14 
 
10000 24  92 
  
15 
 
10000 12  83 
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16 
 
10000 24  73 
  
17 
 
10000 48  83 
  
18 
 
10000 15  89 
  
19 
 
10000 20  69 
  
20 
 
10000 12  95 
  
21 
 
5000 12  98 
  
22 
 
10000 24  71 
  
23 
 
1000 48  98 
  
24 
 
1000 48  98 
  
25 
 
1000 26  94 
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26 
 
 
5000 12  88 
  
27 
 
50 24  23
[d]
 
  
[a] Reaction conditions: 12 (0.5 mmol), [Cp*RhCl2]2 (0.025-5 µmol),  KI (0.1-
0.8 mmol), HCO2H-NEt3 azeotrope solution (3 mL), 40 °C, 12-48 h. [b] 
Substrate/catalyst molar ratio. [c] Yields of isolated products. [d]Conversion 
determined by 
1
H NMR of the crude reaction mixture and normalising the sum 
of the product and starting material integrals to 100%. 
 
      The more challenging quinoxalines and particularly isoquinolines 
were also attempted (Table 3). The latter has not been reduced, until now, 
to tetrahydroisoquinolines under TH due to their stable pyridine-like 
aromaticity. Higher catalyst loading was necessary for the reduction of 
some of these substrates, however. Thus, using 0.2 mol% rhodium 
loading, good to excellent yields were obtained for a range of 
tetrahydroisoquinolines (17a-d). This represents the lowest metal loading 
reported in any metal-catalysed hydrogenation of this class of substrates. 
For 2-methylisoquinoline 16c, satisfactory yields can only be obtained by 
adjusting the HCOOH/Et3N ratio from 2.5:1 to 3.5:1 (Table 3, entry 3), 
which demonstrated another parameter of the current system for potential 
optimisation. Excellent yields were also observed in the reduction of 
several commercially available quinoxalines (16e-i) (Table 3, entries 5-9) 
with as low as 0.02 mol % catalyst loading. The accelerating effect of 
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iodide was again noted. Thus, by control experiments, no reaction was 
observed in the TH of 16a and 16e when the iodide salt was omitted. 
 
Table 3. TH of isoquinolines and quinoxalines with [Cp*RhCl2]2-KI in 
HCO2H-NEt3.
[a] 
 
Entry Product S/C
[b]
 Time [h] Yield [%]
[c]
 
1 
 
 
500 24 83 
2 
 
500 24 95 
3
[d]
 
 
500 24    92 
4 
 
500 24 91 
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5 
 
5000 12 99 
6 
 
5000 12 86 
7 
 
5000 12 92 
8 
 
5000 12 90 
9 
 
500 24 91 
[a] Reaction conditions: 16 (0.5 mmol), [Cp*RhCl2]2 (0.05-0.5 µmol), KI (0.25 
mmol), HCO2H-NEt3 azeotrope solution  (3 mL), 40 °C, 12-24 h. [b] 
Substrate/catalyst molar ratio. [c] Yields of isolated products. [d] HCO2H/NEt3 
= 3.5/1.0. 
      To showcase the practicality of this protocol, we carried out the TH 
of 5 g of 12a with 0.01 mol % rhodium (1.0 mg). The reduction afforded 
13a in 97% isolated yield in 24 h at 40 °C (Scheme 39). 
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Scheme 39: TH of quinoline on gram scale 
 
2.2.3 Mechanistic investigations 
      The beneficial effect of iodide in asymmetric hydrogenation (AH) 
with H2 has been noted in a number of instances, though the mechanistic 
details remain to be delineated.
11a, m, 17a, 18
 In some proposed mechanisms, 
the presence of iodide, commonly as I2, which is proposed to oxidise a 
low valent metal, Ir(I) to Ir(III) for example, was demonstrated to 
enhance both reactivity and enantioselectivity.
11a
 The most well-known 
example is seen in the million tons production of (S)-metolachlor, an 
active ingredient of herbicide Dual Magnum
®
, which uses an Ir-Xyliphos 
catalyst in the presence of iodide for the AH of the imine intermediate.
19 
 
To the best of our knowledge, no examples of iodide effect in TH are 
known, however.  
      We therefore decided to take a further insight into the rate 
acceleration of TH of quinolines by iodide ion. Figure 7 shows the effect 
of iodide concentration [I
-
] on the conversion of 12a to 13a at 4.5 h in the 
HCO2H-NEt3 azeotrope. A dramatic increase in the reaction rate was 
noted when [I
-
] was increased, up to 20 or 50 mol % of 12a; thereafter the 
reaction rate decreased with more iodide added, suggesting that the 
iodide is involved in the turnover limiting step or steps prior to this step. 
This hypothesis finds support from the conversion-time profiles of TH of 
12a shown in Figure 8, obtained by using catalysts [Cp*RhCl2]2, 
[Cp*RhI2]2, and [Cp*RhCl2]2 in the presence of 20 mol% KI (1 mol % 
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rhodium in each case). Clearly, the iodo-dimer [Cp*RhI2]2 catalysed 
significantly faster TH than its chloro analogue [Cp*RhCl2]2. More 
 
 
 
 
 
 
 
 
Figure 7: Effect of the concentration of iodide on the transfer hydrogenation of 
12a (0.5 mmol) catalysed by [Cp*RhCl2]2 (0.05 mol %). Reactions were carried 
out in the HCO2H-NEt3 azeotrope (3 mL) for 4.5 h at 40 ℃. 
 
interestingly, the kinetics for these two catalysts appears distinctively 
different. With the chloro catalyst, the reduction appears to be zero order 
in the concentration of 12a which means decreasing [12a] during the 
reaction does not decrease the reaction rate. However, in the case of the 
iodo catalyst, the profile suggests a rate dependence on [12a]. Decreasing 
[12a] as the reaction proceeds decreases the rate. In the presence of 
excess I
-
 (20 mol % KI), the reduction became faster still, with the initial 
rate being ca 7 times that obtained with [Cp*RhI2]2 and ca 40 times that 
with [Cp*RhCl2]2 alone! These results suggests that in the presence of 
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excess I
-
, an active Cp*Rh-iodo catalyst is generated in situ from 
[Cp*RhCl2]2. The presence of excess I
- 
alters the hydrogenation kinetics, 
with the turnover rate limited by hydride formation with [Cp*RhCl2]2 but 
more likely by hydride transfer when iodide is added.  
 
 
 
 
 
 
 
 
 
Figure 8: Effect of iodide anion on the transfer hydrogenation of 12a (0.8 
mmol ) catalysed by [Cp*RhX2]2 (0.05 mol %) (■ X = Cl, ● X = I, ▲ X = Cl 
plus 20 mol% KI). Reactions were carried out in the HCO2H-NEt3 azeotrope (5 
mL) at 40 ℃. 
      A plausible mechanism is shown in Scheme 40. The key feature of 
the mechanism is that the substrate, which is most likely to be protonated 
under the acidic conditions, is reduced by an anionic diiodo Rh-H, 
probably via a 1,4-addition pathway as indicated by deuterium labelling. 
As shown in Figure 9, when using DCOOH-NEt3, full deuteration at the 
C2 and C4 position of 2-methylquinoline 12a took place. This is 
consistent with a 1,4-hydride addition pathway, in which the 
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hydride/deutride is first added to the C4 position of protonated 12a, 
affording an enamine which isomerises into an iminium species under the 
acidic condition. Finally, addition of a second hydride/deutride at the C2 
leads to the product observed. In support of this, 4-methyl quinolone was 
much more difficult to reduce, showing a 23% conversion of 13aa at S/C 
= 50 and 50 mol % KI after 24 h reaction time (see Table 2, entry 27). 
The anionic charge is quite likely to make the hydride more hydridic, and 
this would be reinforced by the stronger bonding of the soft iodide to 
Rh(III) and its stronger “trans effect” than the hard chloride,20 facilitating 
hydride transfer to the protonated substrate.
  
Increasing [I
-
] increases the 
concentration of the hydride and hence the rate; however, when [I
-
] 
becomes too high, the equilibrium shown in Scheme 40 will favor the  
triiodo species formation, decreasing the concentration of active catalyst 
and so the rate. Therefore, a maximum is expected in the conversion-[I
-
] 
profile seen in Figure 7.  
 
 
Scheme 40: A possible mechanism for the Cp*Rh(III)-catalysed hydrogenation 
of quinoline promoted by iodide 
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Figure 9: Deuteration experiment of iodide-promoted transfer hydrogenation of 
12a catalysed by [Cp*RhCl2]2. (A) with HCOOH-NEt3 azeotrope; (B) with 
DCOOH-NEt3 azeotrope. 
 
2.3 Conclusions and future work     
 
      We have developed a new protocol for the reduction of quinolines, 
isoquinolines and quinoxalines under mild conditions (Scheme 41). The 
most significant discovery is the remarkable accelerating effect of the 
simple iodide ion, which accelerates the TH, presumably by altering the 
reaction mechanism. The reduction is air and moisture stable, practical 
and operationally simple, providing a valuable alternative to currently 
used methods for heterocycle reduction. This protocol can efficiently 
reduce a range of N-heteroaromatics including 2-, 3-, 6-, 7-substituted, 
2,3-disubstituted quinolines, 1-, 3-, 6-substituted isoquinolines and 2-, 5-, 
6-substituted quinoxalines .  
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Scheme 41: Summary of iodide-promoted TH of heteroaromatics 
 
      However, for the quinolines bearing a functional group at the 2 or 8 
position and 4-substituted, the reaction either became very sluggish or 
was almost completely inhibited. Future work may focus on the 
application of this iodide-promoted, highly active reduction system to 
more challenging N-heterocycles, such as pyridines and pyrazines, 
affording industrially valuable piperidines and piperazines. Searching a 
more structurally rigid chiral catalyst, which may tolerate excessive 
iodide ion, could lead to ATH with much lower catalyst loading than 
currently reported asymmetric systems. 
2.4 Experimental  
 
2.4.1 General information 
      Unless otherwise specified, the chemicals were obtained 
commercially from Aldrich, Alfa Aesar or TCI and used without further 
purification. Silica gel plates (GF254) were used for TLC monitoring and 
silica gel (230-400 mesh) was used for running column chromatography. 
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2-Methylquinoline 12a was purchased from Aldrich and purified by flash 
column chromatography. Formic acid-triethyl amine azeotrope was 
distilled prior to use. NMR spectra were recorded on a Bruker 400 MHz 
NMR spectrometer with TMS as the internal standard. The mass spectra 
were obtained by chemical ionization (CI). Quinolines 12b-k, 12r-t, and 
12v-y were prepared according to the literature.
21a
 The NMR and 
elemental analysis data for the synthesized [Cp*RhI2]2 were consistent 
with related literature.
21b
 HPLC analysis was performed on Gilson 
UV/VIS-151 equipped with an OJ column purchased from Daicel 
Chemical Industries. 
 
2.4.2 General procedure for TH of N-heteroaromatics 
      A carousel reaction tube containing a magnetic stirring bar and the 
[Cp*RhCl2]2 dimer (0.0155 mg, 0.025 μmol, measured using a stock 
DCM solution), 2-methylquinoline (12a, 72 mg, 0.5 mmol) and 
potassium iodide (17 mg, 0.1 mmol) in 5 mL HCOOH-Et3N azeotrope 
was sealed without degassing and placed in a carousel reactor. The 
reaction mixture was stirred at 40 
°
C for the time indicated, cooled to 
room temperature and then basified with an aqueous solution of KOH. 
The resulting mixture was extracted with ethyl acetate (3×5 mL) and 
dried over Na2SO4. The solvent was removed under reduced pressure, 
and the product was purified by flash column chromatography using 
hexane/ethyl acetate as eluant. For substrates 13a, 17e and 17i, further 
hydrolysis of the N-formyl byproducts were performed under the 
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following condition according to the literature:
21c 
An aqueous solution of 
18 (crude, about 0.5 mmol) in 20% NaOH (5 mL) was stirred under 
reflux (110 
°
C) for 5 h. After cooling, the mixture was extracted by ethyl 
acetate (3×5 mL) and dried over Na2SO4. The solvent was removed under 
reduced pressure before 
1
H NMR analysis of the residue oil, which 
showed 18 was fully converted to 13a. For substrates 13z, 17a-17d, 17f-
17h, hydrolysis of corresponding N-formyl byproducts were done under 
the following condition according to the literature:
21d 
A 10% NaOH 
aqueous solution was introduced to a stirring crude mixture resulting 
from above substrates in 5 mL EtOH, the mixture was heated under the 
temperature and time indicated. The cooled mixture was extracted with 
ethyl acetate (3×5 mL) and dried over Na2SO4. The solvent was removed 
under reduced pressure, and the product was purified by flash column 
chromatography using hexane/ethyl acetate or dichloromethane/methanol 
as eluant.  
 
2.4.3 Deuteration experiments     
      In a carousel reaction tube containing a magnetic stirring bar was 
charged [Cp*RhCl2]2 dimer (1.3 mg, 0.002 mmol), 2-methylquinoline 
12a (41 mg, 0.27 mmol) and potassium iodide (17 mg, 0.1 mmol). The 
pre-prepared DCOOH-Et3N mixture (DCOOH, 5 mmol, 0.20 mL; Et3N, 
2 mmol, 0.28 mL) was then introduced into the reaction tube, which was 
placed in a carousel reactor. The reaction mixture was stirred at 40 
°
C for 
3 h and TLC indicated that the reaction was finished. After cooling to 
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room temperature and basifying with an aqueous solution of K2CO3, the 
resulting mixture was extracted with ethyl acetate (3×5 mL) and dried 
over Na2SO4. The solvent was removed under reduced pressure, and the 
residue was purified by flash column chromatography to afford the pure 
product 13a (27 mg), which was then analysed by 
1
H NMR. 
1
H NMR 
analysis showed indicates full deuteration at the C2 and C4 of 2-
methylquinoline. 
 
2.5 Analytical data of isolated products 
 
      All analytical data are in agreement with those previously reported in 
the literature, which is referenced accordingly. 
2-Methyl-1,2,3,4-tetrahydroquinoline (13a):
14f
 TH of 12a: 
for 0.5 mmol (72 mg) scale, 91% isolated yield and full conversion in 12 
h, 20 mol % KI, S/C = 10000; for 33.7 mmol (5.00 g) scale, 97% isolated 
yield and full conversion in 24 h, 20 mol % KI, S/C = 10000; 
1
H NMR 
(CDCl3, 400 MHz) δ (ppm): 6.96-6.93 (m, 2H), 6.59 (td, J = 7.4, 1.1 Hz, 
1H), 6.46 (dd, J = 8.4, 1.0 Hz, 1H), 3.43-3.36 (m, 1H), 2.87-2.79 (m, 1H), 
2.75-2.68 (m, 1H), 1.94-1.88 (m, 1H), 1.62-1.53 (m, 1H), 1.19 (d, J = 6.3 
Hz, 3H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 145.2, 129.7, 127.1, 
121.5, 117.4, 114.5, 47.6, 30.6, 27.0, 23.1; MS (CI, m/z, %) 148 (100) 
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[M+H]
+
;  Anal. calcd. for C10H13N: C, 81.59; H, 8.90; N, 9.51; Found: C, 
81.40; H, 8.94; N, 9.54. 
2-Ethyl-1,2,3,4-tetrahydroquinoline (13b):
14f
 93% 
isolated yield and full conversion in 15 h, 20 mol % KI, S/C = 10000; 
1
H 
NMR (CDCl3, 400 MHz) δ (ppm): 6.97-6.93 (m, 2H), 6.59 (td, J = 7.4, 
1.2 Hz, 1H), 6.48-6.45 (m, 1H), 3.71 (br, 1H), 3.16 (ddt, J = 12.8, 6.4, 3.3 
Hz, 1H), 2.85-2.69 (m, 2H), 1.99-1.93 (m, 1H), 1.63-1.48 (m, 3H), 0.98 (t, 
J = 7.5 Hz, 3H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 145.1, 129.6, 
127.1, 121.9, 117.3, 114.5, 53.5, 29.8, 28.0, 26.8, 10.5; MS (CI, m/z, %) 
162 (100) [M+H]
+
;  Anal. calcd. for C11H15N: C, 81.94; H, 9.38; N, 8.69; 
Found: C, 81.83; H, 9.42; N, 8.72. 
2-Propyl-1,2,3,4-tetrahydroquinoline (13c):
14f
 93% 
isolated yield and full conversion in 12 h, 20 mol % KI, S/C = 10000;
 1
H 
NMR (CDCl3, 400 MHz) δ (ppm): 6.96-6.93 (m, 2H), 6.58 (td, J = 7.4 , 
1.0 Hz, 1H), 6.45 (dd, J = 8.5, 1.2 Hz, 1H), 3.73 (br, 1H), 3.27-3.21 (m, 
1H), 2.84-2.68 (m, 2H), 1.98-1.91 (m, 1H), 1.63-1.54 (m, 1H), 1.50-1.36 
(m, 4H), 0.95 (t, J = 7.0 Hz, 3H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 
145.2, 129.7, 127.1, 121.8, 117.3, 114.5, 51.7, 39.3, 28.6, 26.9, 19.3, 14.7; 
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MS (CI, m/z, %) 176 (100) [M+H]
+
; Anal. calcd. for C12H17N: C, 82.23; 
H, 9.78; N, 7.99; Found: C, 82.15; H, 9.83; N, 8.00. 
2-Butyl-1,2,3,4-tetrahydroquinoline (13d):
14f
 96% 
isolated yield and full conversion in 15 h, 20 mol % KI, S/C = 10000;
 1
H 
NMR (CDCl3, 400 MHz) δ (ppm): 6.97-6.93 (m, 2H), 6.59 (td, J = 7.3, 
1.0 Hz, 1H), 6.47 (d, J = 8.2 Hz, 1H), 3.74 (brs, 1H), 3.23 (ddt, J = 9.4, 
6.4, 3.3 Hz, 1H), 2.85-2.69 (m, 2H), 1.99-1.92 (m, 1H), 1.64-1.54 (m, 
1H), 1.50-1.46 (m, 2H), 1.42-1.32 (m, 4H), 0.95-0.91 (m, 3H); 
13
C NMR 
(CDCl3, 100 MHz) δ (ppm): 145.1, 129.7, 127.1, 121.8, 117.5, 114.5, 
52.0, 36.9, 28.6, 28.4, 26.9, 23.3, 14.5; MS (CI, m/z, %) 190 (100) 
[M+H]
+
; Anal. calcd. for C13H19N: C, 82.48; H, 10.12; N, 7.40; Found: C, 
82.32; H, 10.14; N, 7.43. 
2-Pentyl-1,2,3,4-tetrahydroquinoline (13e):
14f
 84% 
isolated yield and 96% conversion in 15 h, 20 mol % KI, S/C = 10000;
 1
H 
NMR (CDCl3, 400 MHz) δ (ppm): 6.96-6.93 (m, 2H), 6.58 (t, J = 7.3 Hz, 
1H), 6.46 (d, J = 7.6 Hz, 1H), 3.74 (br, 1H), 3.22 (ddt, J = 9.4, 6.3, 3.3 Hz, 
1H), 2.84-2.68 (m, 2H), 1.98-1.92 (m, 1H), 1.63-1.54 (m, 1H), 1.51-1.26 
(m, 8H), 0.90 (t, J = 6.8 Hz, 3H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 
145.1, 129.7, 127.1, 121.8, 117.3, 114.5, 52.0, 37.1, 32.4, 28.6, 26.9, 25.8, 
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23.1, 14.5; MS (CI, m/z, %) 204 (100) [M+H]
+
; Anal. calcd. for C14H21N: 
C, 82.70; H, 10.41; N, 6.89; Found: C, 82.31; H, 10.45; N, 6.90. 
2-Hexyl-1,2,3,4-tetrahydroquinoline (13f):
14f
 72% 
isolated yield and 90% conversion in 10 h, 20 mol % KI, S/C = 10000;
 1
H 
NMR (CDCl3, 400 MHz) δ (ppm): 6.97-6.93 (m, 2H), 6.59 (td, J = 7.4, 
0.9  Hz, 1H), 6.48-6.46 (m, 1H), 3.75 (brs, 1H), 3.23 (ddt, J = 9.5, 6.3, 
3.3 Hz, 1H), 2.85-2.69 (m, 2H), 1.98-1.92 (m, 1H), 1.64-1.54 (m, 1H), 
1.51-1.26 (m, 10 H), 0.91-0.88 (m, 3H); 
13
C NMR (CDCl3, 100 MHz) δ 
(ppm): 144.6, 129.1, 126.5, 121.2, 116.7, 113.9, 51.4, 36.6, 31.7, 29.4, 
28.0, 26.3, 25.5, 22.5, 13.9; MS (CI, m/z, %) 218 (100) [M+H]
+
; Anal. 
calcd. for C15H23N: C, 82.89; H, 10.67; N, 6.44; Found: C, 82.85; H, 
10.66; N, 6.39. 
2-Isopropyl-1,2,3,4-tetrahydroquinoline (13g):
14f
  91% 
isolated yield and full conversion in 15 h, 20 mol % KI, S/C = 10000;
 1
H 
NMR (CDCl3, 400 MHz) δ (ppm): 6.97-6.93 (m, 2H), 6.58 (td, J = 7.4, 
1.0 Hz, 1H), 6.47 (d, J = 8.2 Hz, 1H), 3.76 (brs, 1H), 3.03 (ddd, J = 9.9, 
5.9, 2.9 Hz, 1H), 2.84-2.69 (m, 2H), 1.94-1.88 (m, 1H), 1.74-1.60 (m, 
2H), 0.98 (dd, J = 10.3, 6.8 Hz, 6H); 
13
C NMR (CDCl3, 100 MHz) δ 
(ppm): 145.4, 129.6, 127.1, 121.9, 117.2, 114.4, 57.7, 32.9, 27.1, 24.9, 
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19.0, 18.7; MS (CI, m/z, %) 176 (100) [M+H]
+
; Anal. calcd. for C12H17N: 
C, 82.23; H, 9.78; N, 7.99; Found: C, 82.24; H, 9.91; N, 7.97. 
2-Isobutyl-1,2,3,4-tetrahydroquinoline (13h):
14f
 
93% isolated yield and full conversion in 12 h, 20 mol % KI, S/C = 
10000;
 1
H NMR (CDCl3, 400 MHz) δ (ppm): 6.97-6.93 (m, 2H), 6.59 (td, 
J = 7.4, 1.0 Hz, 1H), 6.48-6.45 (m, 1H), 3.74 (brs, 1H), 3.35-3.29 (m, 1H), 
2.82-2.73 (m, 2H), 1.97-1.91 (m, 1H), 1.80-1.70 (m, 1H), 1.63-1.53 (m, 
1H), 1.44-1.29 (m, 2H), 0.94 (d, J = 6.6 Hz, 6H); 
13
C NMR (CDCl3, 100 
MHz) δ (ppm): 145.1, 129.7, 127.1, 121.8, 117.3, 114.5, 49.7, 46.3, 29.0, 
26.8, 24.9, 23.6, 22.9; MS (CI, m/z, %) 190 (100) [M+H]
+
; Anal. calcd. 
for C13H19N: C, 82.48; H, 10.12; N, 7.40; Found: C, 82.50; H, 10.09; N, 
7.37. 
2-(tert-Butyl)-1,2,3,4-tetrahydroquinoline (13i):
14g
 
99% isolated yield and full conversion in 15 h, 20 mol % KI, S/C = 
10000; 
1
H NMR (CDCl3, 400 MHz) δ (ppm): 6.97-6.92 (m, 2H), 6.57 (td, 
J = 7.4, 1.1 Hz, 1H), 6.48 (d, J = 7.9 Hz, 1H), 3.80 (br, 1H), 2.96 (dd, J = 
11.0, 2.6 Hz, 1H), 2.81-2.73 (m, 2H), 1.97 (ddt, J = 12.8, 5.4, 2.7 Hz, 1H), 
1.64-1.53 (m, 1H), 0.96 (s, 9H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 
145.9, 129.4, 127.1, 121.9, 117.1, 114.5, 61.4, 33.8, 27.9, 26.5, 23.6; MS 
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(CI, m/z, %) 190 (100) [M+H]
+
; Anal. calcd. for C13H19N: C, 82.48; H, 
10.12; N, 7.40; Found: C, 82.22; H, 10.09; N, 7.37. 
2-Cyclopropyl-1,2,3,4-tetrahydroquinoline (13j):
14f 
85% isolated yield and 95% conversion in 15 h, 20 mol % KI, S/C = 
10000;
 1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.03-6.99 (m, 2H), 6.64 (td, 
J = 7.3, 1.1 Hz, 1H), 6.53 (d, J = 7.7 Hz, 1H), 4.01 (br, 1H), 2.89-2.79 (m, 
2H), 2.45 (td, J = 9.4, 2.6 Hz, 1H), 2.16-2.10 (m, 1H), 1.89-1.79 (m, 1H), 
0.99-0.90 (m, 1H), 0.62-0.53 (m, 2H), 0.33-0.24 (m, 2H); 
13
C NMR 
(CDCl3, 100 MHz) δ (ppm): 142.7, 127.3, 124.8, 119.3, 114.9, 111.9, 
55.6, 26.4, 24.8, 15.1, 1.1, 0.0; MS (CI, m/z, %) 174 (100) [M+H]
+
; Anal. 
calcd. for C12H15N: C, 83.19; H, 8.73; N, 8.08; Found: C, 83.33; H, 8.79; 
N, 7.96. 
2-Cyclohexyl-1,2,3,4-tetrahydroquinoline (13k):
14f 
96% isolated yield and full conversion in 11 h, 20 mol % KI, S/C = 
10000;
 1
H NMR (CDCl3, 400 MHz) δ (ppm): 6.96-6.92 (m, 2H), 6.57 (td, 
J = 7.3, 0.8 Hz, 1H), 6.46 (d, J = 7.9 Hz, 1H), 3.79 (brs, 1H), 3.02 (ddd, J 
= 9.6, 6.2, 3.1 Hz, 1H), 2.82-2.67 (m, 2H), 1.94-1.87 (m, 1H), 1.86-1.76 
(m, 4H), 1.73-1.63 (m, 2H),  1.41-1.31 (m, 1H), 1.30-0.96 (m, 5H); 
13
C 
NMR (CDCl3, 100 MHz) δ (ppm): 145.4, 129.6, 127.1, 121.9, 117.1, 
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114.4, 57.0, 42.9, 29.6, 29.2, 27.1, 27.0, 26.8, 26.7, 25.0; MS (CI, m/z, %) 
216 (100) [M+H]
+
; Anal. calcd. for C15H21N: C, 83.67; H, 9.83; N, 6.50; 
Found: C, 83.65; H, 9.79; N, 6.49. 
2,6-Dimethyl-1,2,3,4-tetrahydroquinoline (13l):
14f
 76% 
isolated yield and full conversion in 12 h, 20 mol % KI, S/C = 10000;
 1
H 
NMR (CDCl3, 400 MHz) δ (ppm): 6.78-6.76 (m, 2H), 6.40 (d, J = 7.7 Hz, 
1H), 3.39-3.31 (m, 1H), 2.85-2.77 (m, 1H), 2.72-2.65 (m, 1H), 2.20 (s, 
3H), 1.93-1.88 (m, 1H), 1.62-1.52 (m, 1H), 1.19 (d, J = 6.3 Hz, 3H); 
13
C 
NMR (CDCl3, 100 MHz) δ (ppm): 142.9, 130.2, 127.6, 126.7, 121.6, 
114.7, 47.7, 30.8, 27.0, 23.0, 20.8; MS (CI, m/z, %) 162 (100) [M+H]
+
; 
Anal. calcd. for C11H15N: C, 81.94; H, 9.38; N, 8.69; Found: C, 81.58; H, 
9.46; N, 8.26. 
6-Fluoro-2-methyl-1,2,3,4-tetrahydroquinoline 
(13m):
14f
 74% isolated yield in 12 h, 20 mol % KI, S/C = 10000;
 1
H 
NMR (CDCl3, 400 MHz) δ (ppm): 6.69-6.65 (m, 2H), 6.41-6.38 (m, 1H), 
3.38-3.30 (m, 1H), 2.86-2.77 (m, 1H), 2.72-2.66 (m, 1H), 1.94-1.88 (m, 
1H), 1.60-1.50 (m, 1H), 1.20 (d, J = 6.3 Hz, 3H); 
13
C NMR (CDCl3, 100 
MHz) δ (ppm): 155.9 (d, JCF = 233.2 Hz), 141.3, 122.9 (d, JCF = 6.6 Hz), 
115.8 (d, JCF = 21.5 Hz), 115.2 (d, JCF = 7.6 Hz), 113.6 (d, JCF = 22.3 Hz), 
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47.7, 30.2, 27.1, 22.9; HRMS for C10H13FN [M+H]
+
: m/z calcd. 
166.1027, found 166.1023. 
6-Chloro-2-methyl-1,2,3,4-tetrahydroquinoline 
(13n):
14f
 92% isolated yield and 98% conversion in 24 h, 20 mol % KI, 
S/C = 10000;
 1
H NMR (CDCl3, 400 MHz) δ (ppm): 6.92-6.88 (m, 2H), 
6.38 (d, J = 8.4 Hz, 1H), 3.69 (brs, 1H), 3.41-3.33 (m, 1H), 2.83-2.75 (m, 
1H), 2.72-2.65 (m, 1H), 1.94-1.87 (m, 1H), 1.59-1.49 (m, 1H), 1.20 (d, J 
= 6.3 Hz, 3H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 143.7, 129.2, 126.9, 
123.0, 121.7, 115.3, 47.5, 30.1, 26.9, 22.9; MS (CI, m/z, %) 182:184 = 
3:1 (100) [M+H]
+
; Anal. calcd. for C10H12ClN: C, 66.12; H, 6.66; N, 7.71; 
Found: C, 66.25; H, 6.72; N, 7.61. 
7-Fluoro-2-methyl-1,2,3,4-tetrahydroquinoline 
(13o):
14f
 83% isolated yield and 93% conversion in 12 h, 20 mol % KI, 
S/C = 10000;
 1
H NMR (CDCl3, 400 MHz) δ (ppm): 6.85 (t, J = 7.4 Hz, 
1H), 6.27 (td, J = 8.5, 2.5 Hz, 1H), 6.14 (dd, J = 10.9, 2.5 Hz, 1H), 3.76 
(brs, 1H), 3.38 (ddq, J = 9.7, 6.4, 3.1 Hz, 1H), 2.79-2.64 (m, 2H), 1.94-
1.88 (m, 1H), 1.59-1.49 (m, 1H), 1.19 (d, J = 6.3 Hz, 3H); 
13
C NMR 
(CDCl3, 100 MHz) δ (ppm): 162.5 (d, JCF = 238.9 Hz), 146.3 (d, JCF = 
10.4 Hz), 130.5 (d, JCF = 9.8 Hz), 116.9 (d, JCF = 2.4 Hz),  103.7 (d, JCF = 
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21.3 Hz), 100.5 (d, JCF = 24.3 Hz), 47.4, 30.4, 26.4, 22.9; HRMS for 
C10H13FN [M+H]
+
: m/z calcd. 166.1027, found 166.1024. 
6-Methoxy-2-methyl-1,2,3,4-tetrahydroquinoline 
(13p):
14f
 73% isolated yield and 97% conversion in 24 h, 20 mol % KI, 
S/C = 10000;
 1
H NMR (CDCl3, 400 MHz) δ (ppm): 6.60-6.56 (m, 2H), 
6.44 (d, J = 8.3 Hz, 1H), 3.72 (s, 3H), 3.36-3.28 (m, 1H), 2.88-2.80 (m, 
1H), 2.73-2.67 (m, 1H), 1.91 (ddt, J = 12.9, 5.9, 2.9 Hz, 1H), 1.61-1.51 
(m, 1H), 1.19 (d, J = 6.2 Hz, 3H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 
152.3, 139.3, 123.0, 115.8, 115.1, 113.3, 56.2, 47.9, 30.7, 27.3, 23.0; MS 
(CI, m/z, %) 178 (100)  [M+H]
+
; Anal. calcd. for C11H15NO: C, 74.54; H, 
8.53; N, 7.90; Found: C, 74.45; H, 8.59; N, 7.77. 
6-Bromo-2-methyl-1,2,3,4-tetrahydroquinoline 
(13q):
14f
 83% isolated yield and 88% conversion in 48 h, 50 mol % KI, 
S/C = 10000;
 1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.06-7.01 (m, 2H), 
6.34 (d, J = 8.4 Hz, 1H), 3.71 (brs, 1H), 3.37 (ddq, J = 9.8, 6.4, 3.1 Hz, 
1H), 2.83-2.66 (m, 2H), 1.94-1.88 (m, 1H), 1.59-1.43 (m, 1H), 1.20 (d, J 
= 6.2 Hz, 3H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 144.2, 132.1, 129.7, 
123.5, 115.8, 108.7, 47.5, 30.0, 26.8, 22.9; MS (CI, m/z, %) 226:228 = 
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1:1 (100) [M+H]
+
; Anal. calcd. for C11H12BrN: C, 53.12; H, 5.35; N, 
6.190; Found: C, 53.67; H, 5.46; N, 6.13. 
2-(2-(Benzo[d][1,3]dioxol-5-yl)ethyl)-
1,2,3,4-tetrahydroquinoline (13r):
14f
 89% isolated yield and 95% 
conversion in 15 h, 20 mol % KI, S/C = 10000;
 1
H NMR (CDCl3, 400 
MHz) δ (ppm): 6.97-6.93 (m, 2H), 6.74-6.69 (m, 2H), 6.66-6.58 (m, 2H), 
6.45 (d, J = 7.7 Hz, 1H), 5.91 (s, 2H), 3.75 (brs, 1H), 3.27 (ddt, J = 9.3, 
6.3, 3.3 Hz, 1H), 2.84-2.69 (m, 2H), 2.65 (t, J = 7.9 Hz, 2H), 2.01-1.94 
(m, 1H), 1.80-1.75 (m, 2H), 1.70-1.60 (m, 1H); 
13
C NMR (CDCl3, 100 
MHz) δ (ppm): 148.1, 146.1, 144.9, 136.1, 129.7, 127.2, 121.7, 121.5, 
117.5, 114.6, 109.2, 108.7, 101.2, 51.4, 38.9, 32.3, 28.4, 26.6; MS (CI, 
m/z, %) 282 (100) [M+H]
+
; Anal. calcd. for C18H19NO2: C, 76.84; H, 
6.81; N, 4.98; Found: C, 76.37; H, 6.66; N, 4.96. 
2,3-Dimethyl-1,2,3,4-tetrahydroquinoline (13s):
14f
 69% 
isolated yield and 92% conversion in 20 h, 50 mol % KI, S/C = 10000, 
syn : anti = 6:1; For syn isomer: 
 1
H NMR (CDCl3, 400 MHz) δ (ppm): 
6.97-6.94 (m, 2H), 6.62-6.57 (m, 1H), 6.46 (d, J = 7.8, Hz, 1H), 3.44 (dq, 
J = 6.5, 3.0 Hz, 1H), 2.89 (dd, J = 16.2, 5.3 Hz, 1H), 2.47 (dd, J = 16.2, 
6.0 Hz, 1H), 2.07-1.98 (m, 1H), 1.10 (d, J = 6.6 Hz, 3H), 0.92 (d, J = 6.9 
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Hz, 3H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 144.3, 130.2, 127.0, 
120.4, 117.3, 114.3, 50.4, 34.2, 30.9, 18.5, 14.8; MS (CI, m/z, %) 162 
(100) [M+H]
+
; Anal. calcd. for C11H15N: C, 81.94; H, 9.38; N, 8.69; 
Found: C, 81.92; H, 9.35; N, 8.73. 
1,2,3,4,4a,9,9a,10-Octahydroacridine (13t):
14f
 95% 
isolated yield and full conversion in 12 h, 50 mol % KI, S/C = 10000, 
syn : anti = 5:2; For syn isomer: 
 1
H NMR (CDCl3, 400 MHz) δ (ppm): 
6.95-6.92 (m, 2H), 6.56 (td, J = 7.3, 1.0 Hz, 1H), 6.44 (d, J = 7.9 Hz, 1H), 
3.59 (br, 1H), 3.50 (q, J = 3.5 Hz, 1H), 2.89 (dd, J = 16.3, 5.6 Hz, 1H), 
2.51 (dd, J = 16.3, 4.1 Hz, 1H), 1.99-1.92 (m, 1H), 1.70-1.58 (m, 4H), 
1.46-1.28 (m, 4H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 144.3, 130.1, 
127.1, 119.7, 116.8, 113.7, 50.4, 33.4, 32.9, 32.2, 27.7, 25.2, 21.1; MS 
(CI, m/z, %) 188 (100) [M+H]
+
;   Anal. calcd. for C13H17N: C, 83.37; H, 
9.15; N, 7.48; Found: C, 83.22; H, 9.17; N, 7.13. 
9,10-Dihydroacridine (13u):
21e
 98% isolated yield and 
full conversion in 12 h, 50 mol % KI, S/C = 5000; 
1
H NMR (CDCl3, 400 
MHz) δ (ppm): 7.11-7.06 (m, 4H), 6.85 (td, J = 7.4, 1.0 Hz, 2H), 6.66 (d, 
J = 7.9 Hz, 2H), 5.94 (br, 1H), 4.05 (s, 2H); 
13
C NMR (CDCl3, 100 MHz) 
δ (ppm): 140.5, 129.0, 127.4, 121.0, 120.4, 113.8, 31.8; MS (CI, m/z, %) 
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182 (100) [M+H]
+
; Anal. calcd. for C13H11N: C, 86.15; H, 6.12; N, 7.73; 
Found: C, 85.99; H, 6.16; N, 7.69. 
2-(4-Methylpent-3-enyl)-1,2,3,4-
tetrahydroquinoline (13v):
14f
 71% isolated yield and 85% conversion in 
24 h, 50 mol % KI, S/C = 10000;
 1
H NMR (CDCl3, 400 MHz) δ (ppm): 
6.97-6.93 (m, 2H), 6.59 (td, J = 7.4 Hz, 1.0 Hz, 1H), 6.46 (d, J = 8.3 Hz, 
1H), 5.17-5.13 (m, 1H), 3.81 (brs, 1H), 3.25 (ddt, J = 9.4, 6.4, 3.4 Hz, 
1H), 2.85-2.69 (m, 2H), 2.10 (q, J = 7.5 Hz, 2H), 1.99-1.93 (m, 1H), 1.70 
(s, 3H), 1.64-1.51 (m, 6H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 145.1, 
132.5, 129.7, 127.1, 124.4, 121.8, 117.3, 114.5, 51.7, 36.9, 28.5, 26.8, 
26.1, 24.8, 18.1; MS (CI, m/z, %) 216 (100) [M+H]
+
; Anal. calcd. for 
C15H21N: C, 83.67; H, 9.83; N, 6.50; Found: C, 83.82; H, 9.95; N, 6.50. 
2-Phenyl-1,2,3,4-tetrahydroquinoline (13w):
14f
 98% 
isolated yield and full conversion in 48 h, 160 mol % KI, S/C = 1000;
 1
H 
NMR (CDCl3, 400 MHz) δ (ppm): 7.40-7.33 (m, 4H), 7.30-7.26 (m, 1H), 
7.01-6.99 (m, 2H), 6.67-6.63 (m, 1H), 6.53 (d, J = 8.0 Hz, 1H), 4.45-4.41 
(m, 1H), 4.03 (brs, 1H), 2.96-2.88 (m, 1H), 2.76-2.70 (m, 1H), 2.16-2.08 
(m, 1H), 2.05-1.94 (m, 1H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 145.2, 
145.1, 129.7, 129.0, 127.9, 127.3, 127.0, 121.3, 117.6, 114.4, 56.7, 31.4, 
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26.8; MS (CI, m/z, %) 210 (100) [M+H]
+
; Anal. calcd. for C15H15N: C, 
86.08; H, 7.22; N, 6.69; Found: C, 86.14; H, 7.27; N, 6.72. 
2-(4-Fluorophenyl)-1,2,3,4-tetrahydroquinoline 
(13x):
14f
 98% isolated yield and full conversion in 48 h, 160 mol % KI, 
S/C = 1000;
 1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.36-7.33 (m, 2H), 
7.04-6.99 (m, 4H), 6.67-6.63 (m, 1H), 6.53 (d, J = 7.8 Hz, 1H), 4.41 (dd, 
J = 9.4, 3.2 Hz, 1H), 3.99 (brs, 1H), 2.95-2.87 (m, 1H), 2.75-2.69 (m, 1H), 
2.11-2.05 (m, 1H), 1.99-1.91 (m, 1H); 
13
C NMR (CDCl3, 100 MHz) δ 
(ppm): 162.5 (d, JCF = 243.8 Hz), 145.0, 140.9 (d, JCF = 3.0 Hz), 129.7, 
128.5 (d, JCF = 8.0 Hz), 127.4, 121.2, 117.8, 115.8 (d, JCF = 21.2 Hz), 
114.5, 56.0, 31.6, 26.7; HRMS for C15H15FN [M+H]
+
: m/z calcd. 
228.1183, found 228.1178. 
2-(4-Methoxyphenyl)-1,2,3,4-
tetrahydroquinoline (13y):
14f
 94% isolated yield and full conversion in 
26 h, 160 mol % KI, S/C = 1000; 
1
H NMR (CDCl3, 400 MHz) δ (ppm): 
7.32-7.30 (m, 2H), 7.02-6.99 (m, 2H), 6.90-6.87 (m, 2H), 6.64 (td, J =7.3, 
1.1 Hz, 1H), 6.52 (d, J = 8.2 Hz, 1H), 4.38 (dd, J = 9.5, 3.0 Hz, 1H), 3.98 
(brs, 1H), 3.81 (s, 3H),  2.97-2.88 (m, 1H), 2.77-2.71 (m, 1H), 2.11-2.05 
(m, 1H), 2.01-1.91 (m, 1H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 159.4, 
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145.2, 137.3, 129.7, 128.0, 127.3, 121.3, 117.5, 114.4, 114.3, 56.1, 55.7, 
31.5, 27.0; MS (CI, m/z, %) 240 (100) [M+H]
+
; Anal. calcd. for 
C16H17NO: C, 80.30; H, 7.16; N, 5.85; Found: C, 80.46; H, 7.12; N, 5.82. 
3-Methyl-1,2,3,4-tetrahydroquinoline (13z):
8b
 88% 
isolated yield and 96% conversion in 12 h, 50 mol % KI, S/C = 5000; 
Hydrolysis: 100 
o
C and 15 h; 
1
H NMR (CDCl3, 400 MHz) δ (ppm): 6.98-
6.92 (m, 2H), 6.60 (td, J = 7.4, 1.1 Hz, 1H), 6.47 (d, J = 7.9 Hz, 1H), 3.82 
(brs, 1H), 3.25 (ddd, J = 11.0, 3.7, 2.0 Hz, 1H), 2.91-2.85 (m, 1H), 2.79-
2.74 (m, 1H), 2.45-2.39 (m, 1H), 2.11-1.99 (m, 1H), 1.04-1.03 (m, 3H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 144.7, 130.0, 128.1, 127.1, 121.6, 
117.4, 114.3, 49.3, 35.9, 27.6, 19.5; MS (CI, m/z, %) 148 (100) [M+H]
+
; 
Anal. calcd. for C10H13N: C, 81.59; H, 8.90; N, 9.51; Found: C, 81.63; H, 
9.05; N, 9.47. 
1,2,3,4-Tetrahydroisoquinoline (17a):
8b
 83% isolated 
yield and full conversion in 24 h, 50 mol % KI, S/C = 500; Hydrolysis: 
25 
o
C and 20 h; 
1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.13-7.05 (m, 3H), 
6.99-6.96 (m, 1H), 3.99 (s, 2H), 3.11 (t, J = 6.0 Hz, 2H), 2.77 (t, J = 6.0 
Hz, 2H),  1.87 (brs, 1H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 136.4, 
135.2, 129.7, 126.6, 126.4, 126.1, 48.8, 44.4, 29.7; MS (CI, m/z, %) 134 
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(100) [M+H]
+
; Anal. calcd. for C9H11N: C, 81.2; H, 8.32; N, 10.5; Found: 
C, 79.7; H, 8.57; N, 10.4. 
6-Methyl-1,2,3,4-tetrahydroisoquinoline (17b):
21f
 95% 
isolated yield and full conversion in 24 h, 50 mol % KI, S/C = 500; 
Hydrolysis: 40 
o
C and 17 h; 
1
H NMR (CDCl3, 400 MHz) δ (ppm): 6.95-
6.88 (m, 3H), 3.97 (s, 2H), 3.11 (t, J = 6.0 Hz, 2H), 2.75 (t, J = 5.9 Hz, 
2H), 2.29 (s, 3H), 1.93 (br, 1H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 
135.9, 134.9, 133.2, 130.2, 127.0, 126.5, 48.4, 44.3, 29.5, 21.5; MS (CI, 
m/z, %) 148 (100) [M+H]
+
; Anal. calcd. for C10H13N: C, 81.6; H, 8.90; N, 
9.51; Found: C, 79.3; H, 8.68; N, 9.03. 
1-Methyl-1,2,3,4-tetrahydroisoquinoline (17c):
8b 
92% 
isolated yield and 98% conversion in 24 h, 50 mol % KI, S/C = 500, 
HCOOH:Et3N = 3.5:1; Hydrolysis: 80 
o
C and 5 h; 
1
H NMR (CDCl3, 400 
MHz) δ (ppm): 7.16-7.07 (m, 4H), 4.11 (q, J = 6.7 Hz, 1H), 3.27 (dt, J = 
12.4, 5.1 Hz, 1H), 3.06-2.99 (m, 1H), 2.91-2.84 (m, 1H), 2.77-2.70 (m, 
1H), 1.71 (br, 1H), 1.46 (d, J = 6.8 Hz, 3H) ; 
13
C NMR (CDCl3, 100 MHz) 
δ (ppm): 131.0, 135.2, 129.6, 126.33, 126.30, 126.26, 52.0, 42.2, 30.5, 
23.1; MS (CI, m/z, %) 148 (100) [M+H]
+
; Anal. calcd. for C10H13N: C, 
81.6; H, 8.90; N, 9.51; Found: C, 80.2; H, 9.03; N, 9.51. 
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3-Methyl-1,2,3,4-tetrahydroisoquinoline (17d):
8b
 91% 
isolated yield and full conversion in 24 h, 50 mol % KI, S/C = 500; 
Hydrolysis: 60 
o
C and 24 h; 
1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.13-
7.01 (m, 4H), 4.07 (q, J = 16.0 Hz, 1H), 3.06-2.97 (m, 1H), 2.78 (dd, J = 
16.4, 6.0 Hz, 1H), 2.54-2.47 (m, 1H), 1.81 (br, 1H), 1.24 (d, J = 6.0 Hz, 
3H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 135.8, 135.3, 129.5, 126.4, 
126.1, 49.7, 49.0, 37.6, 22.9; MS (CI, m/z, %) 148 (100) [M+H]
+
; Anal. 
calcd. for C10H13N: C, 81.6; H, 8.90; N, 9.51; Found: C, 80.3; H, 9.00; N, 
9.45. 
1,2,3,4-Tetrahydroquinoxaline (17e):
14h
 99% isolated yield 
and full conversion in 12 h, 50 mol % KI, S/C = 5000; Hydrolysis: 120 
o
C and 8 h;  
1
H NMR (CDCl3, 400 MHz) δ (ppm): 6.60-6.47 (m, 4H),  
3.58 (br, 2H), 3.41 (s, 4H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 134.0, 
119.2, 115.2, 41.8; MS (CI, m/z, %) 135 (100) [M+H]
+
; Anal. calcd. for 
C8H10N2: C, 71.6; H, 7.51; N, 20.9; Found: C, 71.4; H, 7.56; N, 21.1. 
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2-Methyl-1,2,3,4-tetrahydroquinoxaline (17f):
14h
 86% 
isolated yield and full conversion in 12 h, 50 mol % KI, S/C = 5000; 
Hydrolysis: 100 
o
C and 4 h; 
1
H NMR (CDCl3, 400 MHz) δ (ppm): 6.60-
6.56 (m, 2H), 6.50-6.48 (m, 2H), 3.55-3.47 (m, 1H), 3.31 (dd, J = 10.7, 
2.9 Hz, 1H), 3.03 (dd, J = 10.6, 8.2 Hz, 1H), 1.18 (d, J = 6.3 Hz, 3H); 
13
C 
NMR (CDCl3, 100 MHz) δ (ppm): 134.0, 133.6, 119.12, 119.11, 114.90, 
114.85, 48.7, 46.1, 20.3; MS (CI, m/z, %) 149 (100) [M+H]
+
; Anal. calcd. 
for C9H12N2: C, 72.9; H, 8.16; N, 18.9; Found: C, 72.7; H, 8.28; N, 18.4. 
5-Methyl-1,2,3,4-tetrahydroquinoxaline (17g):
21g
 92% 
isolated yield and 93% conversion in 12 h, 50 mol % KI, S/C = 5000; 
Hydrolysis: 100 
o
C and 4 h; 
1
H NMR (CDCl3, 400 MHz) δ (ppm): 6.54-
6.49 (m, 2H),  6.43-6.39 (m, 1H), 3.50-3.39 (m, 4H), 2.08 (s, 3H); 
13
C 
NMR (CDCl3, 100 MHz) δ (ppm): 133.6, 132.1, 122.6, 120.9, 118.4, 
113.3, 42.2, 41.6, 17.4; MS (CI, m/z, %) 149 (100) [M+H]
+
; Anal. calcd. 
for C9H12N2: C, 72.9; H, 8.16; N, 18.9; Found: C, 73.1; H, 8.33; N, 19.0. 
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6-Methyl-1,2,3,4-tetrahydroquinoxaline (17h):
21h
 90% 
isolated yield and 96% conversion in 12 h, 50 mol % KI, S/C = 5000; 
Hydrolysis: 100 
o
C and 4 h; 
1
H NMR (CDCl3, 400 MHz) δ (ppm): 6.43-
6.38 (m, 2H),  6.33 (s, 1H), 3.39 (s, 4H), 2.17 (s, 3H); 
13
C NMR (CDCl3, 
100 MHz) δ (ppm): 134.2, 131.6, 128.8, 119.5, 115.9, 115.4, 42.00, 41.98, 
21.1; MS (CI, m/z, %) 149 (100) [M+H]
+
; Anal. calcd. for C9H12N2: C, 
72.9; H, 8.16; N, 18.9; Found: C, 72.6; H, 8.31; N, 18.5. 
2,3-Dimethyl-1,2,3,4-tetrahydroquinoxaline (17i):
14h
 
91% isolated yield and 93% conversion in 12 h, 50 mol % KI, S/C = 500; 
1
H NMR (CDCl3, 400 MHz) δ (ppm): 6.60-6.55 (m, 2H), 6.51-6.47 (m, 
2H), 3.51-3.45 (m, 2H), 1.12 (d, J = 6.0 Hz, 6H); 
13
C NMR (CDCl3, 100 
MHz) δ (ppm): 133.0, 119.0, 114.8, 49.5, 17.6; MS (CI, m/z, %) 163 
(100) [M+H]
+
; Anal. calcd. for C10H14N2: C, 74.0; H, 8.70; N, 17.3; 
Found: C, 74.0; H, 8.72; N, 17.2. 
 (S)-1,2-dimethyl-1,2,3,4-tetrahydroquinoline (15):21i 
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1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.12 (t, J = 7.6 Hz, 1H), 7.01 (d, J 
= 7.2 Hz, 1H), 6.63 (t, J = 7.2 Hz, 1H), 6.58 (d, J = 8.0 Hz, 1H), 3.49-
3.43 (m, 1H), 2.93-2.84 (m, 5H, N-CH3 overlapped with a CH2), 2.72 (d, 
J = 16.1 Hz, 1H), 2.06-1.97 (m, 1H), 1.82-1.76 (m, 1H), 1.17 (d, J = 6.5 
Hz, 3H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 145.6, 128.7, 127.2, 
122.2, 115.5, 110.7, 54.0, 37.1, 28.2, 23.9, 17.7; HRMS for  C10H14N 
[M+H]+: m/z calcd 148.1126, found 148.1131; HPLC (Chiralcel OJ, 
hexane:isopropanol = 99:1, flow rate 0.5 mL/min, 254 nm): tR = 15.3 min 
(minor), tS = 19.4 min (major), 73% ee. The S configuration was 
determined by comparison with 15 obtained from reductive amination of 
(S)-2-methyltetrahydroquinolines. 
1-Formyl-2-methyl-1,2,3,4-tetrahydroquinoline (18):
21j 1
H 
NMR (CDCl3, 400 MHz) δ (ppm): 8.68 (s, 1H), 7.24-7.10 (m, 4H), 4.81 
(sextet, J = 6.3, 1H), 2.87-2.80 (m, 1H), 2.76-2.67 (m, 1H), 2.17-2.09 (m, 
1H), 1.74-1.66 (m, 1H), 1.22 (d, J = 6.6 Hz, 3H); 
13
C NMR (CDCl3, 100 
MHz) δ (ppm): 161.6, 136.7, 130.3, 129.6, 127.6, 125.2, 118.9, 45.6, 29.6, 
24.7, 18.6; MS (CI, m/z, %) 176 (100) [M+H]
+
, 193 (46) [M+NH3+H]
+
; 
Anal. calcd. for C11H13NO: C, 75.4; H, 7.48; N, 7.99; Found: C, 74.8; H, 
7.57; N, 8.12. 
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3.1 Introduction 
 
      Chapter 2 presented an iodide-promoted TH system for reduction of 
benzo-fused N-heteroaromatics including quinolines, isoquinolines and 
quinoxalines, which demonstrates a simple but efficient protocol for 
preparation of a variety of N-heterocyclic compounds.  In comparison, 
reduction of monocyclic N-heteroaromatics such as pyridines, pyrazines 
and pyrroles is significantly more challenging. The corresponding 
saturated compounds are of broad utility; thus efficient, general and mild 
reduction methods are desirable. In this chapter, the efforts to apply the 
above-mentioned TH system for the reduction of pyridines to piperidine 
derivatives will be described.  
     As also stated in Chapter 1, piperidines, which structurally exist in 
abundant natural products and synthetic bioactive compounds, have 
attracted a great deal of attention in the chemical and pharmaceutical 
industries.
1
 For instance, among top-selling prescription drugs, Risperdal 
used for treatment of schizophrenia and bipolar mania,
2
 Concerta for 
attention deficit hyperactivity disorder (ADHD),
3
 Aricept for Alzheimer's 
disease,
4
 Paroxetine as an antidepressant
5
 and Fentanyl as a pain reliever
6 
are piperidine derivatives (Figure 10). 
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Figure 10: Piperidine derivatives as top-selling prescription drugs 
 
      Given their broad pharmaceutical utilities, the synthesis of piperidines 
has been extensively investigated in both industry and academia.
1a, e-i
 
Most of the attention has been paid to constructing the piperidine ring by 
cyclisation, being highlighted by the synthesis of a variety of piperidine 
based natural products and drugs successfully.
1e-g, i 
The disadvantages, 
however, including the lack of general methods and often tedious 
preparation of the substrates, limit their prospective applications. From 
this viewpoint, catalytic hydrogenation of the parent pyridines provides 
arguably the most convenient and atom-economic route for directly 
accessing piperidines.
7
 Over the past several decades, a variety of 
classical heterogeneous catalysts, such as Pd/C, Pt2O3, Rh/Al2O3, and 
Raney Ni, have been used to fully reduce pyridines with hydrogen gas;
7-9 
but most of these catalysts are of low activity and selectivity and often 
require harsh reaction conditions. Recently, several well-defined 
homogeneous Rh, Ir and Ru complexes
10
 have been reported to catalyse 
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the hydrogenation including asymmetric versions (Scheme 42).
11
 An 
organocatalyst
12
 in combination with Hantzsch esters can also realise the 
asymmetric reduction. During the preparation of this thesis, 
diastereomeric hydrogenation of 2,6-disubstituted pyridines was reported 
using a borane-based, metal-free catalyst.
13
 
 
 
Scheme 42: Full hydrogenation of pyridines by transition metal catalysis 
 
      For most of the homogeneous work, the substrates are either limited 
to electron withdrawing groups (EWG), or lack functional group 
compatibility. Furthermore, specific activating groups are often needed to 
be installed on the pyridines and relatively high catalyst loading and 
hydrogen pressure is necessary.  
      Partial reduction of pyridines to give tetrahydropyridines is even 
more interesting, since the resulting unsaturated piperidines with a C=C 
bond can be further transformed to other value-added products via many 
well-established reactions of alkenes, such as asymmetric hydrogenation, 
epoxidation, dihydroxylation, and allyic substitution and isomerisation.
14
 
Consequently, a huge number of reactions have been found for the partial 
reduction of pyridines.
8, 15 
In almost all cases, stoichiometric metal or 
metal hydride reagents, such as Na, NaBH4 and LiAlH4, are employed for 
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these reductions. Apart from being hazardous and generating copious 
amount of toxic waste, using these reagents is often plagued with poor 
selectivity and fails to tolerate functional groups, which limit their 
application in modern synthesis. Partial hydrogenation of pyridines with 
heterogeneous catalysts has also been reported, affording generally only 
2,3-unsaturated piperidines with EWG such as carbonyl and cyano 
(Scheme 43).
16
 Therefore, it remains a great challenge to reduce pyridines 
in an efficient, selective and operationally benign manner.  
 
 
Scheme 43: Partial hydrogenation of pyridines 
 
      In Chapter 2, we described that promoted by iodide, the simple 
[Cp*RhCl2]2 allows for highly efficient transfer hydrogenation of 
quinolines, isoquinolines and quinoxalines using the azeotropic HCOOH-
NEt3 as reductant under mild conditions. It is a natural extension to 
explore the possibility to reduce the more inert pyridines with this 
catalytic system. 
.  
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3.2 Results and Discussion 
 
3.2.1 Discovery of TH of pyridines and further optimisation 
      Bearing in mind that in Chapter 2, 2-methylquinoline (pKa 5.4) was 
reduced smoothly with the [Cp*RhCl2]2-I
-
 catalyst, we chose 2-picoline 
(pKa 6.0) as model substrate, which has similar basicity to 2-
methylquinoline and is expected to be protonated by formic acid (pKa 
3.6).  Surprisingly, no reduction was observed by crude 
1
H NMR even 
with 2.5 mol % catalyst and the starting material was partially recovered. 
Given the fact that the supposed product 2-pipercoline is volatile (118-
119 °C/753 mmHg) and has a good solubility in aqueous solution, we 
were wondering if we missed some reduced product because of the 
insufficient work-up. Therefore, we selected several more hydrophobic 
pyridines such as ethyl nicotinate and 2-benzylpyridine and tested them 
under the identical conditions. However, there was no reduction observed 
as well even at higher temperature (Scheme 44). These results hinted that 
the supposed protonated pyridines were not activated enough for the TH 
and we may need to search other methods to afford more activated 
pyridines.  
 
Scheme 44: TH of neutral pyridines 
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      There are many methods to activate the neutral pyridines by forming 
pyridinium salts, pyridine N-oxides, or N-iminopyridinium ylides for 
example. These lower the LUMO of pyridines, increasing its 
susceptibility to nucleophilic attack by a metal hydride species and 
reduction, while coordinatively saturating the nitrogen atom decreasing 
the tendency to bind to any available metal catalyst. Among these 
activating methods, the most convenient is the alkylation of the pyridines 
to form pyridinium salts. Thus, we prepared N-benzyl-2-picoline bromide 
salt 19a as model substrate, which can be conveniently prepared by 
alkylation of 2-picoline with benzyl bromide. Given the simplicity of 
quaternisation with benzyl halides and the importance of benzyl-
protected piperidines, we set out to examine the TH of 19a. Delightfully, 
the quaternised pyridine salt underwent the reduction readily with 2.5 
mol % catalyst in the presence of 0.5 equivalents KI (Scheme 45).  
 
Scheme 45: TH of pyridinium salts 
 
      Encouraged by this initial result and with further optimisation, the 
reduction could be achieved with much lower metal loading. As can be 
seen from Table 4, catalysed by only 0.005 mol % [Cp*RhCl2]2 with 0.1 
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equivalent KI as additive, the picoline bromide salt 19a was reduced in 
HCOOH-NEt3 at 40 °C, affording N-benzyl piperidine in 85% isolated 
yield (Table 4, entry 1). In order to clarify if iodide ion still plays a key 
role in this TH, we set several control experiments. The results again 
show that the iodide salt KI displays a remarkable accelerating effect on 
the reduction (Table 4, entries 1 vs 2). The reaction proceeds well without 
the iodide, when it was carried out with a much higher catalyst loading 
(Table 4, entry 3). A lower yield was obtained and some unknown 
impurities were noticed by using picoline chloride salt under the same 
conditions (Table 4, entry 4). The halide effect echoed the previous 
results obtained with 2-methylquinoline in Chapter 2. The concentration 
of the iodide salt affects the reduction rates as well, with a slightly higher 
yield obtained using one equivalent KI (Table 4, entry 5 vs entries 1 and 
6), under which a turnover number (TON) of 9000 is generated. To the 
best of our knowledge, this is the highest TON value ever reported in 
catalytic reduction of pyridines. However, higher concentration of I
-
 
deactivates the catalyst (Table 4, entry 6), resembling the results in 
Chapter 2. The yield was slightly improved when increasing the catalyst 
loading to 0.05 mol % (Table 4, entry 7). Control experiments show that 
no reduction occurs without the rhodium catalyst, and other broadly-used 
metal analogues proved to be ineffective once more (Table 4, entries 8-
11). We noticed that excellent yield can be obtained when picolinium 
iodide salt, conveniently prepared by halides exchange of picolinium 
bromide salt with NaI, was subjected to the TH. It reinforces that I
-
 is 
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crucial for the high activity (Table 4, entries 12 vs 2). However, no 
reaction was observed when the anion of the picolinium salt was replaced 
with a non-coordinating anion, SbF6
-
 (Table 4, entry 13), showing again 
the importance of coordinating anion to the catalytic activity (also see 
Chapter 2). 
Table 4. Effect of metal compounds and iodide on the TH of 19a.
[a] 
 
Entry X  Metal, 
mol %[b] 
Additive, 
equiv. 
  Yield[c] 
1 Br  [Rh], 0.005    KI, 0.1   85 
2 Br  [Rh], 0.005    None   9 
3 
4 
Br 
Cl 
 [Rh], 0.5 
 [Rh], 0.5 
   None 
   None 
  84 
  62 
5 Br  [Rh], 0.005    KI, 1.0   90 
6 Br  [Rh], 0.005    KI, 3.0   10 
7 Br  [Rh], 0.05    KI, 1.0   94 
8 Br  None    KI, 1.0   NR 
9 Br  [Ir], 0.5    None   4 
10 Br  [Ru], 0.5    None   NR 
11 Br  RhCl3, 1.0    None   NR 
12 I  [Rh], 0.005    None   92 
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 [a] Reaction conditions: pyridinium salt 19a (0.5 mmol), HCO2H-NEt3 
azeotrope solution (5 mL), 40 °C, 24 h under N2, Bn = Benzyl. [b] [Rh] = 
[Cp*RhCl2]2, [Ir] = [Cp*IrCl2]2 and [Ru] = [RuCl2(p-cymene)]2. [c] Isolated 
yields. NR = No reaction or no desired product observed.  
3.2.2 Substrate scope 
      Having the optimised reaction conditions in hand, a variety of 
pyridinium salts were subjected to TH with 0.05 mol % [Cp*RhCl2]2 in 
the presence of 1 equivalent KI. As shown in Table 5, a range of 2-, 2,3-, 
and 2,6-disubstituted pyridiniums were reduced, affording the 
corresponding N-benzyl piperidines in good to excellent yields. Thus, 2-
alky substituted pyridiniums underwent smooth hydrogenation to give 2-
alky piperidines in high yields (Table 5, entries 1-3). A lower yield was 
obtained with the 2-phenyl piperidine 20d (Table 5, entry 4), probably 
due to steric demand of the phenyl ring and/or its stabilisation of the 
intermediate iminium C=N bond (vide infra). Surprisingly somehow, the 
unsubstituted pyridinium gave a mixture of 3,4-unsaturated piperidine 
and piperidine, with the latter 20e accounting for 60% of the mixture as 
determined by the crude 
1
H NMR (Table 5, entry 5). The formation of the 
unsaturated piperidine is likely a result of competing 1,2-hydride addition 
(vide infra). Most interestingly, substrates bearing hydroxyl and protected 
amino groups at either 2 or 3 positions were tolerated, generating 
synthetically valuable amino alcohol and diamine (Table 5, entries 6-8, 
        13 SbF6  [Rh], 0.5    None   NR 
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10 and 11). For instance, 20j and 20k have found applications in the 
pharmaceutical industry as cyclic β-amino alcohol and diamine.17 
However, conjugated C=C double bond at the 2-postion was reduced to a 
significant degree, leading to 20i probably via 1,4-hydride addition 
beginning at the carbon α to the Ph group (Table 5, entry 9). Notably, 2,3-
disubstuted pyridinium can be hydrogenated to piperidine exclusively as 
the trans isomer, whilst the 2,6-disubstuted pyridinium affords cis 
piperidine as the major product (Table 5, entries 12 and 13). Non-benzyl 
quaternised pyridine is also viable. Thus, the N-phenylethyl piperidine 
20n, an analogue of a well-known σ receptor antagonist for treating 
methamphetamine abuse,
18
 is obtained from the corresponding 
pyridinium salt in excellent yield (Table 5, entry 14). However, 3-
substituted pyridiniums with electron-deficient groups such as fluoro, 
chloro, carbonyl and amide failed to generate any isolated products with 
few exceptions (vide infra).  
 
Table 5. TH of pyridiniums to piperidines.
[a] 
 
Entry Substrate Product Yield [%]
[b]
 
1 
  
94 (90) 
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2 
  
95 
3 
  
85 
4 
  
66 
5 
  
60
[c]
 
6 
  
94 
7 
  
79 
8 
  
96 
9 
  
69 
10 
  
99 (63) 
11 
  
77 
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12
[d]
 
  
94 
13
[d]
 
 
 
98 
14 
  
93 
[a] All reactions were carried out under the standard conditions: 19 (0.5 mmol), 
[Cp*RhCl2]2 (0.25 µmol), KI (0.5 mmol), HCO2H-NEt3 azeotrope solution  (5 
mL), 40 °C, N2, 24 h. [b] Isolated yields; data in bracket was obtained with 
0.005 mol% catalyst.
 
[c] 99% total isolated yield; the product was a mixture of 
20e and 3,4-unsaturated piperidine in a ratio of 3:2. [d] 20i, cis/trans = 3.2:1, 
determined by 
1
H NMR; 20m, trans/cis > 99:1, determined by NOE analysis. 
 
      Inspired by the observation of 3,4-unsaturated piperidine in the case 
of 20e, we wanted to test catalysis on 4-substituted pyridiniums. The N-
benzyl-4-picoline bromide salt 21a was prepared by routinely used 
alkylation procedure with 4-picoline. Thus, under the same conditions as 
above, surprisingly, the reduction of 21a afforded primarily the 3,4-
unsaturated piperidine 22a with 89% yield along with 6% fully reduced 
product (Table 6, entry 1). Prompted by this finding while considering the 
importance of such products, we subsequently examined the 
hydrogenation of a series of 4-substituted pyridiniums. It is noteworthy 
that these 4-substituted pyridiniums can be quantitatively formed under 
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mild conditions. The TH results are summaried in Table 6. To our delight, 
most of the 4-substituted pyridiniums were reduced with high or 
exclusive chemoselectivities toward the 3,4-unsaturated piperidine 
products. Thus, pyridiniums bearing different 4-alkyl substituents were 
hydrogenated with excellent yields (Table 6, entries 1-4), with bulkier 
substituent affording higher chemoselectivity favoring 22. For instance, 
in the case of 4-tert-butyl-substituted 21c, no fully reduced product was 
observed. The same is also true with 4-phenyl substituted pyridinium 21e, 
which led to 22e in almost quantitative yield. Of particular note is that the 
4-arylsubstituted piperidine derivatives have found tremendous medicinal 
uses (vide infra). The pyridiniums bearing electron-withdrawing and 
donating groups (21f, g) and other functionalities, such as hydroxyl (21h), 
ester (21j, k) and protected amine (21g, i), were viable as well, being 
reduced with excellent chemoselectivities and high yields. Conjugated or 
non-conjugated substitutents (Table 6, entries 10 vs 11) have no impact 
on the chemoselectivity. In sharp contrast to the reduction of 19i (Table 5, 
entry 9), the conjugated C=C double bond in 21l was mainly retained. 
The 4-styryl substituted 22l was isolated in 66% yield, exclusively in the 
s-cis conformation (Table 6, entry 12). Moreover, 3,4-disubstituted 
pyridinium 21m was also reduced to its tetrahydro analogue, although a 
higher catalyst loading (0.25 mol %) was required (Table 6, entry 13). 
The benzyl group is again not a necessity, and replacing it with 
phenylethyl did not significantly affect the yield (Table 6, entry 14). More 
interestingly, the benzyl could also be replaced with an allyl group, which 
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is a challenging functionality in heterogeneous hydrogenation (Table 6, 
entry 15). Surprisingly, as opposed to the full reduction of other 3-
electron-rich substitued pyridiniums (Table 6, entries 10 and 11), 21p was 
reduced to 3,4-unsaturated piperidine product (Table 6, entry 16). 
Although a low yield was observed for N-benzyl ethyl nicotinate iodide 
salt 21q, which echoed the unreactive nature of 3-EWG substituted 
pyridinium, the formation of enamine product 22q supports the proposed 
mechanism (vide infra). From these preliminary results, we believe that 
the presence of such a variety of functionalities including alkene, diene, 
hydroxyl, amino, ester and allyl units in these tetrahydropyrindines opens 
a vast space for further well-established reactions, as indicated before. We 
also note that 3,4-unsaturated piperidines can be accessed generally only 
through reduction with boron hydrides.
8
 
 
Table 6. Partial TH of 4-substituted pyridiniums.
[a] 
 
Entry Substrate Product Yield [%]
[b]
 
1 
  
89 (6) 
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2 
  
88 (3) 
3 
  
92 (0) 
4 
  
95 (4) 
5 
  
98 
6 
  
86 
7 
  
77 
8 
  
81 
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9 
  
95 
10 
  
90 
11 
  
81 
12
[d]
 
  
66 
13
[d]
 
  
85 
14 
  
87 (8) 
15 
  
81 
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16 
  
64 
17 
  
21 
[a] Reactions were carried out under the standard conditions given in Table 2. 
[b] Yield of fully reduced product is given in the bracket (determined by 
1
H 
NMR). [c] 0.5 mol % catalyst was used. [d] 0.25 mol % catalyst was used. [e] 
The conformation was determined by NOE analysis. 
 
      To further showcase the synthetic utility of this new protocol, we 
carried out the preparation of compound 22e on a gram scale. As can be 
seen in Figure 10, 4-arylpiperidines are a highly valuable structural unit 
found in drug discovery programs for potential treatment of a variety of 
symptoms such as asthma, hypertension, depression, cocaine abuse, 
migraines, benign prostatic hyperplasia, bacterial infection, estrogen-
related disorders, Alzheimer’s and Parkinson’s disease, and allergic 
rhinitis.
19
 However, the common synthetic methods for their synthesis are 
far from ideal, as presented in Scheme 46. These methods require using 
aryl organometallic species to react with 4-piperidone derivatives, 3,4-
unsaturated or fully saturated piperidines.
19
 Apart from environmental 
concerns, and often harsh and  sensitive conditions arising from using 
Grignard reagents, triflate, zinc, stannane, boron and silane reagents, 
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these methods need to employ costly or not commercially available 
piperidines as starting materials.  
 
 
Scheme 46: Common methods for preparation of 4-arylpiperidines  
 
      Our synthesis began with commercial and inexpensive 4-phenyl 
pyridine, which was quaternised readily with benzyl bromide affording 
21e in quantitative yield. Transfer hydrogenation of 21e (1.0 g) in the 
HCO2H-NEt3 azeotrope with an even lower catalyst loading of 0.0125 
mol % (0.25 mg) in air provided the 3,4-unsaturated piperidine product 
22e with 97% isolated yield in two steps (Scheme 47). This appears to us 
to be the most efficient way for accessing this type of compound, 
regarding cost, effectiveness, practicality and scalability.
19 
      It is also worth noting that for most reactions in Tables 5 and 6, the 
work-up simply involves direct extraction after basifying the reaction 
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mixture without further purification, due to the high solubility of 
pyridinium salts in aqueous solution. 
 
Scheme 47: TH of 4-substitued pyridinium in gram scale 
 
3.2.3 Mechanistic investigations 
      A plausible mechanism explaining the role of iodide and the observed 
chemoselectivity is shown in Scheme 48. As suggested before,
[16,20] 
the 
substrate is likely to be reduced with an anionic diiodo Rh-H hydride 
species. Both the iodide and anionic charge would render the hydride 
more hydridic, facilitating its transfer to the pyridinium. However, excess 
iodide salt is needed in order to suppress the dissociation of iodide anion 
from the active hydride species. As also observed in Chapter 2, too much 
iodide salt is not good, as it would facilitate the displacement of the 
coordinated formate by iodide, leading to catalytically inactive species. In 
the absence of a 4-substituent, the hydride adds preferentially at the 4 
position initially (i.e. 1,4-addition); the resulting enamine isomerises to 
an iminium species and is then reduced via a 1,2-hydride addition. When 
the 4 position is substituted, 1,4-addition becomes almost impossible. 
Instead, 1,2-addtion takes place to give 1,2-dihydropyridine; 
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isomerisation of the resulting enamine followed by another 1,2-adddition 
affords the N-substituted 1,2,3,6-tetrahydropyrindines.  
 
 
Scheme 48: Plausible mechanism for the TH of pyridinium salts 
 
      Consistent with this picture, the 2,4,6-positions of 20a and the 2,6-
postions of 22c were deuterated when DCOOH-NEt3 was used to reduce 
19a and 21c, respectively, as shown in Scheme 49. The analysis of 
1
H 
NMR spectra as indicates that full deuteration was occurred at the C6 and 
major deuteration at C2 and C4 of 19a, while full deuteration was 
detected at the C2 and C6 of 21c (see Section 3.4.4 for experimental 
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details). These deuteration results, can be readily explained with the 
mechanism suggested above, as shown in Scheme 50. 
 
 
 
 
 
 
 
A 
B 
a 
a 
f f 
b 
d e 
c 
g 
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Scheme 49: TH of 19a and 21c catalysed by [Cp*RhCl2]2. (A) with 
HCOOH-NEt3 azeotrope; (B) with DCOOH-NEt3 azeotrope. 
 
 
 
Scheme 50:  Proposed reaction pathways for TH of 19a and 21c with 
DCOOH catalysed by [Cp*RhCl2]2 
A 
B 
d a 
e 
b 
c 
f 
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3.3 Conclusions and future work     
 
      In conclusion, we have developed a simple, efficient catalytic system 
for the TH of pyridines under mild conditions (Scheme 51). In particular, 
this protocol affords not only piperidines but also the 3,4-unsaturated 
variants with high chemoselectivities. A variety of piperidines and 
1,2,3,6-tetrahydropyridines were obtained in good to excellent yields, 
providing valuable intermediates and feedstock for chemical, 
pharmaceutical and agrochemical synthesis. 
 
 
Scheme 51: Summary of the chemoselective TH of pyridinium salts 
 
      The ATH of 2-substituted pyridinium salts would be a natural 
extension of the full TH of pyridines. To seek structurally rigid ligands 
that are compatible with the stoichimetric iodide would probably 
dominate the  efforts. Additionally, a remote idea would be to explore, in 
combination with the well-established reactions of olefin, to realise 
further functionalisation of the retainied C=C bonds in 3,4-unsaturated 
piepridines in a one-pot fashion.  
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3.4 Experimental  
 
3.4.1 General information 
      Unless otherwise specified, the chemicals were obtained 
commercially from Aldrich, Alfa Aesar Apollo Scientific or TCI and 
used without further purification. Silica gel plates (GF254) were used for 
TLC monitoring and silica gel (230-400 mesh) was used for running 
column chromatography. Formic acid-triethyl amine azeotrope was 
distilled prior to use. NMR spectra were recorded on a Bruker 400 MHz 
NMR spectrometer with TMS as the internal standard. The mass spectra 
were obtained by chemical ionization (CI) or electrospray ionization 
(ESI). No significant difference was observed when the reaction was 
carried out in air and non-distilled formic acid-triethyl amine azeotrope. 
3.4.2 Typical procedure for pyridinium salts preparation 
 
      The first step of the above reaction represents a new synthetic 
procedure for the two compounds trans-2-styrylpyridine and trans-4-
styrylpyridine according to the similar Heck reaction conditions,
20a
 while 
the second step demonstrates the general procedure to prepare 
pyridinium salts. 
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      An oven-dried carousel tube containing a stirring bar was charged 
with Pd(OAc)2 (0.25 mmol) and n-Bu4NBr (5.0 mmol). After degassing 
three times with nitrogen, Et3N (7.5 mmol), PhBr (5 mmol), 4-
vinylpyridine (7.5 mmol) and DMF (10 mL) were injected, after which 
the resulting mixture was stirred at 100 °C for 16 h. After cooling down 
to room temperature, the reaction mixture was transferred to pass a short 
silica-gel column to remove all the undissolved materials and washed 
with EtOAc (100 mL). The organic washes were combined and washed 
with 30 mL of brine, then dried over anhydrous Na2SO4 and evaporated 
under reduced pressure. The solid residue was washed with hexane to 
remove the excessive 4-vinylpyridine which was hard to separate in TLC. 
After further dryness under vacuum, yellow solid was obtained (550 mg, 
60%) as the desired product- trans-4-styrylpyridine. For the compound 
trans-2-styrylpyridine (540 mg, 59%), the same procedure was performed 
and the analytical data of the two compounds are in agreement with 
literature.
20b,c
 
      The obtained trans-4-styrylpyridine (500 mg, 2.75 mmol) was mixed 
with benzyl bromide (3.6 mmol, 0.4 mL) and 5 mL CH3CN (For some 
substrates, a different solvent, like acetone or methanol, was chose for the 
quaternisation.) in a carousel tube. The mixture was refluxed at 85 °C for 
15 min, light-yellow precipitates appeared and the reaction was stirred for 
overnight. After cooling down, the slurry was filtered, washed with 
acetone and dried under vacuum to give light-yellow powder 21l (900 mg, 
93%, unknown compound). 
1
H NMR (d
6
-DMSO, 400 MHz) δ (ppm): 
                                                                                                                             Chapter 3 
 
122 
 
9.13 (d, J = 6.4 Hz, 2H), 8.31 (d, J = 6.8 Hz, 2H), 8.06 (d, J = 16.4 Hz, 
1H), 7.78-7.76 (m, 2H), 7.59-7.55 (m, 3H), 7.52-7.41 (m, 6H), 5.80 (s, 
2H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 153.7, 144.8, 141.6, 135.5, 
135.0, 130.9, 129.63, 129.60, 129.5, 129.0, 128.6, 124.7, 123.7, 62.6; 
HRMS (ESI+) for C2H18N [M-Br]
+
 m/z Calcd: 272.1439; Found: 
272.1440. Anal. calcd. for C2H18BrN: C, 68.19; H, 5.15; N, 3.98; Found: 
C, 67.97; H, 5.06; N, 3.90. Substrate 19i was obtained through the same 
procedure as yellow powder (unknown compound). 
1
H NMR (d
6
-DMSO, 
400 MHz) δ (ppm): 9.22 (d, J = 6.4 Hz, 1H), 8.61 (d, J = 4.4 Hz, 2H), 
8.09-8.03 (m, 1H), 7.89 (d, J = 16.0 Hz, 1H), 7.78-7.75 (m, 2H), 7.72 (d, 
J = 16.0 Hz, 1H), 7.50-7.43 (m, 3H), 7.40-7.30 (m, 5H), 6.19 (s, 2H); 
13
C 
NMR (CDCl3, 100 MHz) δ (ppm): 152.6, 146.5, 145.6, 143.4, 135.1, 
134.6, 131.2, 129.5, 129.4, 129.1, 129.0, 128.8, 127.8, 126.5, 126.2, 
118.0, 60.6; HRMS (ESI+) for C2H18N [M-Br]
+
 m/z Calcd: 272.1439; 
Found: 272.1438. Anal. calcd. for C2H18BrN: C, 68.19; H, 5.15; N, 3.98; 
Found: C, 67.79; H, 5.04; N, 3.84. 
 
3.4.3 General procedure for TH of pyridines 
      A carousel reaction tube containing a magnetic stirring bar and 
[Cp*RhCl2]2 (0.155 mg, 0.25 μmol, measured using a stock DCM 
solution), N-benyl-2-methylpyridinium bromide salt (19a, 132 mg, 0.5 
mmol) and potassium iodide (83 mg, 0.5 mmol) in 5 mL HCOOH-NEt3 
azeotrope was sealed after degassing and placed in a carousel reactor. 
The reaction mixture was stirred at 40 °C for 24 h, cooled to room 
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temperature and then basified with an aqueous solution of KOH. The 
resulting mixture was extracted with ethyl acetate (3×20 mL) and dried 
over Na2SO4. The solvent was removed under reduced pressure, and after 
further dryness under vacuum, the product was sent for analysis without 
further purification. In the case of 20c-d, 20f-i, and 20k, 22f-i, 22k-m 
and 22o, the crude product was purified by column chromatography 
(EtOAc/hexane). 
 
3.4.4 Deuteration experiments 
      In a carousel reaction tube containing a magnetic stirring bar was 
charged [Cp*RhCl2]2 (1.8 mg, 0.0028 mmol), 19a (80 mg, 0.3 mmol) and 
potassium iodide (50 mg, 0.3 mmol). The pre-prepared DCOOH-NEt3 
mixture (DCOOH, 10 mmol, 0.40 mL; NEt3, 4 mmol, 0.56 mL) was then 
introduced into the reaction tube, which was placed in a carousel reactor. 
The reaction mixture was stirred at 40 °C for 21 h. After cooling to room 
temperature and basifying with an aqueous solution of KOH, the 
resulting mixture was extracted with ethyl acetate (3×15 mL) and dried 
over Na2SO4. The solvent was removed under reduced pressure, and the 
residue was purified by flash column chromatography to afford the pure 
product 20a (39 mg, 68%), which was then analysed with 
1
H NMR 
(Scheme 49, eq. 1). For TH of 21c, after the same procedure was 
performed, pure product 22c (64 mg, 93%) was obtained, which was also 
analysed with 
1
H NMR (Scheme 49, eq. 2).  
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3.5 Analytic data of isolated products  
1-Benzyl-2-methylpiperidine (20a):
20d
 
1
H NMR (CDCl3, 400 
MHz) δ (ppm): 7.40-7.34 (m, 4H), 7.30-7.26 (m, 1H), 4.07 (d, J = 13.6 
Hz, 1H), 3.26 (d, J = 13.6 Hz, 1H), 2.80 (dt, J = 11.6, 3.7 Hz, 1H), 2.40-
2.32 (m, 1H), 2.01 (td, J = 10.8, 3.6 Hz, 1H), 1.74-1.69 (m, 2H), 1.61-
1.29 (m, 4H), 1.24 (d, J = 6.4 Hz, 3H); 
13
C NMR (CDCl3, 100 MHz) δ 
(ppm): 139.6, 129.7, 128.5, 127.1, 58.8, 56.8, 52.5, 35.1, 26.4, 24.4, 20.0; 
MS (CI, m/z, %) 190 (100) [M+H]
+
;  Anal. calcd. for C13H19N: C, 82.48; 
H, 10.12; N, 7.40; Found: C, 81.87; H, 10.25; N, 7.35. 
1-Benzyl-2-ethylpiperidine (20b):
20e 1
H NMR (CDCl3, 400 
MHz) δ (ppm): 7.39-7.32 (m, 4H), 7.29-7.24 (m, 1H), 4.04 (d, J = 13.6 
Hz, 1H), 3.24 (d, J = 13.6 Hz, 1H), 2.79 (dt, J = 11.6, 3.8 Hz, 1H), 2.28-
2.22 (m, 1H), 2.07-2.01 (m, 1H), 1.75-1.63 (m, 4H), 1.53-1.44 (m, 3H), 
1.38-1.31 (m, 1H), 0.97 (d, J = 7.6 Hz, 3H); 
13
C NMR (CDCl3, 100 MHz) 
δ (ppm): 140.3, 129.4, 128.5, 127.0, 62.3, 58.0, 52.4, 30.2, 25.8, 24.9, 
24.3, 10.2; MS (CI, m/z, %) 204 (100) [M+H]
+
;  Anal. calcd. for C14H21N: 
C, 82.70; H, 10.41; N, 6.89; Found: C, 82.58; H, 10.63; N, 7.18. 
1,2-Dibenzypiperidine (20c):
20e 1
H NMR (CDCl3, 400 
MHz) δ (ppm): 7.37-7.28 (m, 5H), 7.24-7.13 (m, 5H), 4.06 (d, J = 13.6 
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Hz, 1H), 3.49 (d, J = 13.6 Hz, 1H), 3.17 (d, J = 9.6 Hz, 1H), 2.80-2.74 (m, 
1H), 2.68-2.58 (m, 2H), 2.25-2.19 (m, 1H), 1.67-1.60 (m, 1H), 1.54-1.50 
(m, 3H), 1.36-1.23 (m, 3H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 140.9, 
140.1, 129.8, 129.3, 128.64, 128.59, 127.2, 126.2, 62.2, 58.9, 51.3, 36.9, 
29.7, 25.8, 22.9; HRMS for C19H24N [M+H]
+
: m/z calcd 266.1909, found 
266.1908. 
1-Benzyl-2-phenylpiperidine (20d):
20f 1
H NMR (CDCl3, 
400 MHz) δ (ppm): 7.45 (d, J = 7.2 Hz, 2H), 7.32 (t, J = 7.8 Hz, 2H), 
7.26 (d, J = 4.4 Hz, 4H), 7.24-7.17 (m, 2H), 3.76 (d, J = 13.6 Hz, 1H), 
3.10 (dd, J = 11.0, 2.6 Hz, 1H), 2.96 (d, J = 11.6 Hz, 1H), 2.80 (d, J = 
13.2 Hz, 1H),  1.96-1.89 (m, 1H), 1.80-1.74 (m, 2H), 1.67-1.51 (m, 3H), 
1.42-1.30 (m, 1H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 146.2, 140.3, 
129.1, 128.9, 128.4, 127.9, 127.3, 126.9, 69.6, 60.2, 53.8, 37.5, 26.4, 25.7; 
HRMS for C18H22N [M+H]
+
: m/z calcd 252.1752, found 252.1750. 
 (1-Benzylpiperidin-2-yl)methanol (20f):
20g
 
1
H NMR 
(CDCl3, 400 MHz) δ (ppm): 7.34-7.28 (m, 4H), 7.26-7.22 (m, 1H), 4.06 
(d, J = 13.6 Hz, 1H), 3.87 (dd, J = 10.8, 4.0 Hz, 1H), 3.52 (dd, J = 10.8, 
3.6 Hz, 1H), 3.31 (d, J = 13.2 Hz, 1H), 2.89-2.84 (m, 3H), 2.70 (br, 1H), 
2.45 (dq, J = 8.8, 4.2 Hz, 1H), 2.17-2.11 (m, 1H), 1.73-1.52 (m, 4H), 
1.42-1.31 (m, 2H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 139.4, 129.3, 
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128.8, 127.4, 62.7, 61.3, 58.1, 51.2, 27.7, 24.5, 23.9; MS (CI, m/z, %) 206 
(100) [M+H]
+
;  Anal. calcd. for C13H19NO: C, 76.06; H, 9.33; N, 6.82; 
Found: C, 76.11; H, 9.70; N, 7.17. 
tert-Butyl ((1-benzylpiperidin-2-yl)methyl)carbamate 
(20g):
20h
 
1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.34-7.29 (m, 4H), 7.26-
7.23 (m, 1H), 5.05 (br, 1H), 4.00 (d, J = 13.2 Hz, 1H), 3.43 (dt, J = 13.6, 
4.4 Hz, 1H), 3.29-3.23 (m, 1H), 3.20 (d, J = 13.6 Hz, 1H), 2.83-2.79 (m, 
1H), 2.43-2.33 (m, 1H), 2.03 (td, J = 11.1, 2.5 Hz, 1H), 1.73-1.60 (m, 
2H), 1.57-1.49 (m, 2H), 1.45 (s, 9H), 1.40-1.25 (m, 2H); 
13
C NMR 
(CDCl3, 100 MHz) δ (ppm): 156.8, 139.5, 129.3, 128.7, 127.3, 59.9, 58.0, 
52.2, 42.6, 29.3, 28.9, 25.2, 24.1; HRMS for C18H29N2O2 [M+H]
+
: m/z 
calcd 305.2229, found 305.2233. 
Benzyl ((1-benzylpiperidin-2-yl)methyl)carbamate 
(20h, unknown compound): 
1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.35-
7.19 (m, 10H), 5.36 (br, 1H), 5.09 (s, 2H), 3.98 (d, J = 13.6 Hz, 1H), 3.48 
(dt, J = 13.6, 4.4 Hz, 1H), 3.34-3.29 (m, 1H), 3.19 (d, J = 13.2 Hz, 1H), 
2.81-2.75 (m, 1H), 2.43-2.39 (m, 1H), 2.01 (td, J = 11.2, 2.8 Hz, 1H), 
1.70-1.25 (m, 6H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 157.2, 139.4, 
137.2, 129.2, 128.9, 128.7, 128.50, 128.48, 127.3, 67.0 59.7, 58.1, 52.2, 
43.1, 29.3, 25.2, 24.1; HRMS for C21H27N2O2 [M+H]
+
: m/z calcd 
339.2073, found 339.2059. 
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1-Benzyl-2-phenethylpiperidine (20i, unknown 
compound):
 1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.39-7.21 (m, 10H), 
4.04 (d, J = 13.6 Hz, 1H), 3.32 (d, J = 13.6 Hz, 1H), 2.83-2.76 (m, 2H), 
2.70-2.62 (m, 1H), 2.48-2.44 (m, 1H), 2.16-2.08 (m, 1H), 2.04-1.88 (m, 
2H), 1.79-1.71 (m, 2H), 1.64-1.49 (m, 3H), 1.44-1.33 (m, 1H); 
13
C NMR 
(CDCl3, 100 MHz) δ (ppm): 142.9, 129.0, 128.4, 128.2, 126.8, 125.7, 
60.2, 57.4, 51.4, 33.5, 31.7, 29.9, 24.9, 23.5; MS (CI, m/z, %) 280 (100) 
[M+H]
+
;  Anal. calcd. for C12H17NO: C, 85.97; H, 9.02; N, 5.01; Found: C, 
84.74; H, 9.17; N, 4.82. 
1-Benzylpiperidin-3-ol (20j):
20i 1
H NMR (CDCl3, 400 MHz) 
δ (ppm): 7.33-7.22 (m, 5H), 3.81-3.76 (m, 1H), 3.49 (s, 1H), 2.67 (br, 
1H), 2.52-2.43 (m, 3H), 2.35-2.28 (m, 1H), 1.81-1.73 (m, 1H), 1.63-1.48 
(m, 3H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 138.6, 129.5, 128.7, 
127.5, 66.7, 63.5, 60.7, 53.9, 32.2, 22.1; MS (CI, m/z, %) 192 (100) 
[M+H]
+
;  Anal. calcd. for C12H17NO: C, 75.35; H, 8.96; N, 7.32; Found: C, 
73.71; H, 9.01; N, 7.28. 
tert-Butyl (1-benzylpiperidin-3-yl)carbamate (20k):
20j
 
1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.28-7.15 (m, 5H), 4.94 (br, 1H), 
3.68 (br, 1H), 3.39 (s, 2H), 2.43-2.12 (m, 4H), 1.61-1.40 (m, 4H), 1.37 (s, 
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9H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 155.6, 138.7, 129.4, 128.6, 
127.4, 79.4, 63.5, 59.1, 53.8, 46.8, 30.1, 28.9, 22.7; MS (CI, m/z, %) 291 
(100) [M+H]
+
;  Anal. calcd. for C17H26N2O2: C, 70.31; H, 9.02; N, 9.65; 
Found: C, 69.72; H, 9.03; N, 9.57. 
 (±)-cis-1-Benzyl-2,6-dimethylpiperidine (20l):
20k 1
H NMR 
(CDCl3, 400 MHz) δ (ppm): 7.38 (d, J = 6.8 Hz, 2H), 7.28 (t, J = 7.6 Hz, 
3H), 3.81 (s, 2H), 2.54-2.45 (m, 2H), 1.67-1.51 (m, 4H), 1.37-1.33 (m, 
2H), 1.07 (d, J = 6.0 Hz, 6H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 
142.5, 128.5, 128.3, 126.5, 57.7, 54.1, 35.1, 24.7, 22.6; MS (CI, m/z, %) 
204 (100) [M+H]
+
;  Anal. calcd. for C14H21N: C, 82.70; H, 10.41; N, 6.89; 
Found: C, 82.38; H, 10.49; N, 7.14. The ratio of cis-conformation is 
determined by 
1
HNMR integration, according to the literature.
20k
 
 (±)-trans-1-Benzyl-2,3-dimethylpiperidine (20m, unknown 
compound): 
1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.29 (d, J = 7.2 Hz, 
2H), 7.23 (t, J = 7.4 Hz, 2H), 7.15 (t, J = 7.2 Hz, 1H), 3.58 (d, J = 13.6 
Hz, 1H), 3.45 (d, J = 13.6 Hz, 1H), 2.72-2.67 (m, 1H), 2.41-2.35 (m, 1H), 
2.27-2.25 (m, 1H), 1.87-1.80 (m, 1H), 1.52-1.44 (m, 2H), 1.39-1.33 (m, 
1H), 1.24-1.14 (m, 1H), 0.82 (d, J = 6.8 Hz, 3H), 0.78 (d, J = 7.2 Hz, 3H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 140.8, 129.0, 128.5, 126.9, 59.5, 
58.1, 47.0, 35.4, 28.3, 25.4, 18.4; MS (CI, m/z, %) 204 (100) [M+H]
+
;  
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Anal. calcd. for C14H21N: C, 82.70; H, 10.41; N, 6.89; Found: C, 82.37; 
H, 10.76; N, 7.26. The trans-conformation is determined by NOE 
analysis. 
2-Methyl-1-phenethylpiperidine (20n):
20l 1
H NMR (CDCl3, 
400 MHz) δ (ppm): 7.30-7.26 (m, 2H), 7.20-7.17 (m, 3H), 2.97-2.67 (m, 
5H), 2.40-2.30 (m, 2H), 1.71-1.53 (m, 4H),  1.37-1.26 (m, 2H), 1.15 (d, J 
= 6.4 Hz, 3H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 141.4, 129.1, 128.8, 
126.3, 56.7, 55.8, 52.7, 35.2, 31.9, 26.7, 24.6, 19.7; MS (CI, m/z, %) 204 
(100) [M+H]
+
;  Anal. calcd. for C14H21N: C, 82.70; H, 10.41; N, 6.89; 
Found: C, 83.05; H, 10.49; N, 6.97. 
1-Benzyl-4-methyl-1,2,3,6-tetrahydropyridine (22a):
20m 1
H 
NMR (CDCl3, 400 MHz) δ (ppm): 7.41-7.26 (m, 5H), 5.41-5.39 (m, 1H), 
3.60 (s, 2H), 2.98-2.96 (m, 2H), 2.59 (t, J = 5.8 Hz, 2H), 2.11 (br s, 2H), 
1.72 (s, 3H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 138.9, 133.2, 129.7, 
128.6, 127.4, 119.8, 63.3, 53.4, 50.4, 31.3, 23.4; HRMS for C13H18N 
[M+H]
+
: m/z calcd 188.1434, found 188.1435. 
1-Benzyl-4-ethyl-1,2,3,6-tetrahydropyridine (22b):
20n 1
H 
NMR (CDCl3, 400 MHz) δ (ppm): 7.29-7.15 (m, 5H), 5.29-5.27 (m, 1H), 
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3.50 (s, 2H), 2.91-2.88 (m, 2H), 2.48 (t, J = 5.8 Hz, 2H), 2.02 (br s, 2H), 
1.91 (q, J = 7.1 Hz, 2H), 0.93 (t, J = 7.4 Hz, 3H); 
13
C NMR (CDCl3, 100 
MHz) δ (ppm): 138.8, 138.4, 129.7, 128.6, 127.4, 117.8, 63.3, 53.4, 50.4, 
29.9, 29.7, 12.2; HRMS for C14H20N [M+H]
+
: m/z calcd 202.1590, found 
202.1589. 
1-Benzyl-4-(tert-butyl)-1,2,3,6-tetrahydropyridine (22c, 
unknown compound): 
1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.36-7.22 
(m, 5H), 5.41-5.39 (m, 1H), 3.57 (s, 2H), 3.02-3.00 (m, 2H), 2.52 (t, J = 
5.8 Hz, 2H), 2.15 (br s, 2H), 1.02 (s, 9H); 
13
C NMR (CDCl3, 100 MHz) δ 
(ppm): 144.6, 138.8, 129.6, 128.6, 127.4, 116.3, 63.3, 53.9, 50.6, 35.3, 
29.2, 25.9; HRMS for C16H24N [M+H]
+
: m/z calcd 230.1903, found 
230.1906. 
1,4-Dibenzyl-1,2,3,6-tetrahydropyridine (22d):
20o 1
H NMR 
(CDCl3, 400 MHz) δ (ppm): 7.33-7.15 (m, 10H), 5.36-5.35 (m, 1H), 3.55 
(s, 2H), 3.27 (s, 2H),  2.97-2.96 (m, 2H), 2.51 (t, J = 5.8 Hz, 2H), 2.03 (br 
s, 2H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 140.0, 138.8, 136.3, 129.7, 
129.6, 128.69, 128.65, 127.5, 126.5, 121.3, 63.2, 53.4, 50.3, 43.9, 29.4; 
HRMS for C19H22N [M+H]
+
: m/z calcd 264.1747, found 264.1748. 
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1-Benzyl-4-phenyl-1,2,3,6-tetrahydropyridine (22e):
20n 1
H 
NMR (CDCl3, 400 MHz) δ (ppm): 7.39-7.19 (m, 10H), 6.07-6.05 (m, 1H), 
3.64 (s, 2H), 3.18 (q, J = 3.0 Hz, 2H), 2.72 (t, J = 5.6 Hz, 2H), 2.57(br s, 
2H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 141.3, 138.6, 135.4, 129.7, 
128.70, 128.68, 127.5, 127.4, 125.3, 122.3, 63.2, 53.8, 50.4, 28.4; HRMS 
for C18H20N [M+H]
+
: m/z calcd 250.1590, found 250.1593. The reaction 
condition for gram-scale TH of 21e is as follows: 21e (1.01 g), 
[Cp*RhCl2]2 (0.25 mg), KI (515 mg), non-distilled HCOOH-Et3N 
azeotrope (10 mL), 24 hrs in air. 
1-Benzyl-4-(trifluoromethyl)-1,2,3,6-tetrahydropyridine 
(22f):
20p 1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.33 (d, J = 4.4 Hz, 4H), 
7.31-7.25 (m, 1H), 6.28-6.25 (m, 1H), 3.62 (s, 2H), 3.10-3.06 (m, 2H), 
2.63 (t, J = 5.6 Hz, 2H), 2.29 (br s, 2H); 
13
C NMR (CDCl3, 100 MHz) δ 
(ppm): 138.2, 129.4, 128.82, 128.75 (q, JCF = 57.0 Hz), 127.7, 127.2 (q, 
JCF = 31.3 Hz), 124.0 (q, JCF = 268.5 Hz), 62.7, 51.9, 48.9, 23.6; HRMS 
for C13H15NF3 [M+H]
+
: m/z calcd 242.1151, found 242.1153. 
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tert-Butyl (1-benzyl-1,2,3,6-tetrahydropyridin-4-
yl)carbamate (22g):
20q 1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.37-7.22 
(m, 5H), 5.79 (br, 1H), 5.68 (s, 1H), 3.57 (s, 2H), 3.06-3.04 (m, 2H), 2.60 
(t, J = 5.8 Hz, 2H), 2.24 (br s, 2H), 1.45 (s, 9H) ; 
13
C NMR (CDCl3, 100 
MHz) δ (ppm): 153.2, 138.8, 131.3, 129.5, 128.7, 127.5, 106.4, 80.4, 62.8, 
52.1, 49.7, 29.0, 28.7; HRMS for C17H25N2O2 [M+H]
+
: m/z calcd 
289.1911, found 289.1906. 
1-(1-Benzyl-1,2,3,6-tetrahydropyridin-4-yl)ethanol (22h):
20r 
1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.35-7.22 (m, 5H), 5.57 (s, 1H), 
4.15 (q, J = 6.4 Hz, 1H), 3.57 (s, 2H), 3.33 (br, 1H), 2.96 (d, J = 2.4 Hz, 
2H), 2.61-2.51 (m, 2H), 2.15 (d, J = 1.2 Hz, 2H), 1.24 (d, J = 6.4 Hz, 2H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 140.5, 138.1, 129.8, 128.7, 127.6, 
119.2, 71.0, 63.1, 52.8, 50.1, 25.1, 21.9; HRMS for C14H20NO [M+H]
+
: 
m/z calcd 218.1539, found 218.1541. 
tert-Butyl ((1-benzyl-1,2,3,6-tetrahydropyridin-4-
yl)methyl)carbamate (22i, unknown compound): 
1
H NMR (CDCl3, 400 
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MHz) δ (ppm): 7.35-7.29 (m, 4H), 7.27-7.23 (m, 1H), 5.53-5.51 (m, 1H),  
4.60 (br, 1H), 3.66 (d, J = 4.8 Hz, 2H), 3.57 (s, 2H), 2.97 (br s, 2H), 2.57 
(t, J = 5.8 Hz, 2H), 2.10 (br s, 2H), 1.44 (s, 9H); 
13
C NMR (CDCl3, 100 
MHz) δ (ppm): 156.4, 138.6, 134.3, 129.6, 128.64, 128.55, 127.5, 120.9, 
71.0, 63.1, 53.0, 50.0, 46.1, 28.8, 27.6; HRMS for C18H27N2O2 [M+H]
+
: 
m/z calcd 303.2073, found 303.2069. 
Ethyl 2-(1-benzyl-1,2,3,6-tetrahydropyridin-4-yl)acetate 
(22j):
20s 1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.38-7.22 (m, 5H), 5.55 
(br s, 1H), 4.13 (q, J = 7.2 Hz, 2H), 3.58 (s, 2H), 2.99 (s, 4H), 2.59 (t, J = 
5.8 Hz, 2H), 2.18 (br s, 2H), 1.25 (t, J = 7.2 Hz, 3H);  
13
C NMR (CDCl3, 
100 MHz) δ (ppm): 171.9, 138.7, 130.2, 129.6, 128.6, 127.5, 124.0, 63.0, 
61.0, 53.1, 50.1, 42.9, 29.6, 14.7; HRMS for C16H22NO2 [M+H]
+
: m/z 
calcd 260.1651, found 260.1658. 
Ethyl 1-benzyl-1,2,3,6-tetrahydropyridine-4-carboxylate 
(22k):
20t 1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.28-7.17 (m, 5H), 6.80 
(br s, 1H), 4.12 (q, J = 7.1 Hz, 2H), 3.54 (s, 2H), 3.06 (q, J = 3.2 Hz, 2H), 
2.53 (t, J = 5.6 Hz, 2H), 2.34 (br s, 2H), 1.20 (t, J = 7.2 Hz, 3H);  
13
C 
NMR (CDCl3, 100 MHz) δ (ppm): 167.1, 138.4, 137.0, 129.4, 129.3, 
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128.7, 127.6, 62.8, 60.8, 53.1, 49.7, 25.7, 14.7; HRMS for C15H20NO2 
[M+H]
+
: m/z calcd 246.1489, found 246.1491. 
s-cis-1-Benzyl-(trans-4-styryl)-1,2,3,6-tetrahydropyridine 
(22l):
20n 1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.42-7.23 (m, 10H), 6.83 
(d, J = 16.0 Hz, 1H, CH=CHPh), 6.48 (d, J = 16.0 Hz, 1H, CH=CHPh), 
5.85 (s, 1H), 3.67 (s, 2H), 3.18 (s, 2H), 2.67 (t, J = 5.2 Hz, 2H), 2.46 (s, 
2H);  
13
C NMR (CDCl3, 100 MHz) δ (ppm): 138.2, 137.7, 134.3, 130.9, 
129.2, 128.6, 128.3, 127.2, 126.3, 126.0, 62.7, 53.3, 49.7, 25.5; MS (CI, 
m/z, %) 276 (100) [M+H]
+
; Anal. calcd. for C2H21N: C, 87.23; H, 7.69; N, 
5.09; Found: C, 86.91; H, 7.74; N, 5.04. The s-cis conformation is 
determined by NOE analysis. 
1-Benzyl-4,5-dimethyl-1,2,3,6-tetrahydropyridine 
(22m):
20u 1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.37-7.29 (m, 4H), 7.27-
7.23 (m, 1H), 3.55 (s, 2H), 2.83 (s, 2H), 2.50 (t, J = 5.8 Hz, 2H), 2.06 (br 
s, 2H), 1.62 (d, J = 0.8 Hz, 3H), 1.56 (d, J = 0.8 Hz, 3H);  
13
C NMR 
(CDCl3, 100 MHz) δ (ppm): 138.8, 129.7, 128.6, 127.4, 124.9, 124.4, 
63.3, 58.6, 50.7, 32.5, 18.7, 17.0; HRMS for C14H20N [M+H]
+
: m/z calcd 
202.1590, found 202.1589. 
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4-Methyl-1-phenethyl-1,2,3,6-tetrahydropyridine (22n):
20v 
1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.31-7.29 (m, 2H), 7.22-7.18 (m, 
3H),  5.39 (br s, 1H), 3.01 (s, 2H), 2.87-2.83 (m, 2H), 2.68-2.62 (m, 4H), 
2.12 (br s, 2H), 1.69 (s, 3H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 140.9, 
133.2, 129.1, 128.8, 126.4, 119.5, 60.8, 53.2, 50.8, 34.5, 31.3, 23.3; 
HRMS for C14H20N [M+H]
+
: m/z calcd 202.1590, found 202.1590. 
1-Allyl-4-benzyl-1,2,3,6-tetrahydropyridine (22o, 
unknown compound): 
1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.29-7.25 
(m, 2H), 7.20-7.16 (m, 3H),  5.95-5.85 (m, 1H), 5.39-5.36 (m, 1H), 5.20-
5.11 (m, 2H), 3.28 (s, 2H), 3.05 (dt, J = 6.8, 1.2 Hz, 2H), 2.97-2.94 (m, 
2H), 2.52 (t, J = 5.8 Hz, 2H), 2.07-2.04 (m, 2H); 
13
C NMR (CDCl3, 100 
MHz) δ (ppm): 139.9, 136.4, 135.9, 129.5, 128.7, 126.4, 121.3, 118.1, 
61.8, 53.2, 50.3, 43.9, 29.4; HRMS for C15H20N [M+H]
+
: m/z calcd 
214.1590, found 214.1594. HRMS for C14H20N [M+H]
+
: m/z calcd 
202.1590, found 202.1590. 
1-benzyl-5-methoxy-1,2,3,6-tetrahydropyridine (22p, 
unknown compound): 
1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.36-7.23 
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(m, 5H, overlapped with CHCl3 peak), 4.66 (t, J = 4.0 Hz, 1H),  3.60 (s, 
2H), 3.51 (s, 3H), 2.92 (q, J = 1.2 Hz, 2H), 2.52 (t, J = 6.0 Hz, 2H), 2.20-
2.15 (m, 2H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 153.3, 138.2, 129.3, 
128.4, 127.2, 91.2, 62.6, 54.2, 54.1, 50.2, 23.8; HRMS for C13H18NO 
[M+H]
+
: m/z calcd 204.1383, found 204.1388. 
Ethyl 1-benzyl-1,4,5,6-tetrahydropyridine-3-carboxylate 
(22q):
20w
 
1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.55 (s, 1H), 7.37-7.33 
(m, 2H),  7.31-7.27 (m, 1H), 7.23-7.21 (m, 2H), 4.29 (s, 2H), 4.15 (q, J = 
7.2 Hz, 2H), 2.99 (t, J = 5.6 Hz, 2H), 2.29 (t, J = 6.0 Hz, 2H),  1.79 
(quintet, J = 5.6 Hz, 2H), 1.27 (t, J = 7.2 Hz, 3H),; 
13
C NMR (CDCl3, 100 
MHz) δ (ppm): 168.9, 146.3, 137.2, 128.9, 127.8, 127.5, 94.9, 59.9, 59.1, 
45.5, 21.4, 20.1, 14.9; MS (CI, m/z, %) 268 (100) [M+Na]
+
;  Anal. calcd. 
for C15H19NO2: C, 73.44; H, 7.81; N, 5.71; Found: C, 73.07; H, 8.01; N, 
6.01. 
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4.1 Introduction 
 
       In Chapters 2 and 3, we described that a rhodium-catalysed TH 
system, promoted by iodide ion, can reduce a range of N-heteroaromatics 
including quinolines, isoquinolines, quinoxalines and pyridinium salts, 
affording a series of valuable heterocycles under mild conditions. In this 
Chapter, we will present a complementary approach by using a 
cyclometalated iridium catalyst to hydrogenate N-heteroaromatics with 
dihydrogen, which was accidentally discovered during attempts to search 
for new TH catalysts. 
      The hydrogenation of organic compounds with H2 is one of the great 
success stories of homogeneous catalysis. Building on the pioneering 
work of Wilkinson, Crabtree, Knowles and Noyori, highly effective 
hydrogenations of C=C and C=O bonds including the asymmetric 
versions have been developed and widely adopted by the synthetic 
community.
1 
However the field of C=N bond hydrogenation is much less 
well developed and utilised, particularly for the case of N-heterocycles. 
As stated in Chapters 1 and 2, reduced heterocyclic compounds are 
present in many pharmaceuticals, natural products, organic dyes, 
fragrances and as hydrogen storage materials, and as a result, efficient 
methods for the synthesis of these compounds are desirable.
2 
Of these, the 
catalytic hydrogenation of the parent unsaturated N-heterocycles with 
hydrogen gas is the most atom-economical route to these products. 
Additionally, hydrogenation offers an environmentally sound alternative 
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to the traditional reductions, due to the lack of stoichiometric waste 
products associated with the use of reactive metals and metal hydrides or 
other hydrogen sources.
3
 
      In comparison to the hydrogenation of olefins, carbonyls and imines, 
the hydrogenation of N-heterocycles is more challenging due to the 
aromaticity of the N-heterocyles.  Transition metal catalysts based on Rh, 
Ir, Ru, Os, Mo and Fe have been applied to the homogeneous 
hydrogenation of N-heterocycles, including the asymmetric versions.
4, 5 
Unfortunately, these reactions are often characterised with the use of high 
temperatures or hydrogen pressures, while many systems require the use 
of additives such as Brønsted acids
5g
, chloroformates
5h
 or I2
5f  
to activate 
the substrates or catalysts. Furthermore, to the best of our knowledge, 
there is no single reported catalyst capable of hydrogenating quinolines, 
3,4-dihydroisoquinolines, quinoxalines and indoles, let alone under mild 
conditions. Recently, Crabtree and co-workers reported that a 
[Ir(NHC)(PPh3)(COD)]PF6 complex is active for the reduction of  N-
heteroaromatics at room temperature and low H2 pressures (1-5 atm).
5d 
However, additional PPh3 was required for catalytic activity and the 
substrates were limited mainly to quinolines. 
 
4.2 Results and Discussion 
 
4.2.1 Initial results and further optimisation 
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      Recently, Xiao and co-workers reported that cyclometallated 
Cp*Ir(N^C)Cl complexes derived from substituted acetophenone imines 
are highly active catalysts for a range of hydrogen transfer reactions such 
as TH of imines, reductive amination and dehydrogenation of formic 
acid.
6 
Among these catalysts, which are now commercially available, we 
found that a catalyst bearing an electron-donating group can catalyse 
dehydrogenation of various benzo-fused N-heterocycles, releasing H2 as 
the only byproduct.
6e
 As can be seen in Figure 11, using as low as 0.1 
mol% catalyst and in the absence of acceptors and additives, the reaction 
realises the oxidation without oxidants, affording quinolines, indoles, 
quinoxalines, isoquinolines and β-carbolines in high yields. 
 
 
Figure 11: Acceptorless dehydrogenation of N-heterocycles 
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      During this work, we observed that under the same conditions, the 
catalyst for dehydrogenation also can catalyse the hydrogenation of 3,4-
dihydroisoquinoline 23 at 20 °C and 1 atm H2 pressure in excellent yield. 
The stable isoquinoline 16c can be hydrogenated as well in good yield 
although more forcing conditions are needed (Scheme 52). Encouraged 
by these initial results, we wondered if we could find an appropriately 
functionalised complex to catalyse the selective reduction of N-
heterocycles under mild conditions, allowing for the operationally simple 
synthesis of reduced N-heterocyclic compounds. 
 
 
Scheme 52: Hydrogenation of isoquinoline derivatives 
 
      In comparison to cyclic imines, quinolines are more challenging to 
reduce and their mild hydrogenation by homogeneous catalysis is 
scarce.
5d 
Thus, we chose 2-methylquinoline 12a as a model substrate to 
test a range of Cp
*
Ir(N^C)Cl complexes for their hydrogenation ability 
(Figure 12) in as-received 2,2,2-trifluoroethanol (TFE) at ambient 
temperature with 1 mol% catalyst (Table 1). A hydrogen balloon (1 atm 
H2 pressure) was used as the hydrogen source. It was delightful, yet 
surprising, that of the complexes 24a-f, only the electron rich 
3,4-methylenedioxy-substituted complex 24f showed any activity (Table 
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7, entries 1-6). To assess the effect of the N-donor substituent, complexes 
24g-i, 24l-n were prepared and tested,
6
 all of them were found to catalyse 
the hydrogenation although with diminished activity in comparison to 24f 
(Table 7, entries 7-9, 12-14). 
 
Figure 12: Catalysts examined for hydrogenation of N-heteroaromatics 
 
      As with 24a-e, complexes 24j and 24k did not show any activity, 
which indicates that the 3,4-methylenedioxybenzene motif in the catalyst 
is essential to the activity. Furthermore, the more electron-rich N-donors 
are required for higher activity (Table 7, entries 9 vs 7 and 8). In keeping 
with the need for a highly electron rich ligand set, the N-phenyl (24j) and 
N-p-bromophenyl (24k) analogues showed slightly lower activities than 
24f (Table 7, entries 12 and 13). Interestingly, the aldimine derived 
complex 24n was considerably less active than its ketimine analogue 24f 
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possibly due to its less rigid character (Table 7, entry 14). No reaction 
was observed when [Cp*IrCl2]2 (24m) or no catalyst was used (Table 7, 
entries 15 and 24). It is worth to note that the use of distilled TFE did not 
show any significant difference. Screening a variety of different reaction 
solvents suggested that the use of TFE was essential for good catalytic 
activity at 1 atm H2 pressure (Table 7, entries 16-23).  
 
Table 7. Optimisation of the hydrogenation of 12a.
[a]
 
 
Entry Complex Solvent Conversion [%]
[b]
 
1 24a TFE NR 
2 24b TFE NR 
3 24c TFE NR 
4 24d TFE NR 
5 24e TFE NR 
6 24f TFE 100 
7 24g TFE 9 
8 24h TFE 21 
9 24i TFE 77 
10 24j TFE NR 
11 24k TFE NR 
12 24l TFE 87 
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13 24m TFE 88 
14 24n TFE 6 
15 24o TFE NR 
16 24f MeOH NR 
17 24f EtOH NR 
18 24f 
i
PrOH NR 
19 24f DCM NR 
20 24f THF NR 
21 24f toluene NR 
22 24f H2O NR 
23 24f EtOAc NR 
24 None TFE NR 
 [a] Conditions: 2-methylquinoline 12a (0.5 mmol), complex (5 µmol), solvent 
(3 mL), rt, 3h, H2 (1 atm). [b] Conversion determined by 
1
H NMR of the crude 
reaction mixture and normalising the sum of the product and starting material 
integrals to 100%. NR = no reaction. 
    
Figure 13: Molecular structures of 24f (major isomer, left) and 24g 
(minor isomer, right) determined by X-ray diffraction. Thermal ellipsoids 
are shown at 50%.  
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      Ligands bearing the 3,4-methylenedioxy group underwent selective 
cyclometallation with [Cp*IrCl2]2
7
 to give the more hindered products 
with 85:15-95:5 isomeric ratios (Figure 13), due to the ortho-directing 
effect of the oxygen atoms.
8
 In contrast, the 3-OMe group of 24e resulted 
in selective cyclometallation para to the OMe, and 24e proved to be an 
inactive catalyst (Table 7, entry 5).  
 
4.2.2 Substrate scope 
      Using the optimised conditions, a variety of quinolines (including 
substituents at 2-, 3-, 4-, 6- and 8-positions), were hydrogenated to give 
the 1,2,3,4-tetrahydroquinoline products in good to excellent yields 
(Table 8). The reaction was found to be highly tolerant of other 
functionalities such as halides, esters, and free hydroxyl groups (Table 8, 
entries 10, 12-14 and 16). It is worthy to note that 3- and 4-
methylquinolines, which are often challenging substrates,
5b,e
 were 
reduced with full conversion, although a slightly elevated temperature 
and prolonged time was necessary. Reduction of phenanthrolines gave 
the partially hydrogenated 1,2,3,4-tetrahydrophenanthrolines as the 
exclusive products (Table 8, entries 8 and 9). Notably, entry 6 represents 
the first homogeneous hydrogenation of 2,2’-biquinoline. Acridine was 
reduced to the 9,10-dihydro product (Table 8, entry 7). The presence (or 
lack of) 2-substituents did not unduly affect the reaction, showing that 
coordination of the substrate and/or product to the single active site does 
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not hamper the reaction. The catalyst loading can be lowered. For 
instance,  in the reduction of 12a, a TON of 9,200 (85% isolated yield) 
was achieved at 85 
o
C in 16 h and 1 atm H2 pressure, showing the robust 
nature of the hydrogenation reaction (Table 8, entry 2). Mild conversion 
was observed for the 2-functional substrate (Table 8, entry 16) which was 
sluggish by the TH in Chapter 2. Attempting to demonstrate the 
chemoselective reduction of C=N bonds over terminal C=C bonds failed 
(Table 8, entry 17), which may be due to the alkene coordinating to the 
single metal site preventing the formation of Ir hydride. 
 
Table 8 Hydrogenation of quinolines with 24f.
[a] 
 
Entry Product 
Temp 
(°C) 
Time [h] Yield [%]
[b]
 
1 
 
rt 3 96 (100) 
2
[c]
 
 
85 16 85 (92) 
3 
 
rt 3 95 (100) 
4 
 
40 20 97 (100) 
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5 
 
40 20 98 (100) 
6 
 
rt 3 
97 (100) 
4:1 dr 
7 
 
rt 3 99 (100) 
8 
 
40 20 93 (100) 
9 
 
40 20 80 (100) 
10 
 
rt 3 97 (100) 
11 
 
40 3 92 (95) 
12 
 
rt 3 97 (100) 
13 
 
rt 3 96 (100) 
14 
 
rt 3 98 (100) 
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15 
 
40 3 97 (100) 
16 
 
rt 18 (56) 
17 
 
40 96 NR 
[a] Reaction conditions: 12 or 25 (0.5 mmol), 24f  (5 µmol), TFE (3 mL), H2 (1 
atm). [b] Yields of isolated products. Conversion in parentheses determined by 
1
H NMR of the crude reaction mixture and normalising the sum of the product 
and starting material integrals to 100%. NR = no reaction. [c] 0.01 mol% 24f 
was used. 
 
      We also investigated the reductions of a variety of other 
N-heterocycles and imines (Table 9). Quinoxalines were fully reduced, 
which to our knowledge is the first example of homogeneous 
hydrogenation of these substrates under ambient conditions (Table 9, 
entries 1-3). Cyclic imino C=N bonds were also efficiently hydrogenated, 
with 1,2,3,4-tetrahydroisoquinolines and a β-carboline (Table 9, entries 4-
9) obtained in high yields from the corresponding dihydro substrates, 
whilst an acyclic ketimine was smoothly reduced within 3 h at ambient 
temperature. The presence of a nitro group was well tolerated (Table 9, 
entry 10). Unprotected indoles (Table 9, entries 11-13), which are often 
challenging substrates for homogeneous hydrogenation,
9
 could be 
reduced to the corresponding indolines. However, indoles with electron-
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deficient groups were proved to be less active or inactive (Table 9, entries 
14 and 15), maybe a result of the difficulty of enamine-imine 
tautomerisation. Similarly low reactivity was also observed for 2-phenyl 
and 3-substitued indoles (Table 9, entries 16-18). No reaction was 
observed for either ketone or styrene substrates (Table 9, entries 20 and 
21) showing the chemoselectivity of 24f for reduction of C=N bonds over 
C=O and C=C bonds. The isoquinoline which can be fully reduced by the 
[Cp*RhCl2]2-I
-
 catalyst, was inactive in this system (Table 9, entry 19).  
 
Table 9 Hydrogenation of other C=N bonds with 24f.
[a]
 
 
Entry Substrate Product Yield [%]
[b]
 
1
[c]
 
 
 
96 (100) 
2 
  
85 (92) 
3 
  
95 (100) 
4 
  
97 (100) 
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5 
  
98 (100) 
6 
  
97 (100) 
4:1 dr 
7 
  
99 (100) 
8 
  
93 (100) 
9 
  
80 (100) 
10 
  
97 (100) 
11 
  
92 (95) 
12 
  
97 (100) 
13
[d]
 
  
96 (100) 
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14
[d]
 
  
 (9) 
15
[d]
 
  
NR 
16 
  
(40) 
trans:cis = 4:1 
17 
  
NR 
18
[d]
 
  
NR 
19
[d]
 
  
NR 
20 
  
NR 
21 
  
NR 
[a] Reaction conditions: 16, 23 or 27 (0.5 mmol), 24f (5 µmol), TFE (3 mL), rt, 
3 h, H2 (1 atm). [b] Yields of isolated products. Conversion in parentheses 
determined by 
1
H NMR of the crude reaction mixture and normalising the sum 
of the product and starting material integrals to 100%. NR = no reaction. [c] 0.5 
mol% 24f was used. [d] 40 °C, 20 h. 
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      To further demonstrate the utility of complex 24f for the reduction of 
N-heterocycles, three widely used heterogeneous hydrogenation 
catalysts
10 
and five homogeneous catalysts, including systems that have 
been shown to be extremely effective for quinoline hydrogenations,
5c,d,i
 
were compared to 24f for the reduction of 12a (Table 10). Complex 24f 
was found to be over 14 times more active than Rh/C which was the most 
active of the heterogeneous catalysts (Table 10, entry 3) and 6 times as 
active as [IrCl(COD)]2/P-Phos/I2, which was the most active of the other 
homogeneous catalysts previously reported (Table 10, entry 9).
5i 
To 
eliminate the possibility that the use of TFE solvent, rather than the 
choice of catalyst, was responsible for the high activity of 24f, all 
reactions were repeated in TFE. However, the use of TFE did not 
increase the effectiveness of any of the other catalysts (Table 10, entries 
2-6). 
 
Table 10 Comparison of 24f with other commonly used catalysts.
[a] 
 
Entry Catalyst Solvent
[b]
 T(h) 
Conv. 
(%)
[c]
 
1 
24f 
TFE 1 91 
2 Pd/C (10%) MeOH
 
3 5 (0) 
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3 Rh/C (5%) MeOH 3 7 (4) 
4 PtO2 MeOH 3 4 (0) 
5 Rh(PPh3)3Cl
 
MeOH 3 0 (0) 
6 [Ir(Py)(PCy3)COD][PF6] DCM 3 0 (0) 
7
[d]
 
 
toluene
 
1 7 
8 [Ru(p-cymene)Cl2]2 / 5% I2 THF 1 0 
9 [Ir(Cl)COD]2 /P-Phos / 5% I2 THF 1 15 
[a] Conditions: 12a (0.5 mmol), catalyst (1 mol%), solvent (3 mL), rt, H2 
balloon. [b] Dry, degassed solvent was used, apart from TFE. [c] Conversion 
determined by 
1
H NMR of the crude reaction mixture and normalising the sum 
of the product and starting material integrals to 100%. Data in parentheses were 
obtained by using TFE as solvent. [d] Reaction was prepared in an N2 filled 
glovebox. 
 
4.2.3 Mechanistic investigations 
      As was stated before, the use of TFE was essential for good catalytic 
activity at 1 atm H2 pressure (Table 7). However, the reaction was found 
to occur slowly in MeOH and EtOH at 20 bar (Table 11, entries 2 and 3), 
although TFE remained the most effective solvent. The hydrogenation 
did not take place in other commonly used solvents (Table 11, entries 4-
9). 
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Table 11 Hydrogenation of 12a in various solvents at 20 bar H2 
pressure
[a]
 
 
Entry Solvent Solvent pKa
[b] 
Conversion(%)
[c] 
1 TFE 12.5 83 
2 MeOH 15.5 5 
3 EtOH 15.8 1 
4 
i
PrOH 16.5 0 
5 THF - 0 
6 DCM - 0 
7 EtOAc - 0 
8 H2O 15.7 0 
9 toluene 41 0 
[a] Conditions: 12a (0.5 mmol), catalyst 24f (5 µmol), solvent (3 mL), 20 bar 
H2, rt, 1 h. [b] pKa data from http://evans.harvard.edu/pdf/evans_pka_table.pdf. 
[c] Conversion determined by 
1
H NMR of the crude reaction mixture and 
normalising the sum of the product and starting material integrals to 100%.  
 
      TFE is known to solvate chloride ions more strongly than MeOH,
11
 
and so may enhance the dissociation of chloride from the coordinatively 
saturated 18 electron complexes 24, creating a vacant, active site on 
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Ir(III). In line with this, hydrogenations in TFE were found to be 
inhibited by the addition of chloride ions (6 fold decrease in conversion 
with 10% NBu4Cl) or PPh3 (no reaction with 1% PPh3) (Table 12, entries 
2 and 4). It is important to note that NaCl is poorly soluble in TFE so the 
amount of dissolved chloride ions is considerably less than the amount of 
NaCl used in entry 3. In addition, as TFE (pKa 12.4) is more acidic than 
MeOH (pKa 15.5) or EtOH (pKa 15.8),
12
 it can hydrogen bond to 
substrate or product more effectively, and thereby may help prevent them 
from competing with H2 for the single vacant site on Ir(III). Indeed, 
1
H 
NMR showed that upon mixing 12a with TFE in CDCl3, the chemical 
shift of the TFE hydroxyl proton changed from 2.5 to 3.5 ppm, 
suggesting that TFE hydrogen bonds to 12a (Figure 14). Not entirely 
surprisingly, the use of chloride abstracting agents (AgSbF6 and 
NaBAr
F
4) did not allow the reaction to proceed in MeOH at 1 atm H2 
pressure (Table 12, entries 5 and 6), given the weaker hydrogen bonding 
ability of MeOH. 
 
Table 12 Effect of additives on the hydrogenation of 12a.
[a]
 
 
Entry Solvent Additive Conversion (%)
[b]
 
1 TFE none 91 
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2 TFE 10% TBACl 15 
3 TFE 100% NaCl 48 
4 TFE 1% PPh3 0 
5 MeOH
[c]
 1% AgSbF6 0 
6 MeOH
[c]
 2% NaBAr
F
4 0 
[a] Conditions: 12a (0.5 mmol), catalyst 24f (5 µmol), TFE (3 mL), rt, 1 h, H2 
balloon. [b] Conversion determined by 
1
H NMR of the crude reaction mixture 
and normalising the sum of the product and starting material integrals to 100%. 
[c] Dry, degassed solvent was used.  
 
 
Figure 14  Hydrogen bonding between TFE and 2-methylquinoline 12a. 
Superimposed 
1
H NMR spectra (400 MHz, CDCl3) of 12a (bottom, 1 
drop, blue), TFE (middle, 1 drop, red), and 12a and TFE (top, 1 drop 
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each, green). As shown above, the OH proton of TFE hydrogen bonds to 
12a, resulting in a change of its 
1
H NMR shift from 2.5 ppm to 3.5 ppm.  
 
      In order to gain further information about the reaction mechanism, we 
prepared the iridium hydride
13 
species 29 by treating 24f with an excess 
of sodium formate in DCM/H2O. Treatment of 29 with 0.2 equivalents of 
2-methylquinoline 12a did not lead to the formation of 13a. However, the 
reaction of 29 with 0.2 equivalents of 2-methyl quinolinium 
tetrafluoroborate led to the rapid formation of the fully reduced product 
13a (Scheme 53). Repeating the reactions in the presence of TFE did not 
alter the results. These results suggest that the protonated, instead of the 
neutral quinoline, is the species that is reduced in the reaction. 
 
 
Scheme 53: Synthesis and reactions of hydride 29 
 
4.3 Conclusions and future work     
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      In conclusion, this chapter reports the reduction of a diverse range of 
N-heterocyclic compounds under mild conditions (ambient temperature, 1 
atm H2) without the use of any additives (Figure 15). Key to the success 
of the reaction is the choice of ligand and the use of TFE as solvent. The 
reaction was found to be tolerant of a wide range of other, potentially 
reducible, functional groups and could be carried out using standard 
laboratory glassware and non-purified solvent. Thus, our results 
demonstrate a simple, yet highly selective reduction of N-heterocycles 
and imines with hydrogen gas as a highly effective alternative to the 
heterogeneous metal catalysts and borohydrides commonly used for these 
reactions, whilst offering greatly increased reactivity and selectivity. 
Considering the activity enhancement of the electron-rich donor in the 
ligand, future work will focus on installing electron-richer units, which 
may deliver a better catalyst for the mild hydrogenation of N-
heteroaromatics.  
 
Figure 15 Mild hydrogenation of N-heterocycles with Ir(III) complexes 
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4.4 Experimental 
4.4.1 General information 
      All reactions were performed in air unless otherwise specified. 
CH2Cl2 and hexane were dried over CaH and distilled under nitrogen. 
Tetrahydrofuran was dried over sodium in the presence of benzophenone 
and distilled under nitrogen. Toluene was dried over sodium and distilled 
under nitrogen. Methanol and ethanol were dried over magnesium 
turnings and distilled under nitrogen. Acetonitrile was dried over 4Å MS 
and distilled under nitrogen. All other solvents were used as received. 
[Cp
*
IrCl2]2, was purchased from Strem Chemicals Inc. Complexes 24a, 
24b and 24d were prepared as following Wang et al.
6a
 Complex 24c was 
prepared as following Lei et al.
6d 
Complex 24i was prepared as following 
Barnard et al.
6b
 Data was found to be consistent with that reported in all 
cases.
 
Compound 29 was prepared according to the literature.
14
 Ketimine 
ligands were prepared by literature procedures.
6a, 15
 2-Methylquinolinium 
tetrafluoroborate was prepared by a literature procedure.
16a
  All other 
commercial compounds were purchased from Aldrich, Apollo Scientific 
or Alfa Aesar and used without further purification. NMR spectra were 
recorded on a Bruker DPX-400 spectrometer with TMS as the internal 
standard and referenced to the residual solvent peak or TMS if the solvent 
peak was obscured by other resonances (ppm). The mass spectra were 
obtained by electrospray ionisation (ESI) or chemical ionisation (CI) at 
the Department of Chemistry, Liverpool University or by (FAB) at the 
EPSRC National Mass Spectrometry Service Centre, Swansea. Elemental 
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analyses were performed by the Department of Chemistry, Liverpool 
University elemental analysis service.  
4.4.2 Information for hydrogenation of 12a in various solvents at 20 bar 
H2 pressure 
      Although complex 24f is not soluble in toluene on its own, it was 
found that the mixture of 24f (3.3 mg) and 2-methylquinoline (71 mg) 
dissolved completely in all the organic solvent examined to give bright 
yellow, clear solutions. In H2O the catalyst dissolved in the substrate 2-
methylquinoline which subsequently formed a suspension in water. Thus, 
the reaction with H2O as solvent (Table 5, entry 8) is best described as 
‘on water.’ To ensure accurate comparison the reactions were performed 
simultaneously in glass vials within a larger autoclave. This allowed 
slight differences in temperature, time and H2 pressure to be eliminated. 
The vessel was pressurized with H2 and then depressurized 3 times before 
being subsequent pressurized to 20 bar and stirred. After 1 h the H2 
pressure was released and the reactions concentrated in vacuo before 
being analyzed by 
1
H NMR spectroscopy to determine the percentage 
conversion.  
4.4.3 Information for effect of additives on hydrogenation of 12a by 
24f 
      Reductions of 2-methylquinoline 12a (0.5 mmol scale) were 
performed with 1 mol% of the catalyst, in the presence or absence (Table 
6, control experiments) of 10 mol% tetra-n-butylammonium chloride 
(13.9 mg, 0.05 mmol, 10 equivalents w.r.t. catalyst 24f), 100% NaCl 
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(29.2 mg, 0.5 mmol, 10 equivalents w.r.t. catalyst 24f) or 1% PPh3 (1.3 
mg, 0.005 mmol, 1 equivalent w.r.t. catalyst 24f). The reactions were 
analysed by 
1
H NMR spectroscopy after 1 h. For entries 5 and 6, 24f and 
the additive were stirred in 1 mL dry, degassed MeOH under N2 for 30 
minutes in the reaction vessel before the substrate in 2 mL of dry MeOH 
was added by syringe via the septa. For entry 5, the formation of AgCl 
was observed as a white precipitate. The reactions were then stirred under 
H2 as normally.  
4.4.4 Information for reactions of hydride 29 
      Reaction of iridium hydride 29 with 2-methylquinoline. In a dry, 
N2 filled glovebox, a solution of 29 (8 mg, 13 µmol) in MeCN-d3 (0.7 
mL) was prepared and added to a vial containing 2-methylquinoline (0.2 
eq.). The solution was transferred to an NMR tube fitted with a J. Young 
type Teflon
®
 cap, the tube sealed, removed from the glovebox and 
analysed immediately by NMR spectroscopy. 
      Reaction of iridium hydride 29 with 2-methylquinolinium 
tetrafluoroborate. In a dry, N2 filled glovebox, a solution of 29 (8 mg, 
13 µmol) in MeCN-d3 (0.7 mL) was prepared and added to a vial 
containing 2-methylquinolinium tetrafluoroborate (0.2 eq.). A slight 
colour change from orange/yellow to yellow was observed. The solution 
was transferred to an NMR tube fitted with a J. Young type Teflon
®
 cap, 
the tube sealed, removed from the glovebox and analysed immediately by 
NMR spectroscopy.  
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      The above reactions were also repeated the presence of 0.1 mL of 
TFE. 
 
4.4.5 Typical procedure for the hydrogenation reactions 
      In a fume hood in air, a solution of the substrate was prepared by 
adding 3 mL of pre-prepared stock solution of 24f in unpurified 
2,2,2-trifluoroethanol (typically 1.66 M, 0.005 mmol in 3 mL) to a vial 
containing the substrate. Reactions were typically performed on a 0.5 
mmol scale in 3 mL of solvent. The mixture was transferred into a N2-
filled carousel tube and the tube sealed. A H2-filled party balloon 
attached to a length of rubber tubing and a hypodermic needle was 
connected to the reaction by inserting the needle through the septum of 
the carousel tube. The reaction was stirred at the described temperature 
for the appropriate period of time. The hydrogen was then released in the 
fume hood and the solution was concentrated in vacuo and analysed by 
1
H NMR spectroscopy to give the percentage conversion. The reaction 
mixture was then purified by silica gel chromatography to give the 
analytically pure product. 
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Figure 16 The reduction of 0.5 mmol quinoxaline 16e (see Table 3, entry 
1) by 1 mol% 24f at ambient temperature. 
 
4.4.6 Synthesis of the ligands  
      N-Aryl ketimine ligands L24a-L24f, L24j, L24k were prepared by 
the following procedure. A mixture of ketone and amine (0.95 eq.) in dry 
toluene were heated to reflux over 4Å molecular sieves for 18 h. The 
mixture was filtered through celite, eluting with ethyl acetate and the 
solvent removed in vacuo. The crude mixture was recrystallised from 
hexanes to give the pure imine products. Analytical data were consistent 
with that reported in the literature. 
6a, 15 
(E)-N-(1-(Benzo[d][1,3]dioxol-5-
yl)ethylidene)-4-methoxyaniline (L24f). The compound was prepared 
on a 10 mmol scale using the standard method described above. White 
solid; yield 2.04 g, 76%; m.p. 85-90 
o
C; 
1
H NMR (400 MHz, CDCl3)  
7.57 (d, J = 2.0 Hz, 1H), 7.44 (dd, J = 8.0, 2.0 Hz, 1H), 6.90 (d, J = 9.0 
Hz, 2H), 6.84 (d, J = 8.0 Hz, 1H), 6.74 (d, J = 9.0 Hz, 2H), 6.01 (s, 2H) 
3.81 (s, 3H), 2.20 (s, 3H); 
13
C NMR (100 MHz, CDCl3)  155.99, 149.67, 
148.12, 122.15, 121.00, 114.33, 107.81, 107.38, 101.56, two resonances 
were not observed, possibly due to overlapping, 55.61, 17.42; m/z (ES
+
) 
                                                                                                                             Chapter 4 
 
169 
 
270 (100%, MH
+
); HRMS (ES
+
) calcd. for C16H15NO3 (MH
+
) 270.1130; 
found 270.1127. 
2-(Benzo[d][1,3]dioxol-5-yl)pyridine (L24g). To a 
thick-walled glass tube fitted with a J. Young type Teflon
®
 cap was 
added benzo[d][1,3]dioxole-5-boronic acid (500 mg, 3.01 mmol), K2CO3 
(831 mmol, 6.02 mmol) and Pd(PPh3)4 (34 mg, 0.03 mmol). The vessel 
was placed under a N2 atmosphere and the cap replace by a septa. A 1:1 
mixture of propan-2-ol and water (non-degassed) was added via syringe 
followed by 2-bromopyridine (476 mg, 3.0 mmol). The septa was 
replaced by the Teflon
®
 cap, and then the vessel was sealed and heated at 
70 
o
C for 18h. The reaction was diluted with EtOAc (20 mL) and sat. 
NaCl (aq.). The mixture was washed with water (3x20 mL), dried over 
MgSO4, filtered and evaporated to give a crude product which was 
purified by silica gel chromatography (4:1 hexane/EtOAc) to give the 
product. The data was consistent with those reported by Monguchi et 
al.
16b 
White solid; yield 477 mg, 80%; m.p. 50-52 
o
C;  
1
H NMR (400 
MHz, CDCl3)  8.63 (d, J = 4.9 Hz, 1H), 7.69 (t, J = 8.0 Hz, 1H), 7.61 (d, 
J = 8.0 Hz, 1H), 7.52 (s, 1H), 7.49 (d, J = 8.0 Hz, 1H), 7.19 (m, 1H), 6.91 
(d, J = 8.0 Hz, 1H), 6.02 (s,2H); 
13
C NMR (100 MHz, CDCl3)  156.98, 
149.51, 148.61, 148.41, 136.97, 133.82, 121.82, 121.09, 120.17, 108.59, 
107.49, 101.44; m/z (ES
+
) 199.9 (100%, MH
+
). 
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2-(Benzo[d][1,3]dioxol-5-yl)-4,5-dihydrooxazole 
(L24h). Using a modification of the method of Togo,
15c
 ethanolamine (92 
mg, 1.5 mmol) and piperonal (150 mg, 1.0 mmol) were added to thick-
walled glass tube fitted with a stirrer bar, a Teflon
®
 cap and a rubber 
septum along with tert-butanol (15 mL). The reaction was stirred 
vigorously at 30 
o
C for 0.5 h, after which time I2 (317 mg, 1.25 mmol) 
and K2CO3 (414 mg, 3.0 mmol) were added and the mixture stirred 
vigorously at 70 
o
C for 3 h. The mixture was diluted with CH2Cl2 (100 
mL), washed with sat. aqueous Na2S2O3 (100 mL), brine (100 mL) and 
H2O (5x100 mL). The organic layer was separated, dried over Na2SO4, 
filtered and the solvent removed in vacuo to give a crude solid, which 
was washed with hexane to give the pure product. White solid; yield 146 
mg, 75%; m.p. 120-125 
o
C; 
1
H NMR (400 MHz, CDCl3)  7.49 (dd, J = 
8.0, 1.5 Hz, 1H), 7.40 (d, J = 1.5 Hz, 1H), 6.81 (d, J = 8.0 Hz, 1H), 6.00 
(s, 2H), 4.40 (t, J = 9.5 Hz, 2H), 4.02 (t, J = 9.5 Hz, 2H); 
13
C NMR (100 
MHz, CDCl3)  164.37, 150.32, 147.73, 123.26, 121.77, 108.46, 108.18, 
101.64, 67.79, 54.87; m/z (ES
+
) 192 (100%, MH
+
); HRMS (ES
+
) calcd. 
for C10H10NO3 (MH
+
) 192.0655; found 192.0655. 
 (E)-N-(1-(Benzo[d][1,3]dioxol-5-
yl)ethylidene)aniline (L24j). The compound was prepared on a 10 mmol 
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scale using the standard method described above. The product could not 
be obtained in its pure form (~90% purity by 
1
H NMR). The crude 
product was used in the cyclometallation step with the mass adjusted to 
account for the impurity of the imine. 
(E)-N-(1-(Benzo[d][1,3]dioxol-5-
yl)ethylidene)-4-bromoaniline (L24k). The compound was prepared on 
a 10 mmol scale using the standard method described above. The product 
could not be obtained in its pure form (~75% purity by 
1
H NMR). The 
crude product was used in the cyclometallation step with the mass 
adjusted to account for the impurity of the imine. 
 (E)-N-(Benzo[d][1,3]dioxol-5-ylmethylene)-
4-methoxyaniline (L24l). Piperonal (175 mg, 1.67 mmol) and p-
anisidine (143 mg, 1.67 mmol) were dissolved in absolute ethanol (5 mL) 
in a screw top vial. Formic acid (1 drop) was added and the mixture 
stirred at room temperature for 0.5 h.  The mixture was filtered and the 
precipitate washed with cold MeOH (3x5 mL) and dried in vacuo to give 
the product. White solid; yield 222 mg, 75%; m.p. 115-120 
o
C; 
1
H NMR 
(400 MHz, CDCl3)  8.36 (s, 1H), 7.53 (d, J = 8.0 Hz, 1H), 7.27-7.20 (m, 
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2H, overlapped with residual CHCl3), 6.92 (d, J = 8.5 Hz, 2H), 6.88 (d, J 
= 8.0 Hz, 1H), 6.04 (s, 2H), 3.83 (s, 3H); 
13
C NMR (100 MHz, CDCl3)  
158.18, 157.69, 150.35, 148.53, 145.03, 131.56, 125.46, 122.24, 114.47, 
108.33, 106.84, 101.69, 55.62; m/z (ES
+
) 256 (100%, MH
+
); HRMS (ES
+
) 
calcd. for C15H14NO3 (MH
+
) 256.0975; found 256.0972. 
 
4.4.7  Synthesis of cyclometallated iridium complexes 
Complexes were synthesised using the method of Davies et. al.
7
 Unless 
specified, iridium complexes 24 were synthesised from the corresponding 
ligands L24. Ligand (2.05 eq.), [Cp
*
IrCl2]2 (1.0 eq.) and NaOAc (20.0 eq.) 
were added to thick-walled glass tube fitted with a stirrer bar, a Teflon
®
 
cap and a rubber septum. The vessel was degassed 3 times and placed 
under a dry N2 atmosphere. Dry, degassed CH2Cl2 (10 mL) was added via 
syringe through the septum. The reaction was stirred vigorously at room 
temperature for 18 h. The reaction mixture was filtered through celite, 
eluting with CH2Cl2, dried over MgSO4 and filtered. The solvent was 
evaporated to give a crude solid. Recrystallisation from 10:1 
hexanes/DCM and drying in vacuo gave the pure products as fine 
powders often containing a molecule of DCM or H2O of crystallisation. 
Please note that for N-arylketimine derived complexes such as 24e, 24f, 
24j and 24k the resonances for the N-aryl protons are significantly 
broadened due to interaction with the Cp
*
 ligand and the inability of the -
N-aryl ring to rotate due to steric interactions with the Cp
*
 ligand and the 
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ketimine methyl group (see crystal structures in Wang et al.
[S1]
). In 
contrast, in the aldimine derived complex 24l the steric interactions are 
lessened due to the smaller size of H compared to CH3 and such 
broadening effects are not observed. 
Complex 24e: The complex formed as a 
single regioisomer as determined by 
1
H NMR. Red solid; yield 23 mg, 
90%; m.p. >250 
o
C; 
1
H NMR (CDCl3, 400 MHz) δ 7.81 (s, br, 1H), 7.69 
(d, J = 8.5 Hz, 1H), 7.05 (d, J = 3.0 Hz, 1H), 6.94 (dd, J = 8.5, 3.0 Hz, 
1H), 6.80 (s, br, 2H), 3.85 (s, 3H), 3.81 (s, 3H), 2.41 (s, 3H), 1.43 (s, 
15H); 
13
C NMR (100 MHz, CDCl3) δ 181.44, 158.19, 157.84, 155.29, 
151.03 (br), 148.16, 144.44, 135.41, 124.34 (br), 119.63, 113.53, 89.00, 
55.67, 55.60, 17.09, 8.73; m/z (FAB) 582 (100%, M
+
-Cl); HRMS (FAB) 
for C26H31ClIrNO2 (M
+
-Cl), calcd. 582.1984; found 582.1980. 
Complex 24f: The compound was formed 
as a mixture of 2 stereoisomers in a 95:5 ratio (by 
1
H NMR). Data is 
reported for the major isomer. Data was recorded at 298 K leading to 
broadening of the p-anisolyl resonances and lower than expected 
integrals. 
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Yellow solid; yield 30 mg, 94% combined; m.p. >250 
o
C; 
1
H NMR (400 
MHz, CDCl3)  7.18 (d, J = 8.0 Hz, 1H) 6.92 (s, br 2.2 H, corresponds to 
4 protons), 6.56 (d, J = 8.0 Hz, 1H), 6.06 (d, J = 1.5 Hz, 1H), 5.99 (d, J = 
8.0 Hz, 1H), 3.84 (s, 3H), 2.35 (s, 3H), 1.48 (s, 15H); 
13
C NMR (100 
MHz, CDCl3)  181.44, 158.19, 157.84, 155.29, 151.03, 148.16, 144.44, 
135.41, 124.34, 119.63, 113.53 (1 resonance was not observed), 89.00, 
55.67, 55.60, 17.09, 8.73; m/z (ES
+
) 596 (100%, M-Cl); HRMS (FAB) 
for C26H29IrNO3 (M
+
-Cl); calcd. 596.1772; found 596.1765. 
Complex 24g: The reaction was performed at 80 
o
C 
in a sealed vessel. The compound was formed as a mixture of 2 
stereoisomers in an 85:15 ratio (by 
1
H NMR). Data is reported for the 
major isomer. Yellow solid; yield 24.5 mg, 87% combined; m.p. >250 
o
C; 
1
H NMR (400 MHz, CDCl3)  8.62 (ddd, J = 6.0, 1.0, 0.5 Hz, 1H), 7.69 
(d, J = 8.0 Hz, 1H), 7.60 (td, J = 8.0, 1.5 Hz, 1H), 7.32 (d, J = 8.0 Hz, 
1H), 6.99 (td, J = 6.0, 1.5 Hz, 1H), 6.58 (d, J = 8.0 Hz, 1H), 6.03 (d, J = 
1.5 Hz, 1H), 5.98 (d, J = 1.5 Hz, 1H), 1.72 (s, 15H); 
13
C NMR (100 MHz, 
CDCl3)  166.99, 151.39, 151.25, 147.83, 139.73, 138.87, 136.97, 121.59, 
119.85, 118.88, 103.55, 99.42, 89.17, 9.41; m/z (FAB) 561 (100%, M
+
); 
HRMS (FAB) for C22H23IrClNO2 (M
+
) calcd. 561.1033; found 561.1024. 
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Complex 24h: The compound was formed as a 
mixture of 2 stereoisomers in a 90:10 ratio (by 
1
H NMR). Data is 
reported for the major isomer. Yellow solid; yield 19.7 mg, 71% 
combined; m.p. >250 
o
C; 
1
H NMR (400 MHz, CDCl3)  7.08 (d, J = 8.0 
Hz, 1H), 6.51 (d, J = 8.0 Hz, 1H), 6.01 (d, J = 1.5 Hz, 1H), 5.96 (d, J = 
1.5 Hz, 1H), 4.78 (td, J = 8.5, 1.0 Hz, 2H), 4.06 (m, 1H), 3.94 (m, 1H), 
1.82 (s, 15H); 
13
C NMR (100 MHz, CDCl3)  179.59, 151.39, 149.00, 
138.17, 125.88, 122.88, 103.45, 99.44, 88.17, 71.23, 50.19, 9.82; 
elemental analysis for C20H23ClIrNO3
.
0.5H2O, calcd. C 42.74, H 4.30, N 
2.49; found C 42.95, H 4.18, N 2.37. 
Complex 24j: The compound was formed as a 
mixture of 2 stereoisomers in a 95:5 ratio (by 
1
H NMR). Data is reported 
for the major isomer. Data was recorded at 298 K leading to broadening 
of the phenyl resonances and lower than expected integrals. Yellow solid; 
yield 25.6 mg, 85% combined; m.p. >250 
o
C; 
1
H NMR (400 MHz, CDCl3) 
 7.85 (s, br, 1H), 7.42 (s, br, 3H), 7.20 (m, 1H overlapped with residual 
CHCL3),  6.87 (s, br, 1H), 6.58 (d, J = 8.0 Hz, 1H), 6.07 (s, 1H), 6.00 (s, 
1H), 2.37 (s, 3H), 1.47 (s, 15H);
 13
C NMR (100 MHz, CDCl3)  180.91, 
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150.78, 149.99, 149.02, 143.02, 142.94, 125.82, 119.65, 103.17, 99.63 
(two resonances were not observed), 89.75, 17.45, 9.02; elemental 
analysis for C25H27ClIrNO2, calcd. C 49.95, H 4.53, N 2.33; found C 
50.01, H 4.60, N 2.10. 
Complex 24k: The compound was formed 
as a mixture of 2 stereoisomers in a 95:5 ratio (by 
1
H NMR). Data is 
reported for the major isomer. Data was recorded at 298 K leading to 
broadening of the resonances corresponding to one set of 2 protons on the 
p-bromophenyl group. Yellow solid; yield 26 mg, 77% combined; 
m.p. >250 
o
C; 
1
H NMR (400 MHz, CDCl3)  7.78 (s, br, 1H), 7.54 (d, J = 
8.0 Hz, 2H), 7.21 (d, J = 8.0 Hz, 1H), 6.76 (s, br, 1H), 6.58 (d, J = 8.0 Hz, 
1H), 6.07 (s, 1H), 6.01 (s, 1H), 2.37 (s, 3H), 1.48 (s, 15H); 
13
C NMR 
(100 MHz, CDCl3)  180.44, 151.02, 150.75, 148.79, 143.34, 142.69, 
126.28, 125.46, 102.99, 99.56, (two resonances were not observed), 
89.70, 17.45, 8.94; elemental analysis for C25H26BrClIrNO2
.
H2O, calcd. 
C 43.01, H 4.04, N 2.01; found C 42.53, H 4.15, N 2.05. 
Complex 24l: The compound was formed 
as a mixture of 2 stereoisomers in a 95:5 ratio (by 
1
H NMR). Data is 
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reported for the major isomer. Orange solid; yield 24 mg, 24% combined; 
m.p. >250 
o
C; 
1
H NMR (400 MHz, CDCl3)  8.15 (s, 1H), 7.50 (d, J = 
8.0 Hz, 2H), 7.25 (d, J = 8.0 Hz, 1H), 6.89 (d, J = 8.0 Hz, 2H), 6.57 (d, J 
= 8.0 Hz, 1H), 6.07 (d, J = 1.5 Hz, 1H), 6.01 (d, J = 1.5 Hz, 1H), 3.84 (s, 
3H), 1.53 (s, 15H); 
13
C NMR (100 MHz, CDCl3)  173.84, 158.57, 
151.08, 149.15, 145.50, 143.35, 142.82, 126.54, 123.66, 114.04, 103.65, 
99.70, 89.55, 55.67, 9.20; elemental analysis for C25H27ClIrNO3
.
CH2Cl2, 
calcd. C 44.48, H 4.16, N 2.00; found C 44.27, H 4.16, N 1.87. 
Complex 29: A solution of 24f (6.6 mg, 
1x10
-2 
mmol) in freshly distilled CH2Cl2 (2 mL) was added to a thick 
walled glass tube fitted with a J. Young type Teflon
®
 cap. The solution 
was degassed by three freeze-pump-thaw cycles and placed under a dry 
N2 atmosphere. A solution of NaOOCH (6.8 mg, 10 eq., 0.1 mmol) and a 
minimum quantity of TBA
.
OOCH (<0.5 mg) in deionised water (2 mL) 
was prepared and similarly degassed and placed under a dry N2 
atmosphere. The aqueous solution was added to the solution of 24 by 
cannulla and the vessel sealed under N2 and stirred vigorously at room 
temperature. After 18 h the aqueous layer was removed by syringe and 
the organic layer washed with degassed water (5x3 mL) under N2. The 
organic layer was evaporated in vacuo to give a moderately air sensitive 
bright yellow solid (6.0 mg, 99%). Complex 29 was formed as two 
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regioisomers in a 95:5 ratio (by 
1
H NMR), due to the starting compound 
24f existing as a mixture of regioisomers in the same ratio. Data is given 
for the major isomer. 
1
H NMR (400 MHz, CDCl3)  7.19 (d, J = 8.0 Hz, 
1H), 6.99 (s, br, 4H) 6.53 (d, J = 8.0 Hz, 1H), 5.96 (s, 1H), 5.88 (s, 1H), 
3.81 (s, 3H), 2.22 (s, 3H), 1.67 (s, 15H), -15.76 (s, 1H). Unfortunately 
satisfactory elemental analyses could not be obtained for compound 6 and 
its instability in air for prolonged manipulation prevented further 
purification in addition to that described above. Thus 29 was used in its 
semi-crude form for subsequent reactions.  
 
4.5 Analytic data of isolated products 
2-Methyl-1,2,3,4-tetrahydroquinoline (13a):
16d 1
H NMR 
(400 MHz, CDCl3)  6.99-6.96 (m, 2H), 6.62 (td, J = 7.5, 1.0 Hz, 1H), 
6.49 (dd, J = 8.5, 1.0 Hz, 1H), 3.71 (s, br, 1H), 3.42 (m, 1H), 2.85 (m, 
1H), 2.77 (m, 1H), 1.95 (m, 1H), 1.60 (m, 1H), 1.22 (d, J = 6.5 Hz, 3H); 
13
C NMR (100 MHz, CDCl3)  144.87,  129.39, 126.81, 121.24, 117.11, 
114.13, 47.28, 30.25, 26.72, 22.73; m/z (CI
+
) 148 (100%, MH
+
). 
1,2,3,4-Tetrahydroquinoline (26a):
16e
 
1
H NMR (400 MHz, 
CDCl3)  7.03 (m, 2H), 6.70 (m, 1H), 6.54 (d, J = 7.0 Hz, 1H), 3.78 (s, br, 
1H), 3.35 (m, 2H), 2.84 (m, 2H), 2.02 (m, 2H); 
13
C NMR (100 MHz, 
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CDCl3)  144.78, 129.53, 126.74, 121.44, 116.94, 114.23, 41.99, 27.00, 
22.18; m/z (CI
+
) 134 (100%, MH
+
). 
3-Methyl-1,2,3,4-tetrahydroquinoline (13z):
16d
 
1
H NMR 
(400 MHz, CDCl3)  6.99 (m, 2H), 6.65 (td, J = 7.5, 1.0 Hz, 1H), 6.52 
(dd, J = 8.0, 1.0 Hz, 1H), 3.81 (s, br, 1H), 3.30 (ddd, J = 11.0, 4.0, 2.0 Hz, 
1H), 2.92 (t, J = 10.0 Hz, 1H), 2.81 (ddd, J = 16.0, 5.0, 2.0 Hz, 1H), 2.47 
(dd, J = 16.0, 10.0 Hz, 1H), 2.10 (m, 1H), 1.08 (d, J = 6.5 Hz, 3H); 
13
C 
NMR (100 MHz, CDCl3)  144.34, 129.63, 126.79, 121.23, 117.04, 
113.99, 48.93, 35.56, 27.27, 19.15; m/z (CI
+
) 148 (100%, MH
+
). 
4-Methyl-1,2,3,4-tetrahydroquinoline (13aa):
16f
 
1
H NMR 
(400 MHz, CDCl3)  7.07 (d, J = 7.5 Hz, 1H), 6.97 (td, J = 7.5, 1.0 Hz, 
1H), 6.64 (td, J = 7.5, 1.0 Hz, 1H), 6.49 (dd, J = 8.0, 1.0 Hz, 1H), 3.30 (m, 
2H), 2.92 (m, 1H), 2.00 (m, 1H), 1.69 (m, 1H) 1.30 (d, J = 7.0 Hz, 3H); 
13
C NMR (100 MHz, CDCl3)  144.21, 128.58, 126.85, 126.82, 117.18, 
114.37, one resonance was not observed, 39.13, 30.32, 29.95, 22.77; m/z 
(CI
+
) 148 (100%, MH
+
). 
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1,1',2,2',3,3',4,4'-Octahydro-2,2'-biquinoline (26b):
16g
 meso:racemic = 
4.2:1, determined by NMR analysis. Data for the meso compound; m.p. 
139-142 
o
C; 
1
H NMR (400 MHz, CDCl3)  7.05-7.02 (m, 4H), 6.69 (td, J 
= 7.5, 1.0 Hz, 2H), 6.57 (d, J = 8.0 Hz, 2H), 4.00 (br, 2H), 3.48-3.44 (m, 
2H), 2.92-2.80 (m, 4H), 2.02-1.90 (m, 4H); 
13
C NMR (100 MHz, CDCl3) 
 144.79, 129.30, 126.99, 121.52, 117.42, 114.35, 55.37, 26.68, 23.12; 
m/z (CI
+
) 265 (100%, MH
+
). 
9,10-Dihydroacridine (13u):
16d
 m.p. 169-70 
o
C; 
1
H 
NMR (400 MHz, CDCl3)  7.12-7.07 (m, 4H), 6.87 (td, J = 7.5, 1.0 Hz, 
2H), 6.67 (d, J = 7.5 Hz, 2H), 5.96 (s, br, 1H), 4.07 (s, 2H); 
13
C NMR 
(100 MHz, CDCl3)  140.24, 128.73, 127.12, 120.76, 120.16, 113.56, 
31.50; m/z (CI
+
) 182 (100%, MH
+
). 
1,2,3,4-Tetrahydro-4,7-phenanthroline (26c):
16h
 
1
H 
NMR (400 MHz, CDCl3)  8.60 (dd, J = 4.0, 1.5 Hz, 1H) 8.03 (dd, J = 
8.5, 1.0 Hz, 1H), 7.75 (d, J = 9.0 Hz, 1H), 7.28 (q, J = 8.5, 4.0 Hz, 1H), 
6.96 (d, J = 9.0 Hz, 1H), 4.13 (s, br, 1H), 3.35 (t, J = 5.5 Hz, 2H), 2.97 (t, 
J = 7.0 Hz, 2H), 2.10-2.04 (m, 2H); 
13
C NMR (100 MHz, CDCl3)  
145.45, 143.39, 142.40, 129.43, 128.70, 128.34, 121.77, 121.08, 110.62, 
41.59, 22.27, 21.83; m/z (CI
+
) 182 (100%, MH
+
). 
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1,2,3,4-Tetrahydro-1,10-phenanthroline (26d):
16i 1
H 
NMR (400 MHz, CDCl3)  8.70 (dd, J = 4.0, 1.5 Hz, 1H), 8.01 (dd, J = 
8.0, 1.5 Hz, 1H), 7.29 (q, J = 8.0, 4.0 Hz, 1H), 7.17 (d, J = 8.0 Hz, 1H), 
6.98 (d, J = 8.0  Hz, 1H), 5.95 (s, br, 1H), 3.53 (m, 2H), 2.93 (t, J = 6.5 
Hz, 2H), 2.07 (m, 2H); 
13
C NMR (100 MHz, CDCl3)  147.03, 140.77, 
137.59, 135.93, 129.14, 127.44, 120.62, 116.62, 113.17, 41.35, 27.12, 
21.90; m/z (CI
+
) 182 (100%, MH
+
). 
Ethyl 1,2,3,4-tetrahydroquinoline-6-carboxylate 
(26e):
16j
 m.p. 80-82 
o
C; 
1
H NMR (400 MHz, CDCl3)  7.66 (m, 2H), 6.39 
(d, J = 9.0 Hz, 1H), 4.29 (m, 3H overlapped), 3.35 (t, J = 5.5 Hz, 2H), 
2.77 (t, J = 5.5 Hz, 2H), 1.92 (m, 2H), 1.35 (t, J = 7.0 Hz, 2H); 
13
C NMR 
(100 MHz, CDCl3)  167.20, 148.80, 131.36, 129.20, 119.99, 117.93, 
112.72, 60.19, 41.84, 27.02, 21.56, 14.60; m/z (CI
+
) 206 (100%, MH
+
). 
6-Methoxy-2-methyl-1,2,3,4-tetrahydroquinoline 
(13p):
16d 1
H NMR (400 MHz, CDCl3)  6.61-6.58 (m, overlapped, 2H), 
6.46 (d, J = 8.5 Hz, 1H), 3.73 (s, 3H), 3.60-3.00, (s, br) overlapped with 
3.50-3.30 (m, 1H), 2.90-2.81 (m, 1H), 2.74-2.69 (m, 1H), 1.94-1.89 (m, 
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1H), 1.64-1.55 (m, 1H), 1.20 (d, J = 6.5 Hz, 3H); 
13
C NMR (100 MHz, 
CDCl3)  152.05, 138.87, 122.73, 115.54, 114.75, 112.97, 55.92, 47.64, 
30.40, 27.02, 22.64; m/z (CI
+
) 178 (100%, MH
+
). 
6-Bromo-1,2,3,4-tetrahydroquinoline (26f):
5d
 
1
H NMR 
(400 MHz, CDCl3)  7.04 (m, 2H), 6.34 (d, J = 8.5 Hz, 1H), 3.84 (s, br, 
1H), 3.29 (t, J = 5.5 Hz, 2H), 2.72 (t, J = 5.5 Hz, 2H), 1.91 (m, 2H); 
13
C 
NMR (100 MHz, CDCl3)  143.83, 131.95, 129.44, 123.48, 115.61, 
108.26, 41.88, 26.93, 21.77; m/z (CI
+
) 212 (100%, MH
+
) 214 (95%, 
MH
+
). 
6-Chloro-1,2,3,4-tetrahydroquinoline (26g):
16f
 
1
H NMR 
(400 MHz, CDCl3)  6.93 (m, 2H), 6.39 (d, J = 8.5 Hz, 1H), 3.79 (s, br, 
1H), 3.28 (t, J = 5.5 Hz, 2H), 2.73 (t, J = 5.5 Hz, 2H), 1.92 (m, 2H); 
13
C 
NMR (100 MHz, CDCl3)  143.34, 129.07, 126.54, 122.93, 121.15, 
115.16, 41.90, 26.93, 21.78; m/z (CI
+
) 168 (100%, MH
+
), 170 (35%, 
MH
+
). 
8-Hydroxy-1,2,3,4-tetrahydroquinoline (26h):
16f
 m.p. 117-
120 
o
C; 
1
H NMR (400 MHz, CDCl3)  6.60-6.53 (m, 3H), 4.78 (s, 2H), 
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3.31 (s, br 2H), 2.77 (s, br 2H), 1.95 (s, br 2H); 
13
C NMR (100 MHz, 
CDCl3)  143.20, 133.54, 123.65, 122.02, 117.20, 112.53, 41.91, 26.68, 
22.34; m/z (CI
+
) 150 (100%, MH
+
). 
8-Methyl-1,2,3,4-tetrahydroquinoline (26i):
16e
 
1
H NMR 
(400 MHz, CDCl3)  6.91-6.86 (m, 2H), 6.59 (t, J = 7.5 Hz, 1H), 3.76 (s, 
br, 1H), 3.40 (t, J = 5.5 Hz, 1H), 2.81 (t, J = 6.5 Hz, 1H), 2.10 (s, 3H), 
1.96 (m, 2H); 
13
C NMR (100 MHz, CDCl3)  142.70, 127.96, 127.49, 
121.39, 121.06, 116.60, 42.46, 27.39, 22.24, 17.30; m/z (CI
+
) 148 (100%, 
MH
+
). 
1,2,3,4-Tetrahydroquinoxaline (17e):
16d
 m.p. 95-97 
o
C; 
1
H NMR (400 MHz, CDCl3)  6.59 (m, 2H), 6.50 (m, 2H), 3.52 (s, br, 
2H), 3.42 (s, 4H); 
13
C NMR (100 MHz, CDCl3)  133.67, 118.99, 114.94, 
41.46; m/z (CI
+
) 135 (100%, MH
+
). 
2-Methyl-1,2,3,4-tetrahydroquinoxaline (17f):
16d 1
H 
NMR (400 MHz, CDCl3)  6.63 (m, 2H), 6.53 (m, 2H), 3.63 (s, br, 2H), 
3.52 (m, 1H), 3.30 (m, 1H), 3.02 (m, 1H), 1.20 (m, 3H); 
13
C NMR (100 
MHz, CDCl3)  133.58, 133.19, 118.92, 114.72, 114.67, one aromatic 
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resonance is not observed, 48.29, 45.81, 19.92; m/z (CI
+
) 149 (100%, 
MH
+
). 
6-Methyl-1,2,3,4-tetrahydroquinoxaline (17h):
16d 
m.p. 
100-102 
o
C; 
1
H NMR (400 MHz, CDCl3)  6.42 (m, 2H), 6.34 (s, 1H), 
3.40 (s, 6H overlapped), 2.18 (s, 3H); 
13
C NMR (100 MHz, CDCl3)  
133.82, 131.07, 128.64, 119.28, 115.59, 115.19, 41.65, one resonance 
was not observed, 20.79; m/z (CI
+
) 149 (100%, MH
+
). 
1-Methyl-1,2,3,4-tetrahydroisoquinoline (17c):
16k
 
1
H 
NMR (400 MHz, CDCl3)  7.23-7.08 (m, 4H), 4.16 (m, 1H),  3.32-3.27 
(m ,1H) 3.08-3.02 (m, 1H), 2.97-2.87 (m, 1H), 2.78 (m, 2H), 1.49 (d, J = 
6.5 Hz, 3H); 
13
C NMR (100 MHz, CDCl3)  140.53, 134.83, 129.36, 
126.12, 126.04, one resonance was not observed, 51.68, 41.86, 30.09, 
22.79; m/z (CI
+
) 148 (100%, MH
+
). 
1-iso-Propyl-1,2,3,4-tetrahydroisoquinoline (28a):
16k 
1
H NMR (400 MHz, CDCl3)  7.16-7.07 (m, 4H), 3.96 (d, J = 3.0 Hz, 
1H), 3.32-3.28 (m, 1H), 2.97-2.84 (m, 2H), 2.67 (m, 1H), 2.35 (m, 1H), 
1.85 (s, br, 1H), 1.13 (d, J = 7.0 Hz, 3H), 0.75 (d, J = 7.0 Hz, 3H); 
13
C 
NMR (100 MHz, CDCl3)  138.84, 136.34, 129.22, 126.02, 125.84, 
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125.71, 61.09, 42.61, 32.36, 30.50, 20.40, 15.83; m/z (CI
+
) 176 (100%, 
MH
+
). 
1-Cyclohexyl-1,2,3,4-tetrahydroisoquinoline (28b):
16k 
1
H NMR (400 MHz, CDCl3)  7.15-7.06 (m, 4H), 3.92 (d, J = 3.5 Hz, 
1H), 3.29 (m, 1H), 2.96-2.82 (m, 2H), 2.68 (m, 1H), 2.05-1.68 (m, 6H), 
1.40-1.07 (m, 6H); 
13
C NMR (100 MHz, CDCl3)  138.43, 136.28, 
129.25, 126.20, 125.78, 125.74, 60.85, 43.07, 42.42, 31.03, 30.31, 27.17, 
26.76, 26.68, 26.51; m/z (CI
+
) 216 (100%, MH
+
). 
1-Cyclohexyl-6,7-dimethoxy-1,2,3,4-
tetrahydroisoquinoline (28c):
16k
 m.p. 78-80 
o
C; 
1
H NMR (400 MHz, 
CDCl3)  6.63 (s, 1H), 6.55 (s, 1H), 3.85 (s, 3H), 3.84 (s, 3H), 3.25 (m, 
1H), 2.92-2.85 (m, 1H), 2.78-2.71 (m, 1H), 2.60-2.55 (m, 1H), 1.84 (m, 
2H), 1.70 (m, 4H), 1.39-1.12 (m, 7H); 
13
C NMR (100 MHz, CDCl3)  
147.16, 147.12, 130.43, 128.51, 111.79, 109.37, 60.47, 56.18, 55.89, 
43.34, 42.58, 31.01, 29.95, 27.18, 26.80, 26.70, 26.46; m/z (CI
+
) 276 
(100%, MH
+
). 
1-Phenyl-6,7-dimethoxy-1,2,3,4-
tetrahydroisoquinoline (28d):
16k
 m.p. 109-111 
o
C; 
1
H NMR (400 MHz, 
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CDCl3)  7.31-26 (m, 5H), 6.64 (s, 1H), 6.24 (s, 1H), 5.07 (s, 1H), 3.88 (s, 
3H), 3.64 (s, 3H), 3.20 (m, 1H), 3.05 (m, 1H), 2.94 (m, 1H), 2.79 (m, 1H), 
2.43 (s, br, 1H); 
13
C NMR (100 MHz, CDCl3)  147.79, 147.20, 144.44, 
129.48, 129.11, 128.56, 127.61, 127.59, 111.46, 110.99, 61.39, 55.96, 
41.77, 29.16; m/z (CI
+
) 270 (100%, MH
+
). 
1-Methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole 
(28e):
16k
 m.p. 165-170 
o
C; 
1
H NMR (400 MHz, CDCl3)  7.80 (s, br, 1H), 
7.49 (d, J = 8.0 Hz, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.16 (td, J = 8.0, 1.0 
Hz, 1H), 7.10 (td, J = 8.0, 1.0 Hz, 1H), 4.19 (q, J = 6.5 Hz, 1H), 3.40-
3.35 (m, 1H), 3.06 (m, 1H), 2.74 (m, 2H), 1.70 (s, br, 1H), 1.17 (d, J = 
7.0 Hz, 3H); 
13
C NMR (100 MHz, CDCl3)  136.62, 135.80, 127.50, 
121.73, 119.54, 118.24, 110.92, 108.32, 48.26, 42.47, 22.44, 20.56; m/z 
(CI
+
) 187 (100%, MH
+
). 
4-Methoxy-N-(1-(3-
nitrophenyl)ethyl)aniline (28f):
16l
 
1
H NMR (400 MHz, CDCl3)  8.25 
(d, J = 2.0 Hz, 1H), 8.08 (ddd, J = 8.0, 2.0, 1.0 Hz, 1H), 7.72 (d, J = 7.5 
Hz, 1H), 7.48 (t, J = 8.0 Hz, 1H), 6.69 (d, J = 9.0 Hz, 2H), 6.43 (d, J = 
9.0 Hz, 2H), 4.50 (m, 1H), 3.87 (s, br, 1H), 3.69 (s, 3H), 1.53 (d, J = 7.0 
Hz, 3H); 
13
C NMR (100 MHz, CDCl3)  150.36, 146.77, 146.21, 138.83, 
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130.30, 127.73, 120.15, 119.08, 112.92, 112.66, 53.78, 51.98, 23.20; m/z 
(CI
+
) 273 (100%, MH
+
). 
2-Methylindoline (28g):
9b
 
1
H NMR (400 MHz, CDCl3)  
7.09 (d, J = 7.0 Hz, 1H), 7.02 (t, J = 7.5 Hz, 1H), 6.70 (t, J = 7.5 Hz, 1H), 
6.62 (d, J = 7.5 Hz, 1H), 4.00 (m, 1H), 3.59 (s, br, 1H), 3.15 (dd, J = 16.0, 
8.5 Hz, 1H), 2.64 (dd, J = 16.0, 8.0 Hz, 1H), 1.30 (d, J = 6.0 Hz, 3H); 
13
C 
NMR (100 MHz, CDCl3)  150.92, 129.06, 127.34, 124.84, 118.73, 
109.38, 55.35, 37.84, 22.35; m/z (CI
+
) 134 (100%, MH
+
). 
Indoline (28h):
9b 1
H NMR (400 MHz, CDCl3)  7.14 (d, J 
= 7.0 Hz, 1H), 7.04 (t, J = 7.5 Hz, 1H), 6.73 (td, J = 7.5, 1.5 Hz, 1H), 
6.67 (d, J = 7.5 Hz, 1H), 3.73(s, br, 1H), 3.56 (t, J = 8.5 Hz, 2H), 3.05 (t, 
J = 8.5 Hz, 2H); 
13
C NMR (100 MHz, CDCl3)  151.69, 129.40, 127.29, 
124.72, 118.73, 109.53, 47.42, 29.93; m/z (CI
+
) 120 (100%, MH
+
). 
5-Methoxyindoline (28i):
9b 1
H NMR (400 MHz, 
CDCl3)  6.77 (s, 1H), 6.60 (m, 2H), 3.75 (s, 3H), 3.53 (t, J = 8.5 Hz, 2H), 
3.45 (s, br, 1H), 3.01 (t, J = 8.5 Hz, 2H); 
13
C NMR (100 MHz, CDCl3)  
153.62, 145.34, 131.26, 112.18, 111.61, 110.22, 56.03, 47.86, 30.53; m/z 
(CI
+
) 150 (100%, MH
+
). 
 
4.6 Crystallographic data of 24f and 24g minor isomer17 
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C26H29ClIrNO3, M = 631.15, monoclinic, a = 7.4023(9) Å, b = 
15.5707(19) Å, c = 20.203(3) Å, β = 100.426(2)°, V = 2290.2(5) Å3, T = 
569.3, space group P21/c (no. 14), Z = 4, μ(MoKα) = 5.975, 19921 
reflections measured, 4719 unique (Rint = 0.0254) which were used in all 
calculations. The final wR2 was 0.1380 (all data) and R1 was 0.0565 (>2 
sigma(I)). 
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C22H23ClIrNO2, M = 561.06, monoclinic, a = 7.4378(8) Å, b = 
14.0123(16) Å, c = 18.702(2) Å, β = 97.756(3)°, V = 1931.3(4) Å3, T = 
569.3, space group P21/n (no. 14), Z = 4, μ(MoKα) = 7.069, 24448 
reflections measured, 4009 unique (Rint = 0.0368) which were used in all 
calculations. The final wR2 was 0.0394 (all data) and R1 was 0.0167 
(>2sigma(I)).  
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CHAPTER 5 SYNTHESIS OF CHIRAL PIPERIDINES 
FROM PYRIDINES ENABLED BY TRANSAMINATION 
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5.1 Introduction 
 
      Chapter 3 reports an iodide-promoted TH system to effectively 
reduce pyridinium salts to the corresponding piperidines and 3,4-
unsaturated variants with high chemoselectivities. It would be a natural 
extension for us to attempt the ATH of pyridines, which is broadly 
recognised as a challenging and topical research direction. In this chapter, 
an unprecedented reaction discovered by serendipity for the direct 
preparation of optically pure piperidines from pyridines, will be discussed. 
      Small chiral, cyclic amines, such as piperidines are privileged 
chemical scaffolds present in many natural products and pharmaceutical 
compounds.
1
 However, effective methods for their synthesis from simple 
starting materials are rare. An attractive approach is the catalytic 
reduction of the precursors of piperidines, i.e. normal pyridines, using 
hydrogen gas or other hydrogen sources. Although much progress has 
been made in the asymmetric reduction of the more reactive benzo-fused 
N-heteroaromatics, direct synthesis of chiral piperidines by the reduction 
of simple pyridine derivatives remains challenging.
2
 Previous efforts 
have concentrated on the use of well-defined chiral transition metal 
catalysts as well as elaborated substrates activation strategies.  
      The aromatic nature of pyridine (resonance energy 27 kcal/mol), 
coupled with the tendency of pyridines to poison metal catalysts by 
coordination through the basic nitrogen atom makes the reduction of 
pyridines a challenging task, which typically requires heterogeneous 
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catalysts and forcing conditions. As a result, the great advances made in 
homogeneous asymmetric hydrogenation have not been brought to bear, 
and a simple cost-effective asymmetric reduction of pyridines remains 
unrealised.
2
 One method to overcome these problems is the alkylation or 
acylation of the pyridine nitrogen atom. This simultaneously lowers the 
LUMO of pyridine, increasing its susceptibility to nucleophilic attack by 
a metal hydride species and reduction, while coordinatively saturating the 
nitrogen atom, decreasing the tendency to bind to any available metal 
catalyst. 
      In this context, we have recently described the synthesis of piperidine 
derivatives by the TH of N-benzylpyridinium salts using a 5:2 
HCOOH/NEt3 mixture as the hydrogen source and a catalyst generated in 
situ from [Cp*RhCl2]2 and potassium iodide, as also can be seen in 
Chapter 3. Realising the unmet need for a simple and effective 
asymmetric reduction of pyridine derivatives, we sought to develop a 
chiral analogue of this reaction. Progress was hindered by the need for an 
active rhodium catalyst bearing a single Cp* ligand and two iodide 
ligands, making modification of the coordination sphere of Rh(III) by the 
addition of chiral ligands impossible. Although highly effective 
asymmetric reactions based on Rh(III) and chiral Cp ligands have 
recently been reported,
3
 our attempts at using chiral metal complexes as 
catalysts for this transformation were fruitless. 
      Due to the requirement of an additional synthetic step in which an 
auxiliary is attached to the pyridine, with the associated purification steps, 
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we also discounted the use of chiral auxiliaries, despite their effectiveness 
in controlling the stereochemical outcome of similar reactions.
4
 Other 
drawbacks include the prohibitive expense of the frequently used N-acyl 
based auxiliaries (e.g. $314/gram for (-)-8-phenylmenthol), mandating 
their recovery and purification after use, and the limited substrate scope 
(2-substitutents are not tolerated) for the synthesis of chiral N-alkyl 
pyridinium salts by the Zincke reaction.
5 
 
5.2 Results and Discussion 
5.2.1 Initial discovery of in situ transamination  
      To circumvent the problem mentioned above, we pursued the use of 
chiral additives in an attempt to induce asymmetry into the reaction by 
the creation of a chiral local environment through non-covalent 
interactions.
6
 During the course of this work, we surprisingly observed 
the incorporation of the chiral amine (R)-1-phenylethylamine ((R)-
PEA, >98% ee) into the product, resulting from a formal exchange of the 
ethylimido fragment with (R)-1-phenylethylimido as shown in Scheme 54. 
Initially using N-benzyl pyridinium bromide salt led to an unseparated 
mixture, in which there were two structurally similar piperidines 31a and 
20d as determined by 
1
HNMR. In order to obtain pure 31a for further 
analysis, N-ethyl pyridinium iodide salt was subjected to the identical 
reaction conditions, aiming to produce a separable mixture. Delightfully, 
pure 31a was isolated readily as single distereoisomer, although the yield 
was a moderate 42%. Further simple derivatization by debenzylation and 
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Boc-protection was carried out to generate piperidine 33 in 96% 
enantiomeric excess. X-ray crystallography finally confirmed the 
absolute configuration of the transamination product 31a as (R, S) 
(Scheme 54 (e)).  
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Scheme 54: Synthesis of chiral piperidines by in situ 
transamination/transfer hydrogenation. (a) Previously described achiral 
transfer hydrogenation of N-benzyl pyridinium salts. (b) In situ 
transamination of N-benzyl pyridinium bromide salts. (c) In situ 
transamination of N-ethyl pyridinium iodide salts. (d) Derivatisation of 
31a. (e) X-ray structure of product 31a. 
 
      Despite the low yield, the incorporation of the chiral amine (R)-PEA 
into the final product held great promise. Such a process in which a non-
activated substrate is chirally modified by the addition of a chiral 
substrate without modification of the reaction conditions would alleviate 
the need for prior steps in which to attach the chiral auxiliary to a pre-
activated pyridine substrate.
7
 The incorporation of the chiral N-
phenylethyl moiety would render the final reduction of the C=N double 
bond diastereoselective, alleviating the need for complex or costly chiral 
transition metal catalysts.  
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      In addition, PEA is a highly economic chiral reagent (<$1.00/gram), 
of which both enantiomers are readily available, and the chiral N-alkyl 
group can be cleaved using the same conditions required for removal of 
the widely used N-benzyl protecting group, giving chiral piperidine 
products with no additional synthetic steps. 
      Screening a variety of transition metals salts and complexes showed 
that only the group 6 “piano stool” complexes were effective, with 
[Cp*RhCl2]2 being the most active catalyst. Due to the propensity of 
formic acid / PEA mixtures to solidify, a co-solvent was required, with 
CH2Cl2 being optimal. The exclusion of air was neither required, nor 
found to be beneficial, as both the reagents and the Rh(III) catalyst are 
stable to air and moisture in the solid state and in solution. As also can be 
seen in Scheme 54, exchanging the N-benzyl group to an N-ethyl group 
facilitated easier separation of the chiral and achiral products. Despite 
this, the percentage conversion and isolated yield of the chiral product 
was highly changeable and difficult to reproduce. Rigorous drying of the 
solvents and reagents and employing newly received formic acid led to a 
decrease in yield (35%) and the further adding of 3 Å molecular sieves 
significantly hampered 31a formation (Table 13, entries 1 and 2), 
implicating the presence of adventitious traces of water in the highly 
hydroscopic PEA and formic acid as the critical factor. Indeed, the 
addition of water remarkably enhanced the yields of 31a and decreased 
the yields of the undesired product 20b at the same time (Table 13, 
entries 3-6). Changing the anion Br
- 
to I
-
 and N-benzyl to ethyl substituent 
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were found to improve the yield slightly (Table 13, entires 7 and 8). 
Rescreening the water effect using N-ethyl pyridinium iodide salt 30a as 
the substrate (Table 13, entries 8-14) afforded the best yield of 86%, 
demonstrating again the water benefits for the reaction (Table 13, entries 
9-12). However, the reaction was inactive when water was used as sole 
solvent (Table 13, entry 15). The chloride anion considerably inhibited 
the yield of 31a, while a non-coordinating anion, SbF6
-
, was found to 
totally deactivate the reaction (Table 13, entries 16 and 17). 
 
Table 13. Effects of H2O and anion on in situ transamination  of 
pyridinium satls.
[a] 
 
Entry X, R CH2Cl2/H2O 
[mL] 
31a/20d
[b]
 Yield of 
31a [%]
[c]
 
1 Br, Ph 4.00/0.00 1/1.83 35 
2
[d]
 Br, Ph 4.00/0.00 1/8.05 8.6 
3 
4 
Br, Ph 
Br, Ph 
3.75/0.25 
3.50/0.50 
1/0.54 
1/0.40 
60 
71 
5 Br, Ph 3.00/1.00 1/0.36 70 
6 Br, Ph 2.00/2.00 1/0.39 68 
7 I, Ph 3.50/0.50 1/0.22 76 
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 [a] Reaction conditions: pyridinium salt 19d or 30a (0.5 mmol), HCOOH (12 
mmol), (R)-PEA (5 mmol), [Cp*RhCl2]2 (5 µmol), CH2Cl2/H2O mixture (4 mL), 
40 °C, 22 h, in air. Ph = Phenyl, Me = Methyl. CH2Cl2 and (R)-PEA were dried 
over CaH2. [b] Mole ratio, determined by 
1
H NMR analysis; NA = Not 
available.[c] Isolated yields; data in bracket were obtained with 5 eq. (R)-PEA 
and 12 eq. HCOOH. [d] 3 g of 3 Å molecular sieves were added. 
 
5.2.2 Substrate scope 
       Under the optimised conditions, the reaction proceeds smoothly with 
N-ethylpyridium salts bearing a variety of 2-aryl and alkyl substituents, 
affording the corresponding N-(1-phenylethyl)piperidines in good yields 
and uniformly high diastereoselectivities (>20:1) (Table 14). In contrast 
to homogeneous methods, the reduction of the pyridinium ring occurred 
selectively in the presence of other potentially reducible functional 
8 I, Me 3.50/0.50 NA 81 
9 I, Me 4.00/0.00 NA 46 
10 I, Me 4.00/0.01 NA 57 
11 I, Me 3.90/0.10 NA 76 
12 I, Me 3.75/0.25 NA 86 (77) 
13 I, Me 3.00/1.00 NA 79 
14 I, Me 2.00/2.00 NA 71 
15 I, Me 0.00/4.00 NA <2 
16 Cl, Ph 3.50/0.50 1/5.40 14 
17 SbF6, Ph 3.50/0.50 NA <2 
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groups, including, aryl bromides, esters and cyano groups (Table 14, 
entries 4, 5 and 13). Heterocyclic substituents, such as pyridine, 
thiophene and furan, were also well tolerated albeit in diminished yields 
(Table 14, entries 6-8). The presence of other groups including protected 
amines and free alcohols did not inhibit the reaction (Table 14, entries 12 
and 14). Thus, this method allows for a broad range of chiral piperidines 
to be accessed with excellent diastereoselectivities in a single step from 
simple precursors.  
      In some cases, naturally occurring alkaloids such as coniine, 
previously always by multistep synthesis starting from complex materials,
 
could be directly obtained by a simple debenzylation (Table 14, entry 10). 
Chiral bis-piperidines could also be produced by this method (Table 14, 
entry 15), which may find use in asymmetric catalysis as chiral diamine 
ligands.  
Table 14. In situ transamination of 2-substituted pyridiniums to 
piperidines.
[a] 
 
Entry Substrate Product Yield [%]
[b]
 
1 
  
86 
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2 
  
83
[c]
 
3 
  
82 
4 
  
86 
5 
  
70
[c],[d]
 
6 
  
54
[c]
 
7 
  
71 
8 
  
48 
9 
  
88 
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10 
  
82 
11 
  
55 
12 
  
82 
13 
  
68 
14 
  
83 
15
[e]
 
  
75 
[a] All reactions were carried out under the standard conditions: 30 (0.5 mmol), 
[Cp*RhCl2]2 (5 µmol), HCOOH (12 mmol), (R)-PEA (5 mmol), [Cp*RhCl2]2 (5 
µmol), CH2Cl2/H2O (3.75/0.25 mL), 40 °C, 22 h, in air. [b] Isolated yields.
 
[c] 
(S)-PEA was used. [d] The reaction was carried out in 2.5 mmol scale. [e] 
Reaction conditions were the same as standard conditions except for using 
HCOOH (24 mmol), (R)-PEA (10 mmol), [Cp*RhCl2]2 (10 µmol), CH2Cl2/H2O 
(7.5/0.5 mL). 
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      Notably the isolated yields approached 90% in some cases, which 
would be the maximum theoretical yield of the desired product if the 
transamination reaction had reached equilibrium, assuming a 10:1 ration 
of starting material and PEA.  
     Although the in situ incorporation of a PEA auxiliary and subsequent 
reduction to give chiral piperidines is the most immediate use of this in 
situ transamination-reduction reaction, it can also be used to furnish the 
alkylation of piperidines, starting from pyridinium precursors, using 
amines as the alkylating agent, as shown in Table 15. This offers an 
advantage in cases where an effective alkylating agent is not available 
due to its instability or lack of reactivity. For instance, N-
cyclopropylpiperidine 38, which is not obtainable by alkylation or 
reductive amination, was obtained in a yield of 64% using cheap reagents. 
In addition, due to the retention of the nitrogen atom in the reactant amine, 
the stereochemistry of this unit is completely conserved. Using this 
method, a variety of N-alkyl piperidines 34-38 and 20d bearing cyclic 
and acyclic alkyl groups were synthesised in a single step, including 
those bearing optically active N-alkyl groups 34-36 (Table 15, entries 1-
3).  
 
Table 15. In situ transamination of 2-phenylpyridiniums with various 
primary amines.
[a] 
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Entry Amine Product Yield [%]
[b]
 
1 
 
 
 
78 
2  
 
88  
3  
 
77 
4  
 
88 
5 
 
 
 
64 
                                                                                                                             Chapter 5 
 
207 
 
6  
 
83 
[a] Reactions were carried out under the standard conditions given in Table 2 
except for using different amines. [b] Isolated yield. 
 
5.2.3 Mechanistic investigations 
      The [Cp*RhCl2]2/KI-catalysed transfer hydrogenation of pyridnium 
salts to give piperidines occurs via successive hydride addition and 
protonation steps, and corresponding to the addition of 3 equivalents of 
dihydrogen (Scheme 55). 
 
 
Scheme 55: Stepwise reduction of pyridinium salts by transfer 
hydrogenation reaction. The anionic counterions are omitted for clarity. 
Rh-H = Cp*RhI2H 
       
      In order to pinpoint at which of the 3 possible oxidation states the 
transamination reaction occurs, model compounds were synthesised and 
reacted with PEA / acid mixtures under conditions closely related to the 
actual reaction conditions (Scheme 56, (a)-(c)). By replacing the formic 
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acid with acetic acid (which does not act as a hydrogen source), the 
reaction of compound 19d with excess PEA could be studied in isolation 
without the reduction occurring. Chloroform-d (CDCl3) was used in place 
of dichloromethane to allow for in situ analysis of the reaction by 
1
H 
NMR. No exchange was observed in the reaction of the N-
benzylpyridinium starting material 19d (Scheme 56, (a)), suggesting that 
a Zincke
5
 type mechanism was not in operation. The transfer-
hydrogenated product 32 was isolated in high yield without observing 
any transamination product 31a when tetrahydropyridinium 39 was 
employed in the identical conditions, indicating that the amine exchange 
does not happen on this possible intermediate (Scheme 56, (b)). The 
result together with the almost full recovery of 20d (Scheme 56, (c)), 
hints that the amine incorporation probably takes place in the 
dihydropyridinium intermediate. Furthermore, blocking the 4-position of 
pyridines with a bulky substituent, which makes initial 1,4-hydride 
addition impossible, was found to totally hinder the transamination 
reaction, with transfer-hydrogenated product 22c obtained in 87% yield 
(Scheme 56, (d)).  
      A possible mechanism explaining the transamination is shown in 
Scheme 57. The transamination reaction probably occurs after the initial 
reduction of the pyridinium salt to dihydropyridinium and before the 
subsequent reduction to give the piperidine product. The nucleophilic 
addition of amine to the dihydropyridinium leads to the formation of the 
enamine 44, which after isomerisation could be hydrolysed to open the 
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ring. As mentioned, the reaction was found to be aided by the presence of 
water, and was inhibited in a significant degree by the use of anhydrous 
reactants/solvents and the addition of 3Å molecular sieves. This is 
consistent with the proposed hydrolysis of 45 by water. The condensation 
of the ring opened product 46 with the chiral amine unit, followed by ring 
closure, would yield the amine exchange product 47 which may undergo 
further reduction to give the final products 31a.  
The formation of the amine product 42 from the pyridininium 40 in 
similar yield to the incorporated piperidine 41 also gave credit to the 
proposed mechanism (Scheme 56, (e)). 
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Scheme 56: Transamination reactions of model compounds with (R)-
PEA. Reactions were performed under conditions given in the equations. 
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Scheme 57: Proposed mechanism for the in situ transamination of 
pyridinium and the formation of hydrogenated by-product. 
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5.3 Conclusions and future work     
      The use of chiral amines, in place of the commonly used 
triethylamine in the transfer hydrogenation of N-alkyl pyridinium salts, 
led to an unexpected and previously unknown method for the synthesis of 
chiral piperidine derivatives. The reaction requires no prior modification 
of the substrates, and offers an operationally simple, effective method for 
the synthesis of optically active piperidine derivatives.  
      Preliminary mechanistic investigations suggest that addition of a 
amine and water causes the usual transfer hydrogenation process to be 
interrupted after the initial reduction step by a ring opening / 
transamination / ring closing process. This process expands the scope of 
pyridine reduction chemistry and allows for a new method of 
N-alkylation of piperidine ring systems. Future work will focus on 
extending the substrate scope and gaining more mechanistic evidence by 
experimental investigations and computational calculations. 
 
5.4 Experimental  
 
5.4.1 General information 
      Unless otherwise specified, the chemicals were obtained 
commercially from Aldrich, Alfa Aesar, Apollo Scientific or TCI and 
used without further purification. Silica gel plates (GF254) were used for 
TLC monitoring and silica gel (230-400 mesh) was used for running 
column chromatography. NMR spectra were recorded on a Bruker 400 
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MHz NMR spectrometer with TMS as the internal standard. The mass 
spectra were obtained by chemical ionization (CI) or electrospray 
ionization (ESI).  
5.4.2 General procedure for in situ transamination of pyridiniums 
      To a carousel reaction tube containing a magnetic stirring bar and 
(R)-(+)-α-methylbenzylamine (615 mg, 5 mmol) was added formic acid 
(564 mg, 12 mmol) dropwise at room temperature. After stirring the 
amine/acid mixture for 10 min, a pyridinium salt, N-ethyl-2-
phenylpyridinium iodide (157 mg, 0.5 mmol), [Cp*RhCl2]2 (3.1 mg, 5 
µmol), 3.75 mL of CH2Cl2 and 0.25 mL of distilled H2O were introduced 
into the mixture. The reaction system was placed in a carousel reactor. 
The mixture was stirred at 40 
o
C for 22 h, cooled to room temperature 
and then basified with an aqueous solution of KOH. The resulting 
mixture was extracted with ethyl acetate (3×10 mL) and dried over 
Na2SO4. The solvent was removed under reduced pressure, and the 
residue was purified by column chromatography (EtOAc/hexane) to give 
the desired product 31a in 86% yield. 
 
5.5 Analytic data of isolated products 
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 (S)-2-Phenyl-1-((R)-1-phenylethyl)piperidine (31a):
8a 1
H 
NMR (CDCl3, 400 MHz) δ (ppm): 7.49-7.42 (m, 4H), 7.35-7.18 (m, 6H), 
3.83 (q, J = 10.8 Hz, 1H), 3.50 (dd, J = 16.2, 4.6 Hz, 1H), 2.56 (dt, J = 
18.6, 4.2 Hz, 1H), 2.22 (td, J = 17.8, 4.8 Hz, 1H), 1.80-1.26 (m, 6H), 1.18 
(d, J = 10.8 Hz, 3H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 145.4, 144.9, 
128.6, 127.9, 126.68, 127.65, 127.0, 126.2, 65.7, 55.1, 45.2, 37.3, 26.4, 
25.8, 8.2; HRMS for C19H24N [M+H]
+
: m/z calcd 266.1903, found 
266.1906. 
1-Ethyl-2-phenylpiperidine (32):
8b
 
1
H NMR (CDCl3, 400 
MHz) δ (ppm): 7.37-7.20 (m, 5H), 3.17 (d, J = 11.2 Hz, 1H), 3.01 (dd, J 
= 11.2, 2.8 Hz, 1H), 2.57-2.49 (m, 1H), 2.10-1.95 (m, 2H), 1.81-1.53 (m, 
5H), 1.41-1.31 (m, 1H), 0.91 (t, J = 7.2 Hz, 3H); 
13
C NMR (CDCl3, 100 
MHz) δ (ppm): 145.4, 128.5, 127.6, 126.9, 68.9, 52.7, 49.2, 36.7, 26.2, 
25.3, 11.1; HRMS for C13H20N [M+H]
+
: m/z calcd 190.1590, found 
190.1589. 
  (S)-tert-Butyl 2-phenylpiperidine-1-carboxylate (33):
8c 1
H 
NMR (CDCl3, 400 MHz) δ (ppm): 7.34 (t, J = 8.0 Hz, 2H), 7.24-7.21 (m, 
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3H), 5.42 (brs, 1H), 4.05 (d, J = 13.6 Hz, 1H), 2.80-2.73 (m, 1H), 2.33-
2.29 (m, 1H), 1.93-1.84 (m, 1H), 1.62-1.37 (m, 14H); 
13
C NMR (CDCl3, 
100 MHz) δ (ppm): 155.6, 140.3, 128.5, 126.5, 126.3, 99.9, 79.5, 40.1, 
28.4, 28.1, 25.4, 19.3. HPLC (Chiralcel AD-H, hexane:isopropanol = 
99:1, flow rate 1.0 mL/min, 220 nm): tR = 7.3 min (minor), tS = 8.0 min 
(major), 96.5% ee. The S configuration was determined by comparison 
with reported results in literature. 
1-Butyl-2-phenylpiperidine (41):
8d 1
H NMR (CDCl3, 400 
MHz) δ (ppm): 7.33-7.19 (m, 5H), 3.18 (d, J = 11.2 Hz, 1H), 2.98 (dd, J 
= 11.2, 2.8 Hz, 1H), 2.45-2.37 (m, 1H), 2.03 (td, J = 11.4, 3.4 Hz, 1H),  
1.90-1.83 (m, 2H), 1.79-1.52 (m, 5H), 1.39-1.03 (m, 5H), 0.77 (t, J = 7.4 
Hz, 3H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 145.7, 128.4, 127.6, 
126.8, 69.3, 55.3, 53.4, 36.9, 28.4, 26.3, 25.3, 20.7, 14.2; HRMS for 
C15H24N [M+H]
+
: m/z calcd 218.1903, found 218.1908. 
(4-(tert-Butyl)phenyl)methanamine (42):
8e 1
H NMR (CDCl3, 
400 MHz) δ (ppm): 7.37 (d, J = 8.4 Hz, 2H), 7.27 (d, J = 8.0 Hz, 2H), 
4.62 (brs, 2H), 3.84 (s, 2H), 1.29 (s, 9H); 
13
C NMR (CDCl3, 100 MHz) δ 
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(ppm): 150.6, 136.9, 127.6, 125.8, 44.9, 34.6, 31.5; MS (CI, m/z, %) 147 
(100) [M+H-NH3]
+
. 
1-Benzyl-4-(tert-butyl)-1,2,3,6-tetrahydropyridine (22c):
8f 
1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.36-7.22 (m, 5H), 5.41-5.39 (m, 
1H), 3.57 (s, 2H), 3.02-3.00 (m, 2H), 2.52 (t, J = 5.8 Hz, 2H), 2.15 (br s, 
2H), 1.02 (s, 9H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 144.6, 138.8, 
129.6, 128.6, 127.4, 116.3, 63.3, 53.9, 50.6, 35.3, 29.2, 25.9; HRMS for 
C16H24N [M+H]
+
: m/z calcd 230.1903, found 230.1898. 
 (S)-1-((R)-1-Phenylethyl)-2-(4-
(trifluoromethyl)phenyl)piperidine (31b, unknown compound):
 1
H 
NMR (CDCl3, 400 MHz) δ (ppm): 7.43 (d, J = 7.6 Hz, 2H), 7.38 (d, J = 
8.0 Hz, 2H), 7.27 (d, J = 7.6 Hz, 2H), 7.17 (d, J = 7.4 Hz, 2H), 6.86 (d, J 
= 8.8 Hz, 2H), 3.83 (q, J = 6.8 Hz, 1H), 3.76 (s, 3H),  3.45 (dd, J = 10.8, 
2.8 Hz, 1H), 2.55 (d, J = 11.6 Hz, 1H), 2.20 (td, J = 11.4, 2.6 Hz, 1H), 
1.78-1.26 (m, 6H), 1.17 (d, J = 6.8 Hz, 3H); 
13
C NMR (CDCl3, 100 MHz) 
δ (ppm): 158.6, 145.0, 137.5, 128.6, 127.9, 127.6, 126.1, 114.0, 65.0, 
55.4, 54.9, 45.3, 37.4, 26.6, 25.8, 8.2; HRMS for C20H26NO [M+H]
+
: m/z 
calcd 296.2009, found 296.2005. 
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 (S)-2-(4-Bromophenyl)-1-((R)-1-
phenylethyl)piperidine (31c, unknown compound):
 1
H NMR (CDCl3, 
400 MHz) δ (ppm): 7.46-7.34 (m, 6H), 7.29 (t, J = 7.4 Hz, 2H), 7.19 (d, J 
= 7.2 Hz, 2H), 3.78 (q, J = 6.8 Hz, 1H), 3.48 (dd, J = 10.8, 2.6 Hz, 1H), 
2.55 (d, J = 11.6 Hz, 1H), 2.21 (td, J = 11.6, 2.4 Hz, 1H), 1.79-1.72 (m, 
2H), 1.66-1.28 (m, 4H), 1.18 (d, J = 7.2 Hz, 3H); 
13
C NMR (CDCl3, 100 
MHz) δ (ppm): 144.47, 144.46, 131.8, 129.4, 128.0, 127.6, 126.3, 120.5, 
65.0, 55.1, 45.1, 37.3, 26.3, 25.6, 8.3; HRMS for C19H23BrN [M+H]
+
: 
m/z calcd 346.0988, 344.1009, found 346.0987, 344.0995. 
4-((R)-1-((S)-1-Phenylethyl)piperidin-2-
yl)benzonitrile (31d, unknown compound): 
1
H NMR (CDCl3, 400 MHz) 
δ (ppm): 7.65-7.57 (m, 4H), 7.41 (d, J = 12.8 Hz, 2H), 7.34-7.18 (m, 3H), 
3.71 (q, J = 10.8 Hz, 1H), 3.59 (dd, J = 16.8, 4.8 Hz, 1H), 2.58 (d, J = 
19.0 Hz, 1H), 2.23 (td, J = 18.0, 4.6 Hz, 1H), 1.83-1.72 (m, 4H), 1.67-
1.28 (m, 4H), 1.20 (d, J = 10.8 Hz, 3H); 
13
C NMR (CDCl3, 100 MHz) δ 
(ppm): 151.2, 144.0, 132.6, 128.3, 128.1, 127.4, 126.5, 119.1, 110.8, 65.3, 
55.6, 44.9, 37.2, 26.1, 25.4, 8.5; HRMS for C20H23N2 [M+H]
+
: m/z calcd 
291.1856, found 291.1854. 
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2-((R)-1-((S)-1-phenylethyl)piperidin-2-yl)pyridine (31e, 
unknown compound):
 1
H NMR (CDCl3, 400 MHz) δ (ppm): 8.53 (d, J = 
4.8 Hz, 1H), 7.67-7.61 (m, 2H), 7.46 (d, J = 8.0 Hz, 2H), 7.30 (d, J = 7.6 
Hz, 2H), 7.19 (t, J = 7.4 Hz, 1H), 7.13 (ddd, J = 7.2, 5.0, 1.8 Hz, 1H), 
3.78 (dd, J = 10.8, 2.8 Hz, 1H), 3.72 (q, J = 6.8 Hz, 1H), 2.59 (d, J = 11.2 
Hz, 1H), 2.28 (td, J = 11.2, 2.8 Hz, 1H), 1.91-1.86 (m, 1H), 1.81-1.77 (m, 
1H), 1.70-1.33 (m, 4H), 1.26 (d, J = 6.8 Hz, 3H); 
13
C NMR (CDCl3, 100 
MHz) δ (ppm): 164.9, 149.0, 144.5, 136.7, 128.0, 127.6, 126.3, 122.0, 
121.9, 67.2, 56.0, 44.9, 35.8, 26.2, 25.2, 8.8; HRMS for C18H23N2 
[M+H]
+
: m/z calcd 267.1856, found 267.1863. 
 (S)-2-(Furan-2-yl)-1-((R)-1-phenylethyl)piperidine (31f, 
unknown compound): 
1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.39 (t, J = 
7.6 Hz, 3H), 7.27 (d, J = 7.6 Hz, 2H), 7.18 (t, J = 7.2 Hz, 1H), 6.31 (dd, J 
= 3.0, 1.8 Hz, 1H), 6.25 (d, J = 3.2 Hz, 1H), 3.79 (dd, J = 9.2, 3.2 Hz, 
1H), 3.66 (q, J = 6.8 Hz, 1H), 2.52 (dt, J = 11.2, 4.0 Hz, 1H), 2.55 (td, J = 
10.4, 2.8 Hz, 1H), 1.97-1.72 (m, 3H), 1.54-1.30 (m, 3H),  1.26 (d, J = 6.8 
Hz, 3H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 157.2, 145.0, 141.3, 
128.0, 127.8, 126.3, 110.0, 106.8, 57.3, 57.1, 45.4, 32.7, 26.0, 24.3, 11.2; 
HRMS for C17H22NO [M+H]
+
: m/z calcd 256.1696, found 256.1689. 
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 (S)-1-((R)-1-phenylethyl)-2-(thiophen-2-yl)piperidine 
(31g, unknown compound):
 1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.42 (t, 
J = 7.6 Hz, 3H), 7.48-7.15 (m, 6H), 6.93-6.83 (m, 2H), 3.92-3.75 (m, 2H), 
2.62 (dt, J = 11.2, 4.0 Hz, 1H), 2.18 (td, J = 10.4, 2.8 Hz, 1H), 1.88-1.27 
(m, 6H), 1.20 (d, J = 6.8 Hz, 3H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 
149.5, 144.7, 127.9, 127.7, 126.3, 126.0, 124.4, 60.1, 55.4, 45.1, 37.9, 
26.0, 25.3, 9.0; HRMS for C17H22NS [M+H]
+
: m/z calcd 272.1467, found 
272.1463. 
 (R)-2-Methyl-1-((R)-1-phenylethyl)piperidine (31h):
8g 1
H 
NMR (CDCl3, 400 MHz) δ (ppm): 7.42 (d, J = 7.2 Hz, 2H), 7.29 (t, J = 
7.2 Hz, 2H), 7.19 (t, J = 7.6 Hz, 1H), 4.04 (q, J = 6.8 Hz, 1H), 2.84-2.77 
(m, 1H), 2.36-2.31 (m, 1H), 2.15-2.09 (m, 1H), 1.72-1.56 (m, 2H), 1.43-
1.28 (m, 4H), 1.25 (d, J = 6.8 Hz, 3H), 1.12 (d, J = 6.4 Hz, 3H); 
13
C 
NMR (CDCl3, 100 MHz) δ (ppm): 145.9, 128.0, 127.8, 126.3, 56.7, 52.1, 
45.0, 34.8, 26.5, 23.5, 17.2, 12.6; HRMS for C14H22N [M+H]
+
: m/z calcd 
204.1747, found 204.1747. 
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 (R)-1-((R)-1-Phenylethyl)-2-propylpiperidine (31i):
8g
 
1
H 
NMR (CDCl3, 400 MHz) δ (ppm): 7.41 (d, J = 7.6 Hz, 2H), 7.28 (t, J = 
7.6 Hz, 2H), 7.19 (t, J = 7.4 Hz, 1H), 4.01 (q, J = 6.6 Hz, 1H), 2.72 (brs, 
1H), 2.36 (ddd, J = 11.2, 8.0, 3.2 Hz, 1H), 2.23-2.18 (m, 1H), 1.69-1.28 
(m, 10H), 1.25 (d, J = 6.4 Hz, 3H), 0.92 (t, J = 7.2 Hz, 3H); 
13
C NMR 
(CDCl3, 100 MHz) δ (ppm): 146.4, 128.1, 127.6, 126.3, 56.9, 55.8, 45.2, 
31.1, 29.7, 25.9, 22.8, 19.0, 14.9, 14.7; HRMS for C16H26N [M+H]
+
: m/z 
calcd 232.2060, found 232.2057. 
  (S)-2-Benzyl-1-((R)-1-phenylethyl)piperidine (31j, 
unknown compound):
 1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.40 (d, J = 
7.2 Hz, 2H), 7.32-7.17 (m, 8H), 4.02 (q, J = 6.8 Hz, 1H), 3.19-3.14 (m, 
1H), 3.01 (dd, J = 13.2, 3.6 Hz, 1H), 2.75 (dd, J = 13.0, 10.6 Hz, 1H), 
2.46-2.32 (m, 2H), 1.64-1.40 (m, 6H),  1.37 (d, J = 6.4 Hz, 3H); 
13
C 
NMR (CDCl3, 100 MHz) δ (ppm): 146.7, 141.0, 129.4, 128.4, 128.3, 
127.5, 126.6, 125.8, 58.9, 57.0, 45.2, 32.8, 28.3, 25.9, 21.3, 17.8; HRMS 
for C20H26N [M+H]
+
: m/z calcd 280.2060, found 280.2062. 
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tert-butyl (((S)-1-((R)-1-Phenylethyl)piperidin-2-
yl)methyl)carbamate (31k, unknown compound):
 1
H NMR (CDCl3, 400 
MHz) δ (ppm): 7.38 (d, J = 7.2 Hz, 2H), 7.31 (t, J = 7.4 Hz, 2H), 7.22 (t, 
J = 7.2 Hz, 1H), 4.98 (s, 1H), 4.12 (q, J = 6.8 Hz, 1H), 3.40-3.35 (m, 1H), 
3.29-3.23 (m, 1H), 2.72 (brs, 1H), 2.54-2.49 (m, 1H), 2.34 (ddd, J = 12.0, 
8.8, 2.8 Hz, 1H), 1.71-1.64 (m, 3H), 1.44 (s, 10H), 1.38-1.25 (m, 5H); 
13
C 
NMR (CDCl3, 100 MHz) δ (ppm): 156.5, 145.1, 128.3, 127.6, 126.7, 79.1, 
56.0, 55.2, 44.1, 41.1, 28.6, 28.2, 24.7, 23.3, 13.4; HRMS for C19H31N2O2 
[M+H]
+
: m/z calcd 319.2380, found 319.2396. 
Ethyl 2-((S)-1-((R)-1-phenylethyl)piperidin-2-
yl)acetate (31l):
8h 1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.35-7.21 (m, 
5H), 4.18 (q, J = 7.2 Hz, 2H), 3.86 (q, J = 6.4 Hz, 1H), 2.84-2.80 (m, 1H), 
2.76-2.73 (m, 1H), 1.90-1.83 (m, 1H), 1.68-1.43 (m, 6H), 1.32-1.26 (m, 
8H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 174.7, 146.6, 128.5, 126.9, 
126.8, 60.1, 55.1, 53.5, 44.6, 30.0, 25.7, 24.8, 23.4, 23.0, 14.5; HRMS for 
C17H26NO2 [M+H]
+
: m/z calcd 276.1958, found 276.1965. 
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 ((S)-1-((R)-1-Phenylethyl)piperidin-2-yl)methanol 
(31m)
8i
 :
 1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.38-7.19 (m, 5H), 4.25 
(q, J = 10.8 Hz, 1H), 3.62 (d, J = 10.8 Hz, 2H), 2.78-2.68 (m, 1H), 2.66-
2.54 (m, 2H), 1.79-1.40 (m, 5H), 1.35 (d, J = 8.8 Hz, 3H), 1.31-1.19 (m, 
1H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 144.9, 128.4, 127.6, 126.9, 
61.2, 56.4, 56.2, 42.9, 25.6, 23.2, 22.7, 15.4; HRMS for C14H22NO 
[M+H]
+
: m/z calcd 220.1696, found 220.1692.  
1,3-bis((S)-1-((R)-1-Phenylethyl)piperidin-2-
yl)propane (31n, unknown compound):
 1
H NMR (CDCl3, 400 MHz) δ 
(ppm): 7.41  (d, J = 7.0 Hz, 4H), 7.29  (t, J = 7.0 Hz, 4H), 7.23-7.15 (m, 
2H), 4.00 (q, J = 6.8 Hz, 2H), 2.73-2.70 (m, 18H), 2.41-2.33 (m, 2H), 
2.25-2.15 (m, 2H), 1.65-1.30 (m, 2H), 1.24 (d, J = 6.8 Hz, 6H); 
13
C NMR 
(CDCl3, 100 MHz) δ (ppm): 146.3, 128.1, 127.6, 126.6, 57.0, 56.1, 45.1, 
29.7, 29.4, 25.9, 22.8, 22.0, 14.8; HRMS for C19H43N2 [M+H]
+
: m/z 
calcd 419.3421, found 419.3419. 
(S)-2-Phenyl-1-((R)-1-phenylpropyl)piperidine (34, 
unknown compound): 
1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.54 (d, J = 
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7.6 Hz, 2H), 7.43 (t, J = 7.6 Hz, 2H), 7.36-7.29 (m, 5H), 7.25 (t, J = 6.4 
Hz, 1H), 3.62 (d, J = 10.4 Hz, 1H), 3.51 (dd, J = 9.6, 3.4 Hz, 1H), 2.78 (d, 
J = 11.6 Hz, 1H), 2.32 (t, J = 11.2 Hz, 1H), 1.93-1.30 (m, 8H), 0.68 (t, J 
= 7.2 Hz, 3H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 145.3, 142.2, 128.9, 
128.6, 128.0, 127.8, 127.1, 126.4, 65.8, 63.1, 45.5, 36.7, 26.4, 25.6, 15.3, 
12.1; HRMS for C20H26N [M+H]
+
: m/z calcd 280.2060, found 280.2060. 
(R)-1-((S)-1-Cyclohexylethyl)-2-phenylpiperidine (35, 
unknown compound):
 1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.30-7.16 (m, 
5H), 3.32 (dd, J = 10.8, 2.8 Hz, 1H), 2.78 (d, J = 11.6 Hz, 1H), 2.25-2.09 
(m, 3H), 1.76-1.49 (m, 9H), 1.35-1.00 (m, 5H), 0.73 (d, J = 6.4 Hz, 3H), 
0.69-0.62 (m, 1H), 0.58-0.48 (m, 1H); 
13
C NMR (CDCl3, 100 MHz) δ 
(ppm): 145.7, 128.2, 128.1, 126.6, 65.7, 57.5, 44.9, 41.1, 37.6, 31.2, 30.6, 
26.9, 26.8, 26.6, 25.8, 8.4; HRMS for C19H30N [M+H]
+
: m/z calcd 
272.2373, found 272.2378. 
(S)-1-((R)-3,3-Dimethylbutan-2-yl)-2-phenylpiperidine (36, 
unknown compound):
 1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.23-7.10 (m, 
5H), 3.19-3.16 (m, 1H), 2.89 (d, J = 11.2 Hz, 1H), 2.20-2.11 (m, 2H), 
1.69-1.47 (m, 5H), 1.27-1.16 (m, 1H), 0.73-0.71 (m, 12H); 
13
C NMR 
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(CDCl3, 100 MHz) δ (ppm): 145.8, 128.5, 128.1, 126.8, 67.3, 60.2, 48.4, 
37.2, 35.2, 28.9, 26.6, 25.9, 5.6; HRMS for C17H28N [M+H]
+
: m/z calcd 
246.2216, found 246.2209. 
1-Cyclohexyl-2-phenylpiperidine (37, unknown compound):
 
1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.32-7.19 (m, 5H), 3.41 (dd, J = 
10.8, 2.8 Hz, 1H), 3.02 (d, J = 11.2 Hz, 1H), 2.32-2.25 (m, 2H), 1.77-1.25 
(m, 12H), 1.14-0.73 (m, 4H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 
145.6, 128.4, 127.5, 126.7, 65.7, 58.2, 46.4, 37.3, 31.8, 26.72, 26.68, 
26.64, 26.0, 25.6, 23.8; HRMS for C17H26N [M+H]
+
: m/z calcd 244.2060, 
found 244.2063. 
1-Cyclopropyl-2-phenylpiperidine (38, unknown compound):
 
1
H NMR (CDCl3, 400 MHz) δ (ppm): 7.31-7.21 (m, 5H), 3.17 (d, J = 
11.6 Hz, 1H), 3.09 (dd, J = 10.4, 3.2 Hz, 1H), 2.25 (td, J = 11.8, 3.0 Hz, 
1H), 1.85-1.51 (m, 5H), 1.45-1.26 (m, 2H), 0.28-0.13 (m, 2H), -0.01--
0.26 (m, 2H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 144.4, 128.7, 127.9, 
127.0, 71.3, 56.1, 39.1, 34.6, 26.1, 24.9, 9.6, 4.0; HRMS for C14H20N 
[M+H]
+
: m/z calcd 202.1590, found 202.1595. 
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1-Benzyl-2-phenylpiperidine (20d):
8f 1
H NMR (CDCl3, 400 
MHz) δ (ppm): 7.46 (d, J = 7.2 Hz, 2H), 7.31 (t, J = 7.8 Hz, 2H), 7.28 (d, 
J = 4.4 Hz, 4H), 7.25-7.18 (m, 2H), 3.76 (d, J = 13.6 Hz, 1H), 3.11 (dd, J 
= 11.0, 2.6 Hz, 1H), 2.96 (d, J = 11.6 Hz, 1H), 2.81 (d, J = 13.2 Hz, 1H),  
1.98-1.89 (m, 1H), 1.81-1.74 (m, 2H), 1.67-1.53 (m, 3H), 1.42-1.31 (m, 
1H); 
13
C NMR (CDCl3, 100 MHz) δ (ppm): 145.9, 140.0, 128.8, 128.6, 
128.1, 127.6, 127.0, 126.6, 69.3, 59.9, 53.5, 37.2, 26.1, 25.4; HRMS for 
C18H22N [M+H]
+
: m/z calcd 252.1752, found 252.1748. 
 
5.6 Crystallographic data of 31a 
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C19H23N, M = 265.38, orthorhombic, space group P212121 (no. 19), a = 
7.8158(6) Å, b = 10.3447(7) Å, c = 18.8075(14) Å, V = 1520.63(19) Å3, 
Z = 4, T = 100.0 K, μ(Mo kα) = 0.499 mm-1, Dcalc = 1.159 g/mm3, 
13955 reflections measured (9.4 ≤ 2Θ ≤ 149.24), 3073 unique (Rint = 
0.0281) which were used in all calculations. The final R1 was 0.0305 
(>2sigma(I)) and wR2 was 0.0776 (all data). 
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      This thesis describes our contribution to TH of N-heteroaromatic 
compounds. In the previous chapters, we identified the challenges in the 
realm of TH and new protocols to tackle these problems were developed 
in our research. 
      An efficient and mild TH protocol was developed for the reduction of 
quinolines, isoquinolines and quinoxalines to the corresponding 
tetrahydro products. This system was also applied to the reduction of 
more challenging pyridines to afford not only piperidines but also the 3,4-
unsaturated derivatives in a highly chemoselective manner. In this study, 
the remarkable accelerating effect of the iodide ion was discovered, 
which offers a solution for practical preparation of various N-heterocyclic 
compounds. The iodide-promoted system also found its use in the 
reduction of alkenes to alkanes, nitrobenzene to aniline, as well as 
alkynes to alkenes with an exclusively trans manner, which is not 
described in the thesis.  
     In the hydrogenation of N-heterocycles with H2, a simple bridging 
electron-donor was found to convert an inactive cyclometalated iridium 
complex into a most active catalyst at ambient conditions without using 
any additives.  
      A new reaction was serendipitously discovered, leading to the direct 
preparation of a range of N-substituted piperidines, particularly the chiral 
versions from pyridines. The unprecedented diastereo- and 
enantioselectivities for a variety of substrates were demonstrated using 
this TH-transamination process.  
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      A summary of the research in this thesis is shown in scheme 58. 
 
 
Scheme 58: Schematic summary of the research of the thesis 
 
      Considering the high activity of iodide-accelerated TH of N-
heteroaromatic compounds, future work could aim at developing chiral 
catalysts with more structurally rigid ligands, such as chiral Cp ligand,
1
 
which may resist the attack of excessive iodide, thereby achieving 
industrially viable ATH with a higher efficacy than currently available 
asymmetric methods. 
      Encouraged by recently arising iron-catalysed TH of carbonyls,
2
 
imines
2
 and nitroarenes,
3a
 and decomposition of formic acid,
3b
 search for 
more cost-efficient metal catalysts, such as iron complexes, could be a 
future direction for a greener TH-transamination process. 
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